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Genotoxicity testing is required for all new compounds utilising 2D assays, such as the in 
vitro micronucleus (MN) assay, before moving to in vivo assays such as the rodent bone 
marrow MN assay. Two-dimensional cell culture has traditionally been used for in vitro 
research. However, the in vivo setting comprises a three-dimensional (3D) environment and 
within the bone marrow (BM), mesenchymal and haematopoietic stem cells interact 
together. It has been found that even though the in vitro MN assay is intended to be predictive 
of the in vivo BM, glucocorticoids were found to have an increased level of micronuclei in 
vivo than predicted within the in vitro MN assay, therefore these have been labelled 
pharmacological positives. As 3D cell culture has been shown to simulate the in vivo 
scenario more closely, the aim of the current study was to create a reproducible model of the 
BM, using cell lines, which simulates the level of genotoxicity and cytotoxicity seen with 
the in vivo setting, for eventual use of identifying the mechanism(s) by which this change in 
MN induction occurs.  
 
Initially, an appropriate scaffold was identified for the primary culture of the fibroblast cell 
line HS-5. Once evaluated, a pre-culture of HS-5 cells on the scaffold established a 
microenvironment suitable for later seeding of the TK6 cell line. Together with medium 
changes and optimised seeding a model was developed which supported an exponential 
phase of growth suitable for executing the MN assay in three-dimensions. Utilising this 
novel 3D model, TK6 cells were then dosed with known genotoxic positive (mitomycin c, 
etoposide and paclitaxel), negative (caffeine) and pharmacological positive (dexamethasone 
and prednisolone) compounds for induction of micronuclei in comparison to in vitro and 
historical in vivo data. 
 
The expression of 84 genes associated with metabolism was compared between 2D HS-5 vs 
3D HS-5 ± TK6 to identify if this may play a role in the induction of MN. Those expressed 
in 3D HS-5 ± TK6 were more comparable to the in vivo BM than those HS-5 grown in 2D. 
 
In conclusion, this 3D in vitro model simulates the induction of genotoxic and cytotoxic 
damage of compounds, seen within the in vivo BM, with more accuracy than the 
conventional 2D in vitro MN assay. This research provides a more in vivo relevant setting 
for further in vitro investigation of the mechanism behind compound toxicity allowing a safe 
drug discovery pathway.  
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1.1. Bone marrow 
 
Bone marrow (BM) is one of the largest human organs, accounting for 4-5% of total body 
weight (Torisawa, 2019). The BM is composed of cartilage, haematopoietic and fat 
containing marrow, connective tissues and a meshwork of thin-walled capillary veins upon 
a core of extracellular collagen matrix (ECM) (Andrews et al., 2013). These components fill 
the space of the trabecular ‘spongy’ bone, a lattice of fine bone plates which is surrounded 
by a protective barrier of ‘compact’ cortical bone (Zhao et al., 2011; Cordeiro-Spinetti et al., 
2015). It is an adaptive organ which changes in functionality due to increasing age but 
maintains the haematopoietic and immunological systems throughout its life (Karampinos 
et al., 2017). At birth the bone consists predominantly of haematologically active red 
marrow, however this is replaced gradually by yellow marrow consisting mainly of 
adipocytes. The conversion of red to yellow occurs over a 25-year period, primarily in the 
appendicular skeleton, leaving only the axial and long bones haematologically active in 
adults (Malkiewicz & Dziedzic, 2012; Hardouin et al., 2014). The red marrow gains its 
colouration from haematopoietic tissue islands which facilitates differentiation of 
haematopoietic stem cells (HSCs) (Seita & Weissman, 2010). These HSCs have the ability 
to self-renew and develop into mature blood cells of both the myeloid and lymphoid lineages 
(Figure 1-1) (Birbrair & Frenetic, 2016; Jagannathan & Zon, 2013). This differentiation 
called ‘haematopoiesis’ occurs in the space between the outer surface of the BM blood 
vessels and trabecular/ cortical bone, aided by the vascular or perivascular BM niche (Anaei 
& Catafal, 2018).  
 





Figure 1-1. Schematic representation of the progression of haematopoietic stem cells (HSC) into their differentiated 
myeloid and lymphoid progenitors. The CD markers which are present (+) and absent (-), associated with key stages in 
maturation, are highlighted and are common to all subsets. This figure is drawn by the author based on information from 




























































































1.1.1. The bone marrow microenvironment  
 
Differentiation and regulation of HSCs is thought to be regulated by the complex interplay 
of immature and terminally differentiated cellular components within an environment that 
only the BM microenvironment can provide such as, changes in oxygen tension, circadian 
rhythms and blood supply (Figure 1-2) (Tikhonova, 2019; Anaei & Catafal, 2018). The 
interaction between soluble factors, microRNAs, exosomes, extracellular matrix proteins 
and metabolism enzymes secreted from the array of cell types which populate the 
microenvironment ensure successful and intact haematopoiesis (Xu et al., 2018; Kumar et 
al., 2018; Duarte et al., 2018). In this hierarchical, self-amplifying, self-renewing ecosystem 
dwell a small number of mesenchymal stem cells (MSCs); ~1 in 3.4x104 cells (Wexler et 
al., 2003). These BM MSCs are multipotent, clonogenic, self-renewing stem cells which 
have the capacity to differentiate into osteogenic, chondrogenic and adipogenic derived 
cells, depending on expression of soluble factors which reside within the same perivascular 
niche as the HSCs (Figure 1-2) (Al-Nbaheen et al., 2013; Wu et al., 2018; Sasine et al., 
2016; Zhou et al., 2014; Kowalski et al., 2018). Residing upon the ECM lies a cellular 
population of MSC derived cells including endothelial, osteoblasts, adipocytes, fibroblasts, 
chondrocytes, macrophages and stromal cell lineages that make up the stroma of the BM 
(Figure 1-3) (Baryawno et al., 2019).   
 
The differentiated BM MSC lineages help support HSC self-renewal and multipotency by 
releasing chemokines, cytokines and metabolic enzymes into their surroundings creating a 
specialised haematopoietic perivascular niche (Abbuehl et al., 2017). Reticular cells, which 
cover and synthesise the ECM of the BM, abundantly express the C-X-C motif chemokine 
12 (CXCL12 also known as stromal cell-derived factor 1 (SDF1); Gomariz et al., 2018). 
CXCL12 mediates the mobilisation, homing and retention of HSCs to the BM 
haematopoietic niche for differentiation into differing blood lineages (Yi et al., 2019; Zhang 
et al., 2016; Janssens et al., 2018). This is achieved through the binding of CXCL12 to C-
X-C chemokine receptor 4 (CXCR4) present on HSCs, stimulating the dissociation of 










Figure 1-2. Schematic model of the bone marrow microenvironment. The schematic shows a selection of common cell 
types found within the bone marrow, which interact through soluble factors to regulate and repopulate the blood system 
and bone marrow microenvironment. The perivascular niche (high oxygen level which contains vascularity) and the 


























Figure 1-3. A schematic representation of the development of mesenchymal stem cells (MSC) through commitment, 
progression, differentiation and eventual maturation into their specific lineages and eventual tissues. The CD 
markers which are present (+) and absent (-), associated with primary uncommitted MSCs, have also been highlighted.  
This figure is drawn by the author based on information from Firth & Yuan, (2012); Kalinina et al., (2011); Maleki et al., 
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Once HSCs have homed to the BM stroma, fibroblast and endothelial cells start to express 
the cytokine stem cell factor (SCF) (Li & MacDougald, 2019; Antony & Link, 2014; Addo 
et al., 2019). SCF binds to the type III receptor tyrosine kinase (c-KIT) which is found on 
the membrane of many cell types including HSCs and MSCs in the BM stroma (Ho et al, 
2017; Czarna et al., 2017). This binding promotes a signalling cascade which causes the 
proliferation of HSCs only, as c-KIT expression is lost after differentiation with around only 
1% of peripheral blood cells expressing it (Babaei et al., 2016). Once residing within the 
perivascular BM niche, HSCs differentiation can occur. The stromal cells release interleukin 
7 (IL-7), which will lead HSCs down the lymphoid lineage. This cytokine is critical for the 
development of B and T lymphoid cells and is released in response to feedback loops 
(Rodrigues et al., 2018; Yang et al., 2018). To replenish the myeloid lineage, BM epithelial 
and fibroblasts release interleukin 3 (IL-3) and granulocyte-macrophage colony stimulating 
factor (GM-CSF) into the BM niche (Wittwer et al., 2017; Beecher et al., 2016; Ushach & 
Zlotnik, 2016).  
 
It is this delicate interaction between the BM microenvironment and HSCs which provide 
the fundamental structural and functional support for healthy human life. Deletion, mutation 
or disruption of the genes which encode any of the cellular proteins and pathways above, 
can lead to varying disease states (Turner et al., 2018). The loss or alteration of the CXCL12 
gene from expressing stromal cells, results in a decrease in long-term repopulation activity 
of HSC. This lack of repopulation of the blood and lymphatic system can lead to primary 
bone marrow failure (Greenbaum et al., 2013; Risitano et al., 2007). Likewise, a loss of 
function mutation to the SCF gene again causes HSC numbers to decrease and eventually 
deplete from the BM leading to complete primary bone marrow failure requiring an 
immediate bone marrow transplant (Ding et al, 2012). The c-KIT gene codes for the c-KIT 
receptor for SCF, and is an example of a proto-oncogene. The receptor for SCF, c-KIT is an 
example of a proto-oncogene. The deregulation of c-KIT through gain/loss- of function 
mutation, due to chromosomal damage, is correlated with cancer (Babaei et al., 2016; Wang 
et al., 2018; Foster et al., 2018). Similarly, loss of function mutation caused by single 
nucleotide substitutions in the IL-7 gene, is associated with autoimmunity disorders 
(Lundstrom et al., 2012). A gain-of function mutation of the IL-3 gene causes an 
overexpression of the ligand seen in patients with haematological malignancies (Borriello et 
al., 2019; Schreiber et al., 2019). 
 
 





The BM, as described above, is an active organ constantly replenishing cells of the blood 
and BM microenvironment through the release of soluble factors in order to maintain a 
healthy system. Therefore, is extremely sensitive to toxic insults (Robin & Durnad, 2010; 
Weng et al., 2016). As described previously, induced DNA damage to any one of these cell 
lineages causes an alteration in the soluble factors released within the BM microenvironment 
which can have a devasting effect on the human. The vulnerability of this organ to toxic 
insults affecting the DNA, makes it an appropriate organ for assessing new drug compounds 
for their ability to induce alteration in the DNA. In order to predict the outcomes of a 
compound on cells of the BM pharmaceutical companies employ cell lines of the BM, 
expose these to concentrations of new compounds and assess the induced damage in a 
discipline of toxicology called genetic toxicology. If a compound does cause alterations in 
the DNA of the BM cell line, that compound is noted as being genotoxic.  
 
1.2. Genetic toxicology 
 
Toxicology encompasses many different disciplines including, but not limited to, cardiac, 
hepatic, respiratory, gastric and genetic. Testing for these different safety liabilities is 
conducted throughout the drug development process (Figure 1-4; target selection through to 
phase launch), in an effort to treat patients quickly, by early identification and elimination 
of drug candidates that will ultimately fail due to toxicity (Hornberg et al., 2014). To identify 
potential compounds that have a detrimental effect on DNA (not as their intended effect), 
pharmaceutical industries have utilised genetic toxicology. Genetic toxicology is the study 
of the genetic alterations that may occur in somatic and/ or germ cells, including exposure 
to chemical compounds. A chemical compound could induce changes in DNA through 
indirect and/ or direct mechanisms in DNA replication (Hasselgren et al., 2019).






Figure 1-4. The drug development process within industry and where toxicology including genetic toxicology is located within this. GLP (good laboratory practice).  









Toxicology (including genetic toxicology)





1.2.1. Types of genotoxic DNA damage. 
 
The exposure of DNA to a genotoxic compound can result in DNA damage and/or 
mutational events, like those seen in Figure 1-5, where the corresponding repair pathway is 
unable to resolve the damage. Single strand breaks (SSB) within the DNA are the most 
frequent form of damage and are resolved via the base excision repair (BER) pathway which 
can also resolve small alkyl or oxidative lesions (Caldecott, 2008). A SSB occurs when one 
strand of the DNA duplex is separated, usually accompanied by the loss of a single 
nucleotide and damage at the 5′- and /or 3′- end of the site break (Eustermann et al., 2015). 
The SSB, consisting of 3′-hydroxyl and 5′-deoxyribose phosphate ends, is identified by the 
corresponding damage-specific protein. These convert the 5′- and /or 3′- termini into 5′-
phosphate and 3′-hydroxyl ends, allowing the inclusion of a short (single nucleotide 
replacement) or long-patch (2–10 new nucleotides are inserted) (Wallace, 2014). 
The most dangerous genotoxic lesion occurs through the formation of double strand breaks 
(DSB). A DSB arises when both strands of the DNA duplex are cut, promoting potentially 
lethal chromosomal rearrangements (Wright et al., 2018). The two repair mechanisms that 
can be implemented in the repair of DSB are homologous recombination (HR) and non-
homologous end joining (NHEJ) with each differing in fidelity and template requirements. 
The HR pathway employs an undamaged homologous chromosome as a template, leading 
to an error free replication of the original sequence. In contrast, NHEJ cleaves the 5′- and 3′- 
termini and ligates them to each other regardless of homology leading to deletions and /or 
insertions (Piers et al., 2017; Davis & Chen, 2013). 
 
The formation of crosslinks, either intrastrand (between bases on the same strand) or 
interstrand (between bases on opposite DNA strands), can be extremely toxic to cells. The 
formation of a usually irreversible covalent interstrand crosslink prevent the separation of 
DNA, halting replication. However, intrastrand crosslinks residing only on one strand are 
less toxic as DNA polymerases can bypass this lesion on the unaltered strand (Deans & 
West, 2011). Similar to crosslinks, the formation of bulky adducts within the DNA halts 
replication, resulting in an increase in mutagenic and carcinogenic potential. An adduct is 
the result of an electrophilic chemical compound (e.g. polycyclic aromatic hydrocarbon) 
covalently bonded to the nucleophilic site in DNA (Ewa & Danuta, 2017). The repair of 
crosslinks and adducts utilises nucleotide excision repair. First the DNA lesion is identified, 
incisions made either side, the affected oligonucleotide removed, a new sequence is then 




synthesised using an undamaged complementary strand and ligated into the original 
sequence allowing replication to continue (Spivak, 2015; Huang et al., 2016). Finally, single 
nucleotides can be mutated, substituted, deleted or inserted, which can occur de novo as well 
as a consequence of a compound. In general, these alterations can be resolved via the 
mismatch repair pathway (MMR). The MMR pathway identifies mismatched nucleotides 
after the formation of a new DNA strand, HR or replication, cuts are made either side of the 
mismatch which is removed followed by ligation of a complementary nucleotide into the 
sequence (Marinus, 2012). 
 
Hence, for a novel compound to be approved by regulatory bodies for use around the world, 
pharmaceutical companies must follow a strict regulatory drug development process to 
assess a compound’s ability to produce these DNA lesions. If these lesions are not resolved 
adequately by their associated pathways, this may lead to unintended outcomes which could 
cause carcinogenicity. Therefore, pharmaceutical companies must identify any potential risk 
a compound may have before assessment within in vivo subjects is conducted. 
 
 
Figure 1-5. Differing types of DNA damage that can occur as a result of drug interaction. This figure has been adapted 


































1.2.2. Regulatory testing of new compounds 
 
Genetic toxicology is a key part of the safety assessment of new compounds in order to 
assess any carcinogenic risk they may possess. This testing is required for all compounds 
including oncology drugs, but due to their intended use are governed by a separate regulation 
put forward by the International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) (ICHS9, 2009). Compounds recognised to have this 
inherent liability will not be allowed to progress into healthy volunteers or patients and are 
tested for evidence of genotoxicity throughout the whole development process from target 
selection to phase I clinical trials. To assess this risk within new compounds, governing 
bodies have put forward criteria in helping meet governmental regulatory requirements. The 
ICH has produced two options (Table 1-1) which incorporates individual in vitro (Table 1-2) 
and in vivo (Table 1-3) assays to produce a battery of tests (Nesslany, 2017). In order for 
each test within this strategy to meet governing regulations around the world, the 
Organisation for Economic Co-operation and Development (OECD) has created a set of 
guidelines. These guidelines are used by pharmaceutical companies to meet the requirements 
of the ICH. The pharmaceutical company AstraZeneca (AZ) has adopted option one (as it 
reduces unnecessary testing in animals) and routinely utilises the Ames assay, the in vitro 





















Table 1-1. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human 
Use (ICH), strategies for genotoxicity test batteries (ICH, 2011) 
 Test regime 
 i ii iii 
Option 1 A gene mutation 
test in bacteria 
(Ames test). 
A cytogenetic assay 
e.g. the in vitro micronucleus 
assay 
An in vivo genotoxicity 
assay 




Option 2 A gene mutation 
test in bacteria 
(Ames test). 
An in vivo assay in two 
differing tissue types e.g. 
micronuclei induction in 
rodent haematopoietic cells 
and an in vivo mammalian 
























Table 1-2. An overview of standard in vitro genotoxic assays conducted by pharmaceutical companies (in accordance 
with regulatory guidelines) (Corvi & Madia, 2017).  









Reverse mutation of 
the artificially mutated 
-/- histidine gene. 










A forward mutation in 
the thymidine kinase 
(TK) locus of ± 
lymphoma cells.  










The induction of 
micronuclei separate 
from the main nucleus. 









Single/ double strand 
breaks in DNA, 
quantified through 
amount of fragmented 
DNA  electrophoresed 
from the point of origin 
under alkaline 
conditions. 






CHO (Chinese hamster ovary), CHL/IU (Chinese hamster lung), TK6 (human lymphoblast), L5178Y (mouse lymphoblast) 









Table 1-3. An overview of standard in vivo genotoxic assays conducted by pharmaceutical companies (in accordance 
with regulatory guidelines) (Corvi & Madia, 2017) 
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electrophoresed from 
the point of origin 
under alkaline 
conditions. 
















The induction of 
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from the main 
nucleus. 














1.2.2.1. In vitro/ in vivo micronucleus assay 
 
The micronucleus (MN) assay is used to identify DNA damage in actively proliferating cells 
and is most commonly used in pharmaceutical studies. During normal mitosis two daughter 
cells are produced each with a full complement of chromosomes in their nucleus. If a 
compound has a genotoxic effect, the daughter cell may lose genetic material producing a 
secondary smaller ‘micro’ nucleus (Figure 1-6) (Rodrigues et al., 2018). Depending on the 
mechanism of action of the compound the MN may contain fragments of, or whole 
chromosomes, which have separated from the main nuclei leading to possible 
carcinogenic/mutagenic events (Smart et al., 2019). The in vitro MN assay utilises a single 
cell culture (either human or rodent) and is conducted within a 48 hour timescale (24 hour 
treatment & 24 hour recovery). If the compound is thought to be a pro-drug then the rat liver 
fraction (S9) is added at drug administration. In order to produce the S9 fraction, rats are 
treated with aroclor 1254 or phenobarbital to induce phase 1 drug metabolism enzymes such 
as the cytochrome P450 (CYP) family by the liver, from which the S9 fraction is taken. More 
specifically, aroclor 1254 or phenobarbital increases the expression of CYP1A and CYP2B 
isozymes but decreases the expression of CYP2C or CYP2D within the S9 fraction. 
However, as the S9 fraction is cytotoxic to cells, the testing regime is reduced to a 24-hour 
period (3hr treatment and 21-hour recovery) (Kishino et al., 2019).  
 
The in vivo MN assay conducted within the in vivo BM, utilises the development of 
proliferating erythrocytes in rodents to visualise this damage. Erythrocytes have no nucleus 
as it is extruded when the erythroblast matures. If a compound is genotoxic, when the nucleus 
is extruded, a MN can be clearly visible within the erythrocytes with no main nucleus (Figure 
1-6 B). The visualisation of MN can give an indication of the level of genotoxicity the 
compound induces in vivo (Hayashi, 2016).  
 





Figure 1-6. The in vitro and in vivo micronucleus assay. The in vitro assay (A) was performed in L5178Y cells with the 
white arrows identifying micronuclei. The in vivo assay (B) utilised cells from the bone marrow of rodents with the white 
arrow highlighting a micronucleus within an erythroblast (Images provided by AstraZeneca). 
 
1.2.2.2. The mechanism by which clastogenic and aneugenic compounds 
induce genotoxicity and their use in the in vitro and in vivo MN assay 
 
The MN assay, both in vitro and in vivo, are used to identify compounds which induce gross 
structural damage to DNA which could be the result of clastogenic or aneugenic events 
(Figure 1-7). A clastogenic compound affects the DNA directly by causing sections of the 
chromosome to be deleted, duplicated and rearranged through fragmentation (Chondrou et 
al., 2018). A clastogenic compound will produce a MN with no centromere and daughter 
cells with a full complement of chromosomes but with shortened p/q arms (Hasselgren et 
al., 2019). Conversely, an aneugenic compound doesn’t affect DNA directly, instead it 
disrupts the cellular mechanisms around mitosis (specifically metaphase) such as disruption 
in spindle formation or inhibition of mitotic kinases resulting in chromosome lagging 
(Bernacki et al., 2019). An aneugenic compound should produce a MN with a centromere, 
due to whole chromosome loss, and daughter cells with aneuploidy (Santovito et al., 2018). 
As part of new compound assessment and validation, it is important to compare each new 
drug with a known well characterised genotoxic compound. Due to their genotoxic potential 
both clastogenic and aneugenic compounds are used as positive controls within the MN 
assay. 
A B 





Figure 1-7. Mechanism by which clastogenic/ aneugenic compounds interrupt cellular mitosis inducing 
micronuclei and aneuploidy within daughter cells. This figure was drawn by the author with information provided 
from Kishino et al. (2019). 
 
In order to measure the capability of a new compound to induce DNA damage using the MN 
assay, known clastogenic drugs including, but not limited to, mitomycin C (MMC), 
etoposide, 4-nitroquinoline 1-oxide (4NQO), cyclophosphamide (CPM) and benzo[a]pyrene 
(BaP) are used as a positive control routinely, with CPM and BaP requiring metabolic 
activation. A known aneugenic compound used in regulatory genetic toxicology is paclitaxel 
(Heard et al., 2017). However, each compound above regardless of its clastogenic or 
aneugenic effect, has a different mechanism of action by which DNA damage is produced 
and MN created.  
 
The antitumor antibiotic MMC, isolated from Streptomyces caespitosus, is used in the 
treatment of breast, stomach, colon, anal and bladder cancers (Amer et al., 2018; Fang et al., 
2018). This antineoplastic compound exerts its therapeutic effect by inducing inter-strand 
crosslinks that alkylates double stranded DNA. The interstrand crosslinks produced between 
opposite deoxyguanosine residues at CpG sites, inhibit cell mitosis by blocking DNA 
synthesis leading to highly genotoxic DSBs (Ma et al., 2013; Arranz-Marquez et al., 2019; 
Lev et al., 2017; Deans & West, 2011). Etoposide, a topoisomerase-II (TopoII) inhibitor 
derived from Podophyllum peltatum, is also used as an antineoplastic in lung, lymphoma, 
gastric, breast and testicular cancers (Qiu et al., 2019). The TopoII enzyme uncoils DNA by 
Aneugen
Spindle inhibition







Micronucleus with centromereMicronucleus without centromere




cutting both strands of the DNA helix simultaneously, causing DSB. The TopoII in the 
second step of the reaction re-ligates each strand of the DSB (Montecucco et al., 2015). 
Etoposide exerts its therapeutic effect by binding to the TopoII cleavage complex attached 
the DSB. This binding stabilises the complex, inhibiting re-ligation and maintaining the DSB 
causing genotoxic and cytotoxic damage (Mehta et al., 2018). The clastogen, 4NQO, is 
widely used in the study of DNA damage and repair to generate mutants for genetic screens 
(Downs et al., 2014). It is a water-soluble quinoline derivative which forms stable bulky 
adducts on purines, primarily at the N2/ C8 positions of guanine and N6 position of adenine, 
leading to base pair substitution which in high numbers and left unrepaired, induces damage 
(Wang et al., 2016; Brusehafer et al., 2016). 
 
Those compounds requiring metabolic activation include the pro-drug CPM, which is an 
alkylating agent used in the treatment of breast cancer, multiple myeloma and renal disease 
(Teles et al., 2017). It is activated to its cytotoxic form, phosphoramide mustard (PM), by 
the CYP450 enzymes CYP2B6, 2C19, 3A4 and 2C9 via oxidation of CPM (Kurauchi et al., 
2017). The resulting PM alkylates the N-7 position of guanine and forms phosphotriester 
monoadducts, N-7 monoadducts and N-7-guanine-N-7 guanine interstrand crosslinks. It is 
these crosslinks that block replication leading to DSB and cytotoxicity (Johnson et al., 2012; 
Ganesan & Keating, 2015). The polycyclic aromatic hydrocarbon, BaP (formed through the 
process of incomplete combustion), also requires metabolic activation via the CYP450 
enzymes (specifically CYP1A1, 1A2, 1B1 and to a lesser extent 2C9 and 3A4) to exert its 
clastogenic effect (Hardonnière et al., 2016; Reizer et al., 2019; Loss & Yu, 2018). The 
bioactivation of BaP requires CYP dependent epoxygenation to 7,8-dihydrodiol-9, 10-
epoxide (BPDE). BPDE then reacts with DNA at the N2 position of guanine to producing 
an adduct at this location leading to a block in replication and DSB (Arlt et al., 2008; Siddens 
et al., 2012; Liamin et al., 2017). The aneugenic compound paclitaxel, naturally produced 
in the bark and needles of Taxus brevifolia, is used in the treatment of ovarian, breast and 
lung cancers (Stage et al., 2018; Zhu & Chen, 2019). It exerts its therapeutic effect by 
promoting and stabilising the assembly of microtubules during mitosis. This stabilisation of 
the a and b tubulin, that make up the spindle microtubules, reduces their attachment to the 
kinetochores of the chromatids. This in turn activates a signal cascade that delays mitotic 
progression leading the cell into arrest. If this cascade doesn’t activate, uneven separation of 
chromosomes occurs leading to aneuploidy (Weaver, 2014). These compounds have been 
tested within both the in vitro and in vivo MN assay routinely with both tests coming back 
positive for genotoxicity. However, compounds can return a positive result for genotoxicity 




in vivo but negative in vitro with no obvious clastogenic or aneugenic mechanism and thus 
are called pharmacological positives.  
 
1.2.2.3. Pharmacological positives  
 
Whilst this fundamental MN in vitro assay is meant to be predictive of the in vivo 
environment, AstraZeneca (AZ) noted that 16 out of 21 compounds in the last 10 years were 
positive in the in vivo MN assay but negative in the in vitro MN assay (Ponten et al., 2013). 
Studies within the company found that known non-genotoxins such as glucocorticoid 
receptor (GR) agonists, gave a weak in vivo positive but were negative in vitro. Steroids of 
this nature, such as dexamethasone and prednisolone (used to reduce the formation, release 
and activation of inflammatory cytokines), have been on the market for a long period of time 
with no carcinogenic effect (WHO, 2019). Glucocorticoids (named for their effect on 
carbohydrate metabolism) are a class of corticosteroid (steroid hormones) that bind to 
glucocorticoid receptors and are generally used as anti-inflammatory agents (Kameyama et 
al., 2018). They can be used to treat asthma, allergies, septic shock, arthritis, inflammatory 
bowel disease and multiple sclerosis (Ramamoorthy & Cidlowski, 2016). The glucocorticoid 
receptor-glucocorticoid complex up-regulates the production of inflammatory proteins via 
transactivation and inhibits the production of proinflammatory proteins via trans-repression 
(Paragliola et al., 2017; Rhen & Cidlowski, 2005). Prednisolone is a short acting synthetic 
anti-inflammatory glucocorticoid which is four times more potent than cortisol. 
Dexamethasone, a long-acting synthetic anti-inflammatory glucocorticoid, however, has an 
affinity to its receptor seven times greater than prednisolone suppressing 
adrenocorticotrophic hormone levels (Ponticelli & Locatelli, 2018).  
 
As these GR agonists are only synthetic versions of naturally occurring steroid hormones 
within the body, questions have been asked over the mechanism by which these compounds 
are giving an in vivo positive. One hypothesis is that the compound is influencing cellular 
processes, such as increased production of erythrocytes, rather than directly affecting DNA 
synthesis and causing a genotoxic event (Hayes et al., 2013). Tweats et al. (2007), found 
when reviewing the literature that physiological disturbances could alter the induction of 
MN within the rodent BM. The review found that changes in the core temperature (hypo- 
and hyperthermia) caused an increase in MN formation. The in vivo BM, however, is a 
complex, 3D environment (as stated above), and may be the key to unlocking the true 
mechanisms behind pharmacological positives. 





1.2.3. The protective role of the bone marrow microenvironment 
 
The BM stroma is a metabolically competent system, and has been seen to express drug 
metabolising enzymes, including those of the CYP family involved in the oxidation, 
reduction, hydrolysis, hydration, conjugation, condensation or isomerisation of drug 
compounds and has been hypothesised as the cause of resistance and altered MN induction 
of compounds (Alonso et al., 2015; Li et al., 2016; Jeong et al., 2009; McDonnell & Dang, 
2013). The key cytochrome P450 enzymes expressed by the stroma include: 
 
• CYP1A1: Involved in the oxidation of polycyclic aromatic hydrocarbons (PAH) to 
their carcinogenic state (Manzella et al., 2018). 
• CYP2B1: Involved in the hydroxylation of oxazaphosphorine such as CPM into the 
carcinogenic metabolite PM (Salazar et al., 2018). 
• CYP2D6: Metabolises and eliminates ~20% of over-the-counter drugs including 
codeine, amitriptyline, fluvoxamine, risperidone, fluoxetine, aripiprazole, paroxetine 
and dextromethorphan via hydroxylation, demethylation and dealkylation (Pan et al., 
2017). 
• CYP3A4: Involved in the oxidative metabolism and mainly detoxification of ~30-
40% of marketed drugs including antibiotics (erythromycin), antidepressants 
(diazepam) and steroids (testosterone). The expression of the enzyme has been seen 
to increase with the use of glucocorticoids (Fang et al., 2017). 
 
The cells used within the 2D in vitro MN assay (TK6 and L5176Y) do not express the 
CYP450 enzymes neither do they express the soluble cytokines and chemokines denoted 
previously within the BM (Revollo et al., 2016). Therefore, in order to incorporate these 
soluble factors into a regulatory assay, to identify the mechanism behind alteration between 
the in vitro and in vivo results, a more in vivo relevant assay is required which combines 











1.3.  The need for 3D modelling  
 
1.3.1. 3D vs 2D cell culture 
 
For over a decade, 2D platforms consisting of a monoculture of cells within a plastic flask, 
have been used in genetic toxicology to assess a compound’s initial genotoxicity 
(Chaicharoenaudomrung et al., 2019).  These assays are easy to use, cheap, reproducible 
between laboratories and widely accepted by the governing bodies, however, they do not 
reflect the tissue architecture (e.g. ECM), cell-cell contact, change in oxygen content 
(hypoxia) and cellular necrosis seen in vivo (Riedl et al., 2017; Lee et al., 2019; Anton et 
al., 2015). A 3D cell culture system is an artificial environment (fluidics and bioreactors) 
which was brought about to try to simulate the in vivo setting, where multi/co-cultured 
cells can interact with one another upon an artificial (hard or soft man-made)/ self-
constructed (spheroid or organoid) scaffold in three dimensions (Huh et al., 2011). The 
current published literature has shown that the morphology/ physiology, proliferation, drug 
exposure and gene expression of cells differ between simple 2D and 3D cultures (Rocha et 




















Table 1-4. An overview of cellular characteristics seen in simple 2D and 3D cultures. Adapted from Edmondson et al. 




Morphology Adherent cells form a mono-layer 
sheet along the bottom of the flask, 
they appear to be stretched and 
irregular when compared to the in 
vivo environment. 
Cells have begun to proliferate into a 
natural, spheroid structure around the 
aggregate. 
Cells are less stretched and appear 
more like the in vivo counterpart.  
  
Proliferation Cells will proliferate faster, as the 
culture conditions are kept stable 
for all cells (5% CO2, 36oC) and 
medium can flow freely. 
Cells proliferate at a reduced rate due 
to differing niches developing within 
the culture (hypoxic/ vascular) and 
access to medium. 
Exposure As the cells are sitting as a 
monolayer or free floating, every 
cell is equally exposed to the 
medium/ drug.  
The medium/ drug may not be 
distributed to all cells especially in 
large spheroid cultures where the core 
is tightly surrounded. 
Sensitivity As the compound is applied 
directly to the cells the drug can be 
seen as extremely effective. 
As the drug cannot reach all cells 
within the culture its effects are 
reduced, this is similar to responses 
found in vivo.  
Expression 
(Gene/ Protein) 
Cells have a change in the 
expression of genes related to 
adherence and morphology 
compared to in vivo. 
Gene and protein expression directly 
correlate with that seen in the in vivo 
setting.  
 





In a traditional 2D assay, adherent cells form a monolayer on a flat plastic surface. These 
cells are allowed to spread, only hindered by the size of the plastic surface, therefore 
increasing dramatically in size compared to their in vivo counterparts. This morphology 
allows a greater surface area of cells to receive homogenous amounts of nutrients, growth 
factors and compound (Jensen & Teng, 2020). Conversely within a 3D system, cells are 
diffused throughout with cellular projections wrapped around an artificial matrix. The 
distribution throughout the 3D system can reduce oxygen levels leading to hypoxic regions 
as is the case in vivo. This can change gene expression, with hypoxic cells upregulating genes 
in aerobic glycolysis, lactic acid production and E-cadherin whilst in the same culture as 
normoxic cells (Nath & Devi, 2016). This change in morphology impacts the organisation 
and distribution of structures within the cell affecting secretion, cell signalling, cell cycle 
and response to external stimuli (Kapałczyńska et al., 2018; Lee et al., 2019). This gradient 
of factors throughout the system leads to cells of differing stages of lineage, unlike 2D, with 
upregulation of stemness markers such as CD133, Oct4, Sox2, Nestin, MSI1, MSI2, BMI-1 
and c-Myc which have a marked effect on proliferation (Bodgi et al., 2019; Jia et al., 2018).  
 
In static 2D culture, the monolayer of cells will only proliferate to the size of the vessel they 
are in. Proliferation will then cease once contact-inhibition has developed, unlike 3D, where 
the scaffold on which the cells sit has a larger surface area for expansion and hence allows 
for a longer culture time (Khurshid et al., 2018; Li et al., 2017). The expression of N-
cadherin has a marked increase in 3D compared to 2D signifying a greater cell-cell 
interaction (Zhou et al., 2017). However, due to the larger surface area and distribution of 
factors throughout 3D cellular cultures, the proliferation rate decreases compared to 2D, 
signified by a decreased expression of the proliferating cell nuclear antigen protein marker, 
but this decrease in proliferation rate aligns with the in vivo environment (Souza et al., 2018; 
Edmondson et al., 2014). This reduction in proliferation has been found to increase integrins 
such as b1 and b4 which serve as in vivo markers of polarisation and differentiation (Duval 
et al., 2017; Zhou et al., 2017). The change in morphology, distribution and proliferation 
affects the exposure and how sensitive a cell is to a compound.  
 
As already mentioned, the distribution of cells throughout a 3D system and use of an 
artificial matrix (ECM) has an effect on a compound’s toxicity, showing an increased 
resistance to such drugs as dacarbazine and cisplatin (Fontoura et al., 2020). The 
bioavailability of the compound to cells throughout the system appears as a key source of 




resistance and can be greatly increased by several factors (Lee et al., 2018). Firstly, 
depending on the artificial matrix or the introduction of flowing medium, the compound can 
be taken up and retained, irreversibly, by the matrix reducing the concentration delivered to 
cells (Casey et al., 2016). Secondly, those cells closest to the core of an artificial matrix have 
little to no uptake of the compound, unlike the outer layer of cells and those grown in 2D, 
which have a direct high dose (Kim et al., 2019). Finally, within a 3D co-culture system, 
cellular enzymes such as the CYP450 family have an upregulation in detoxification genes 
such as GJB6, AKR1C1, CYP1A1 and 1B1 reducing a compound’s toxicity before it reaches 
the cells of interest similar to that seen within the in vivo BM (Langhans, 2018; Schmidt et 
al., 2016).  
 
The changes in morphology/ physiology, proliferation, drug exposure and gene expression 
between a 2D and 3D culture can be seen above, with the method of 3D culturing being the 
fundamental factor in the changes seen between 3D and 2D.  
 
1.3.2. Common 3D culture methods used within supplementation systems 
 
Within 3D culture systems several differing methods are used in order to create a 3-
dimensional platform for which the cells can adhere and interact. These include, but are not 
limited to, scaffold free self-constructing spheroids, soft hydro-gels, prefabricated hard 
scaffolds (Table 1-5) and 3D bioprinting.





Table 1-5. Overview of current matrices for 3D culture. Extracellular matrix (ECM). 
Scaffold overview Advantages Disadvantages Example References 
Spheroids - Cells cultured into a 3D spheroid 
with cells proliferating out from a 
central core. 
- Can be achieved utilising the 
hanging drop method, multi-well 
plates, spinner flasks and matrix 
embedded.  
- Can recreate specific organ 
functions (liver). 
- Can be used for cancer modelling. 
- Easy to produce even in high 
throughput. 
- Can be recreated in a wide range of 
adherent cell types.  
- Drug may not reach the centre 
in larger spheroids.  
- Hypoxic core in large 
spheroids. 
- No ECM for cells to adhere and 
interact with. 
- Studies limited by spheroid 
size.  
 
Fennema et al. (2013) 
Verjans et al. (2017) 
Lin & Chang (2008) 
Chen et al. (2019) 
Hydrogels - Material with >99% water by 
volume. 
- Contains a diluted polymer and 
cross-linking agent. 
- Structure given by the induction of 
intermolecular crosslinks. 
- Can be found in nature (collagen, 
Matrigel, alginate) or be synthetic.  
- Fluid environment can protect cells 
and drug.  
- Mimics ECM. 
- Gel can be infused with cells/ 
cytokines etc. 
- If the gel is naturally found in the 
body (collagen) more in vivo 
relevant. 
- Can be chemically degraded to 
retrieve cells. 
- Can be mechanically weak if 
not adequately crosslinked. 
- Hard to manipulate. 
- Time consuming due to loading 
cells into the gel itself. 
- Difficult to sterilise. 
- Cells can die if cross-linker 
concentration is too strong. 
 Worthington et al. 
(2015) 
Weber et al. (2006) 
Chirani et al. (2015) 




- Fabricated from a wide range of 
materials such as metal, ceramic, 
glass and polymers (PCPU) each 
with differing properties. 
 
- Strong rigid scaffold which is easy 
to handle and sterilise. 
- Mimics ECM. 
- Each scaffold is uniform to the next 
as microspores aren’t chemically 
induced.  
- Hard to get all cells out of the 
scaffold. 
- Scaffold could chip or break. 
- Cells cannot be incorporated 
into the scaffold itself. 
 











1.3.2.1. The use of scaffold free spheroids for 3D culture 
 
The spheroid is a self-assembling aggregate of adherent cells, binding together to form a 3D 
structure without the need for an artificial scaffold at its core (Zuppinger, 2019). Due to the 
cell-cell contact and morphology formed within a spheroid, alterations in metabolism and 
signalling pathways are unaltered, unlike in a 2D culture where cells are spatially separated 
and flat against the plate. Spheroids can be manufactured using several different methods as 
indicated by Sant & Johnston (2017): 
 
• Matrix embedded/ encapsulated: A small aggregate core of cells is suspended into a 
medium such as agarose, Matrigel or hydrogel and allowed to proliferate over time 
around the core. 
• Ultra-low attachment plates: Cells are added to culture plates with a non-adherent 
surface to prevent them adhering to the plate, they instead adhere to one another. 
Similar to a spinner flask, a gyrating plate can be used to ensure that cells only 
adhere to one another. 
• Hanging drop: A cellular population in medium is added as a single drop to a plate. 
The plate is then inverted or forced through a micropore creating a hanging drop. 
This drop utilising gravitation force to congregate the cells at the tip, with nothing 
to adhere to, cells instead adhere to one another. 
 
The most common spheroid in use utilises human hepatocytes (HepG2 cells) in order to form 
an artificial liver structure. The liver spheroid has been found to have increased expression 
of CYP450 enzymes, which is maintained over a 35-day period, when compared to that of 
the 2D counterpart (Kozyra et al., 2018). However, spheroid size needs to be tightly 
controlled depending on the eventual outcome needed from the assay. A 48 hour long culture 
can generate a small spheroid (200µm in diameter) of a uniform size and homogeneity, a 
culture time of > 4 days will generate a large heterogeneous spheroid (>500 µm in diameter). 
As cells expand from the core and the spheroid becomes larger, the gradient of oxygen and 
nutrients reduces to the core. Larger spheroids (>500 µm in diameter) become hypoxic and 
then necrotic at the core producing a spheroid consisting of cells of different proliferation 
kinetics, thereby making these suitable for pathophysiological studies only (Nath & Devi, 




2016). Due to the limit on cell number and size required with spheroids, the use of artificial 
scaffolds has been seen as more beneficial but still with limitations. 
 
1.3.2.2. The use of hydrogels and prefabricated hard scaffold for 3D 
culture 
 
Hydrogels are soft and elastic structures, typically made of 98-99% aqueous media, 
consisting of a dilute polymer or naturally occurring protein which is crosslinked to form a 
rigid scaffold (Anderson et al., 2015). Hydrogels can be produced using many differing 
materials, depending on the assay, including but not limited to: 
 
• Gelatin-methacryloyl (GelMA): GelMA is a hydrogel obtained by the derivatisation 
of biocompatible gelatine with methacrylic anhydride, resulting in modification of 
lysine and hydroxyl residues with methacrylamide and methacrylate side groups. The 
GelMA hydrogel is then subjected to ultraviolet light (UV) which initiates 
polymerisation resulting in covalent crosslinks producing a gel which is transparent 
and stable at physiological temperatures. However, due to the use of UV light, cells 
cannot be incorporated into the gel before crosslinking (Pepelanova et al., 2018) 
• Matrigel: Matrigel is a natural, reconstituted basement membrane-derived extract 
secreted from the Engelbreth-Holm-Swarm mouse sarcoma tumour. Cells are 
incorporated into the matrix and left to proliferate over time however, due to its soft 
gelatinous nature Matrigel is hard to manipulate long term (Nguyen-Ngoc et al., 
2014) 
• Alginate: Alginate, naturally found in the cell walls of brown algae, is a linear 
polysaccharide. It can be crosslinked via chelation of divalent cations such as 
calcium chloride and can also be fully dissolved. The resulting hydrogels can 
encapsulate cells, without damage, for long term cell culture (Armstrong et al., 
2016). 
 
The new field of bioprinting can incorporate these hydrogels, in the form of bioinks, with 
and without the inclusion of cells, growth factors and signalling molecules into a scaffold 
with exact pore sizes in any design or shape to suit the assay needs (Kim et al., 2019). 
Hydrogel materials, before crosslinking, such as gelatine, collagen, HA and alginate, are 
added as semi-solid bioinks into the 3D printer (Jia et al., 2016). The bioink is then deposited 




onto the printing bed layer-by-layer utilising a micro-extrusion printing nozzle (Berg et al., 
2018). The bed is heated to 37 oC so that the bioink semi-solidifies on contact before the 
addition of further layers. Once printed the semi-solid structure can be crosslinked with the 
relevant agent (Cidonio et al., 2019). As hydrogels require some form of reaction to create 
a rigid structure and the structure may not last prolonged culture, prefabricated solid 
scaffolds have also been seen as an alternative 3D matrix. 
 
Prefabricated solid scaffolds do not require chemical or enzymatic crosslinking in order to 
create a scaffold, instead they are usually made out of solid, man-made materials and arrive 
ready to use. Due to this, cells cannot be incorporated into the scaffold itself but only adhere 
to it. However, as these are mass manufactured from man-made materials, pore-size, total 
size and rigidity is kept constant (Salerno et al., 2019). These types of scaffold can be made 
utilising, but not limited to, materials such as hydroxyapatite (ceramic calcium phosphate 
composite) which is poured into moulds as a slurry and left to set, nanofibres (electrospun 
to mimic the ECM), polycarbonate polyurethane-urea (PCPU), glass and metal (Koski et al., 
2018; Wang et al., 2017; Zhang et al., 2016). Each scaffold above has the capacity to allow 
cells to adhere and proliferate in a 3D environment. However, an appropriate system to 
deliver medium supplementation and simulate the in vivo conditions is required. 
 
1.3.3. 3D culture supplementation systems 
 
A 3D culture supplementation system is required to simulate the in vivo environment as close 
as possible, in vitro, by controlling temperature, pH, medium flow rate, oxygen, nutrient 
supply, and waste metabolite removal for cells residing on the scaffold. The selection of a 
culture system requires an analysis of what produces an in vivo environment but is also easily 
reproducible and cheap for any laboratory to use. Current 3D culture systems can be broadly 
defined as static or fluidic. 
 
A static culture system involves the incorporation of a 3D scaffold into a flask or well plate, 
covered in medium containing cells and left to incubate. This system is easy to replicate 
between laboratories, requires no other external pumps or filtration systems and thus is 
cheaper to set up than modern fluidic systems (Kutscher et al., 2019). However, as there is 
no movement of the medium within the system, cells are exposed to a constant drug dose, 
accumulation of waste products and metabolites throughout the entirety of the study (Tsai et 
al., 2019). This can be combated with regular medium changes with or without a rocker 




system for a gentle flow, but this could alter cellular communication established within the 
culture and requires further expense.   
 
A fluidic system, unlike a static, requires some form of medium movement, which can be 
created in a number of ways, such as pumps, rotation, mixing in an effort to simulate the 
sheer force seen within the in vivo environment. However, if the sheer force is too great cells 
will be removed from the scaffold or apoptose, and if sheer force is too small, it won’t 
recreate the force necessary to express the associated growth and signalling pathways 
(Khurshid et al., 2018). Several systems have been used within the published literature to 
recreate this, including but not limited to, bioreactors and microfluidics. The bioreactor has 
been adapted for 3D culture and has precise control of all factors mentioned above. 
Bioreactors fall into four categories rotating wall vessel, direct perfusion, mechanical force 
and spinner flasks each inducing a fluidic environment (Anton et al., 2015; McKee & 
Chandhry, 2017; Izzo et al., 2019; Schmid et al., 2018) 
 
Similar to direct perfusion bioreactors, microfluidic systems provide a constant stream of 
nutrients, oxygen and sheer force to cells through micro-channels (100 nm-500 µm) in some 
cases removing waste products (Chen et al., 2018). This system still requires the use of a 
medium reservoir, pump and polydimethylsiloxane tubing (used for its ease of use, gas 
permeability and low cost) to create the fluidic system. Due to their relatively small size, 
microfluidic devices can be integrated into downstream analytical devices such as 
electrochemistry and spectroscopy without altering cellular processes (Castiaux et al., 2019). 
Recently, microfluidics has been used to try to create an organ/ human-on-a-chip. These 
culture systems try to simulate the structure, function, physiology and pathology of that 
specific organ in vitro by combining cell culture and microfluidics. The eventual goal of this 
combination is to connect each organ together for pharmacodynamic and pharmacokinetic 
study (Bein et al., 2018). However, there are many setbacks that individual organ chips can 
overcome, unlike a whole-body system, as cells within differing organs require different 
media supplementation, multiple pumps and tubing which is costly and cells of differing 
organs require changes in sheer pressure (Kimura et al., 2018). Every culture system has 
their advantages and disadvantages but how complex and expensive does a 3D system need 









1.3.4. Current 3D models of the bone marrow for genetic toxicology testing. 
 
Research into the use of 3D cell cultures within the toxicology industry has grown  
exponentially over the past decade as increasing publications highlight the similarities 
between cells cultured in an in vitro 3D model and those within an in vivo animal/ human. 
The current literature highlights the advanced development of static toxicity models of the 
liver, brain, kidney and skin, combining conventional toxicology assays with cutting edge 
3D scaffolds and culture systems (Duque-Fernandez et al., 2016; Reisinger et al., 2018; 
Fizesan et al., 2019; DesRochers et al., 2015; Salama et al., 2018; Zhou et al., 2019).  
The field of BM toxicology specifically genetic toxicology, however, seems to be lacking 
for such a crucial organ. The current literature, in an effort to replicate the delicate 
microenvironment seen within the in vivo BM, first employs the use of primary human MSC 
monocultures in static models upon simple scaffolds such as Matrigel, collagen, 
hydroxyapatite, gelatine and scaffold free spheroids (Yeung et al., 2019; Inglis et al., 2019; 
Yu et al., 2018). Further research utilises primary MSCs as a feeder layer upon the scaffolds 
previously mentioned. Primary human/ animal HSCs from both normal and diseased states 
(e.g. multiple myeloma) are then co-cultured within bioreactors and microfluidics in order 
to gauge the response of drug treatments, including pro-drugs, without the need for S9 as 
MSC derived cells have been seen to be metabolically competent (Elango et al., 2019; 
Braham et al., 2018; Fairfield et al., 2019). These types of multi/ co-culture have shown 
drug response and differentiation into both lymphoid and myeloid lineages similar to that of 
the in vivo setting but with varying degrees of reproducibility from assay to assay (Sieber et 
al., 2018; Sun et al., 2011). Human primary cells, those directly isolated from the in vivo 
tissue, retain their morphological and functional characteristics of the multicellular tissue, 
thus, seem like a good start in recreating an in vivo relevant in vitro model. However, primary 
cells can differentiate naturally which can hinder reproducibility of an assay between 
cultures and laboratories due to their heterogeneity. As they are directly taken from the tissue 
of interest, primary cell cultures are more costly compared with their cell line alternative 
(Paster et al., 2010; Stacey, 2006). The use of primary cultures in a 3D environment has 
become extremely useful but due to a lack of reproducibility and the high cost of bioreactors 
and microfluidic systems, these are not a viable option for routine genotoxicity studies of 
new compounds. 
 




To combat the lack of reproducibility and to decrease overall cost whilst still providing a 3D 
environment for cellular cultures, the use of cell lines has gained increasing interest. Cell 
lines, unlike primary cultures, are cells which have been taken from the tissue of interest and 
genetically immortalised, either though viral or cancerous manipulation, at a specific stage 
in differentiation. This allows long term culture of cells which have homogeneity with each 
sub-culture at a greatly reduced purchase cost. However, due to this genetic manipulation, 
cell lines may not accurately depict the primary cells from which they were taken (Kaur & 
Dufour, 2012). The human bone marrow stromal cell line HS-5, virally transformed by the 
human papilloma virus, has been used routinely as a surrogate for primary MSC-derived 
fibroblasts. The HS-5 cell line, when seeded onto artificial scaffolds in static cultures, has 
similar gene expression and resistance to drugs such as melphalan compared to primary 
fibroblasts (Kabrah et al., 2016; Limongi et al., 2020; Windus et al., 2013). This cell line, 
however, has only been used in combination with normal or cancerous primary HSC (Belloni 
et al., 2018; Bartnicka et al., 2018; Karimpoor et al., 2018).  
 
In commercial 2D MN genotoxic assessment of compounds, the human TK6 or mouse 
L5176Y lymphoblastoid cell line is used to replace the erythroblast/ erythroid cells assessed 
for MN within the in vivo assay due to their proliferation rate. However, as mentioned 
previously TK6 do not express cytokines, chemokines and metabolic enzymes seen within 
the in vivo BM microenvironment. To predict the response in vivo, the in vitro assay must 
simulate the necessary components of the BM to uncover the mechanism behind this 
alteration between in vivo and in vitro results. As the TK6 cell line has been routinely used 
for regulatory genetic toxicology due to its proliferation time and sensitivity to genotoxic 
compounds, it has an archive of historical data for comparison. Therefore, these appear to 
be a suitable foundation for the addition of BM cell lines and ECM in an effort to simulate 















1.4. The focus of this current study 
 
This research will aim to develop a reproducible, 3D in vitro physiologically relevant model 
of the human BM in vivo using a co-culture of commercial cell lines (HS-5 and TK6) for 
MN assessment of compounds. The results gained from this in vitro model will be compared 
to those gathered from standard in vitro and historical in vivo testing to ascertain whether 
our model is more in vivo relevant than conventional 2D testing.





1.5.  Aim 
 
1. To develop a static in vitro model of the human BM, utilising a co-culture of cell 
lines which are viable and proliferating upon a novel commercially available 
scaffold. 
2. To expose the model to known positive genotoxic compounds, negative compounds, 
and pharmacological positive compounds and compare these results to historical in 
vivo and 2D MN data. 
3. To characterise the model’s expression of phase 1 and 2 metabolic enzymes, seen in 
vivo, and HS-5's ability to metabolise the pro-drug CPM into its cytotoxic form 
without the use of S9. 
 
1.6.  Objectives 
 
To meet aim one 
• Prefabricated solid scaffolds and hydrogels will be evaluated for relevant 
morphology and ease of manipulation. 
• HS-5 culture conditions such as seeding density, culture time, retrieval of cells and 
proliferation index will then be assessed and optimised for the addition of TK6 cells, 
to model the current in vitro MN testing. 
• TK6 in co-culture with HS-5 cells, upon the scaffold, will be assessed and optimised 
for seeding density, culture time, retrieval of cells and proliferation index for 
compound dosing during the exponential phase of TK6 cell growth for MN 
production. 
• Analysis of markers residing on TK6 only will be identified for separation of TK6 
cells from HS-5 for MN assessment. 
To meet aim two 
• Known positive, negative and pharmacological positive genotoxic compounds will 
be assessed in a 2D in vitro MN assay, utilising TK6 for MN induction at a range of 
concentrations spanning an RPD of >50% and <50%. 
• The optimised 3D co-culture model, utilising TK6 and HS-5 cells, will be exposed 
to each compound concentration tested within the 2D in vitro MN assay, to elucidate 




if 3D can identify MN production seen with historical in vivo data not identified 
within 2D. 
To meet aim three 
• HS-5 cells grown in a 2D monoculture, 2D well insert co-culture (with TK6), 3D 
scaffold monoculture and 3D co-culture (with TK6), will be extracted for RNA and 
analysed via qPCR for the expression of genes relating to phase 1 and 2 metabolic 
enzymes. 
• TK6 with and without co-cultured HS-5 cells or S9 will be exposed to CPM for 

































Materials and Methods 




All reagents, unless otherwise stated, were purchased from Sigma-Aldrich (Poole, UK).  
To align experimental approaches and normalise data between University of the West of 
England (UWE) and AZ, for the purposes of comparing outcomes in the 3D BM model with 
historical data, several experiments were conducted at both AZ and UWE and where relevant 
will be highlighted. 
 
2.2. Tissue culture 
 
All cell cultures were seeded into T-75 vented flasks and incubated at 37oC, 5% CO2 in a 
humidified chamber. All cultures were grown in RPMI 1640 supplemented with 10% heat 
inactivated foetal bovine serum, L-glutamine (2 mM), penicillin (100 U/ml) and 
streptomycin (100 µg/ml) and will be referred to as complete medium. The human bone 
marrow stromal cell line, HS-5, was acquired from American Type Culture Collection 
(ATCC) (LGC standards, Bury) and grown as an adherent monolayer at an initial seeding 
density of 1.3x104 cells/cm2.  Medium was demi-depleted every two days and cells passaged 
every four days at a density of 4x103 cells/cm2. Culture time did not exceed passage 6. As 
the surface area of the scaffolds was unknown, once the HS-5 adherent monolayer was 
trypsinised, HS-5 cells were seeded as cells/scaffold not cells/cm2. The human 
lymphoblastic B cell line, TK6, was acquired from AZ (Cambridge, UK) and grown in 
suspension at an initial seeding density of 3x105 cells/ml. These cells were originally 
purchased by AZ from the European Collection of Cell Cultures (cell number 95111735).  
Cultures were maintained at a concentration between 3x105 and 9x105 cells/ml. Culture time 
did not exceed four weeks to reduce the accumulation of mutations through prolonged 
culture. The human liver carcinoma cell line, HepG2, was acquired from ATCC (LGC 
standard, Bury) and grown as an adherent monolayer at an initial seeding density of 1.3x104 




cells/cm2. A 50% medium change was conducted every two days and cells passaged every 
four days, at a density of 4x103 cells/cm2. Culture time did not exceed passage 11. 
 
2.2.1. Cell count and viability  
 
Cell counts at UWE were assessed using a haemocytometer chamber and Luna-FLTM 
automated fluorescence cell counter (Labtech International Ltd, East Sussex, UK). Cell 
counts at AZ were conducted using the Beckman Coulter Counter (Beckman Coulter, 
Indianapolis) and Countess II (ThermoFisher Scientific, Loughborough). Counts were 
compared between UWE and AZ for consistency between the two laboratories. Cell count 
and viability was determined using trypan blue (TB) utilising the Luna-FLTM automated 
fluorescence cell counter at UWE and Countess II at AZ. TB enters cells that have a 
compromised membrane, using a 1:1 dilution (10µl of sample and 10µl of TB). The 
Beckman coulter counter does not assess cell viability but only particles and thus was only 
used for the 2D micronucleus assay at AZ, as this is done routinely within the company. 
 
2.2.2. Identifying TK6 exponential phase in 2D 
 
The TK6 cell line was cultured utilising the method outlined in section 2.2 for a seven-day 
period. The cells were seeded into T175 flasks at a seeding density of 5x104 or 1x105 cells/ml 
in 25 ml of medium and grown over a five-day period with samples taken at 11am and 5pm 
each day. At each sampling point the flask was gently mixed and an aliquot (10 µl) was 
taken from each flask to assess cell number and viability using TB. Population doubling 
(PD) was calculated using the following equation from the OECD guideline 487 (2016): 
 
PD = Time	between	samples	x	log2log	(6789:	:;7) − log 	(6789:	79>) 
 
 
2.2.3. Cryopreservation and thawing of cell lines 
 
All cell lines were batch cultured at low passages (1-3) before being cryopreserved. Cells 
were counted, collected by centrifugation (300 xg, 7 minutes) and the pellet resuspended in 
FBS (50%) rich culture medium and ice-cold freezing medium containing DMSO (20%) in 




a 50:50 ratio to a density of 1x106 cells/ml. Cells (1ml) were transferred to 2 ml cryovials, 
frozen for 24 hours at -80oC before being transferred to liquid nitrogen. Cell lines were 
thawed using 5 ml of warmed complete medium, added dropwise until the cell pellet was 
resuspended. Cells were collected by centrifugation (300 xg, 7 minutes) and resuspended in 
T75 cm2 flasks in 20 mls of complete medium.  
 
2.2.4. Trypsinisation of adherent cells  
 
When adherent cell lines (HS-5 and HepG2) reached a confluence of 80 – 90%, the medium 
was completely removed, cells washed twice with phosphate buffered saline (PBS) and 
0.25% trypsin in EDTA added to cover the base of the flask. Flasks were incubated (37oC, 
5% CO2) for <10 minutes, until 100% of the cells had detached from the flask identified 
through light microscopy. Complete medium was added to a total volume of 15 ml to 
deactivate the trypsin, cell suspension harvested and centrifuged at 350 xg for 7 minutes. 
The cell pellet was resuspended in 1ml of complete medium and counted using the method 
described in section 2.2.3.        
     
2.3.  The finalised AlgiMatrix™ scaffold seeding protocol  
 
2.3.1. Initial HS-5 seeding and long-term culture 
 
HS-5 cells were seeded onto AlgiMatrix™ scaffolds at 2.5 x 105 cells in 500 µl of 50 % 
firming buffer, which was supplied by the manufacturer in order to solidify the AlgiMatrix™ 
scaffold, transferred to a 12 well plate, 3 ml complete medium added and left to incubate for 
24 hours. After 24 hours a 100% complete medium change was conducted with scaffolds 
incubated for a further 144 hours with a 50% medium change conducted every 48 hours.  
 
2.3.2. Addition of TK6 cells  
 
After the initial seeding of HS-5 described in section 2.3.1, TK6 were then combined with 
each AlgiMatrix™ scaffold at an initial concentration of 0.5 x 105 cells/ml. A 50% medium 
change was conducted every 24 hours over a 72 hour period, compound dosing was then 
conducted on hour 72. 
 




2.4.  Flow cytometry 
 
A brief overview of the fluorescent antibodies used within the body of work can be found in 
Table 2-1. The staining protocol for intracellular (Ki67), membrane bound and confocal 
staining (CD19 and CD20) differed, therefore reference to the location of these staining 
methodologies can also be found in Table 2-1. In order to assess the presence or absence of 
the fluorescent antibodies described in Table 2-1, a gating strategy was first employed to 
isolate single cells and exclude doublets and cellular debris. The criteria used to gate cells 
was adapted from Saskia (2015), utilising the side vs front scatter strategy seen in Figure 
2-1. The population of interest was first identified using a side scatter (SSC) area vs forward 
scatter (FSC) area plot discarding debris or cellular remnants. This population was then 
further gated by granulation (SSC area vs SSC height) and then size (FSC area vs FSC 
height) to reduce contamination from doublets before assessing the population for the 
presence or absence of antibody fluorescence (for antibodies see Table 2-1).  Flow cytometry 
was conducted on a Fortessa utilising the FACSDiva software at AstraZeneca and the Accuri 
C6, with accompanying software at UWE (Becton Dickinson (BD), New Jersey).  
 






Figure 2-1. Flow cytometry gating strategy. The cellular population of interest was first identified using a side scatter (SSC) area vs forward scatter (FSC) area plot (A). This population was then further gated 
by granulation (SSC area vs SSC height) (B) and size (FSC area vs FSC height) (C) before assessing the population for the presence or absence of fluorescence (D).  
A B C D





Table 2-1. Details of the antibodies used for flow cytometry and confocal microscopy. 












IgG1, monoclonal to 











IgG1, monoclonal to 
CD19, FITC 









IgG2b, monoclonal to 
CD20, PerCP-cy 5.5 




CD19 (confocal)  Primary: Mouse anti-
human, IgG2a, 
monoclonal to CD19, 














CD20 (confocal) Primary: Mouse anti-
human, IgG2a, 
monoclonal to CD20, 













FACS (fluorescence-activated cell sorting buffer) 
 
 




2.5. Microscopic examination  
 
Light and phase contrast microscopy was used to assess the morphology, distribution and 
identification of cellular colonies, spheroids and MN within sample populations. As light 
was able to pass through the AlgiMatrix™ scaffold, cellular morphology, distribution and 
identification of cellular colonies was also conducted with those cells residing on the 
scaffold. Microscopic images were taken utilising a Nikon Eclipse TE300 microscope with 
an attached Nikon Coolpix 950 camera.  
 
2.6. Screening of positive, negative and potential genotoxic compounds in 2D. 
 
In order to make a comparison between 2D and 3D in vitro MN results, each compound was 
assessed using the in vitro MN assay (IVM) following OECD 487 (2016) guidelines for MN 
induction. It was hypothesised that a higher concentration would be required when moving 
each compound into a 3D model. Therefore, a greater concentration of each compound was 
tested using the IVM to assess cytotoxicity.  
 
2.6.1. Industrial in vitro micronucleus assay 
 
TK6 cells in exponential phase (3x105 - 9x105), identified in section 2.5.1.1 were seeded into 
T25cm2 flasks at 1x105 cells/ml and a baseline cell count recorded to confirm the seeding 
density. Following culture for 24 hours, cells in ‘baseline flasks’ were counted to ensure that 
TK6 cells were within the exponential phase (3x105- 9x105) and thus are actively 
proliferating. Cells were treated with the vehicle control of <1% DMSO or drug for 24h. 
After treatment, the cells were collected by centrifugation (300 x g, 5 minutes, room 
temperature (RT)), washed once in fresh complete medium before being counted and 
adjusted to 3x105 cells/ml. Cells were maintained for a further 24 hours to allow them to 
complete cell cycle, counted and an RPD calculated. Utilising the OECD guideline 487 
(2016): 





Where population doubling (PD) is calculated: 






log 2  
 
Cell cultures with an RPD of >50% ± 5% (OECD, 2016) were adjusted to 1x105 cells/ml 
ready for addition to cytofunnels. Cells were spun onto the glass slides utilising a cytospin 
3 (Shandon, ThermoFisher) at 800 rpm for 8 minutes, fixed in 100% methanol (10 minutes, 
RT), stained for 1 minute with acridine orange (AO) (12mg/ 100ml phosphate buffered 
saline (PBS), RT), washed once for 10 minutes in PBS then washed again in fresh PBS for 
a further 15 minutes.  
 
To keep in-line with regulatory bodies, the OECD guideline 487 (2016) was utilised in 
performing the MN assay at both UWE and AZ. The main criteria adopted within this 
guideline are as follows: 
 
1. A dose which can be scored for MN induction must have an RPD of >50% ± 5%; an 
RPD lower than this cannot be scored as MN induction cannot be clearly differentiated 
from apoptosis. 
2. At least one dose per compound must induce an RPD of 50% ± 5%, this shows that the 
compound has been tested to its cytotoxic limit. 
3. Four doses must be scored per compound (excluding the negative and positive control) 
for the MN result to be accepted. 
4. A total of 2000 mononucleated cells per culture must be scored for the presence of MN, 
for a concentration to be deemed as “scored”. 
5. If all other criteria are met, a positive result for a compound can be called if the MN 
induction is at least double that of the negative control. 
6. When reporting results, concentration of compound should be expressed as ng/ml and/ 
or nM. 
These OECD guidelines were followed closely when identifying a greater concentration of 
each compound for use in the 3D model. However, as the RPD <50% ± 5% (guideline 1), 








2.6.2. Scoring of micronuclei 
 
The criteria utilised for scoring of MN and mononucleated cells was adapted from the 
Fenech (2003) paper and was as follows: 
1. MN has a diameter of less than one third of the main nucleus, any bigger is considered 
a binucleated cell. 
2. MN have a round or oval morphology. 
3. MN will not refract light unlike other artefacts within the culture. 
4. MN cannot be counted if they are connected to the main nucleus. 
5. A clear boundary must be seen between the main nucleus and the MN to be counted. 
6. Those cells going through mitosis will not be counted. 
7. MN will have a similar colouration and fluorescent intensity as the main nucleus 
 
Common morphologies seen when assessing the presence of MN can be seen in Figure 2-2.






Figure 2-2. Photomicrographs of the characteristic morphologies identified when scoring MN. The addition of acridine orange identifies nucleic material as fluorescent green and cytoplasm as light orange. 









2.7. Statistical Analysis 
 
All values are presented as mean ± standard deviation (SD) of 3 biological repeats, unless 
otherwise stated. All statistical analysis and graphical illustrations were conducted using raw 
data inputted into GraphPad Prism 7.0 software. Firstly, all samples were analysed for 
normal distribution using the Shapiro-Wilk test. A Two-Way ANOVA was used to compare 
samples in chapter 3 and 4 for simple effects within rows, followed by a Dunnett’s test to 
identify pairs with significant differences. A One-Way ANOVA, followed by a Dunnett’s 
test was also used in chapter 4 to identify significant increases in micronuclei from the 
vehicle control. Within chapter 5, statistical comparisons between results obtained with 
CPM were performed using a Two-Way ANOVA followed by a Tukeys test to correct for 
multiple comparisons. The difference between means within the qPCR data was calculated 
based on a Student’s t-test of the replicate 2(- ΔCT) values for each gene in the control group 
and treatment groups. A p-value of ≤0.05 was considered significant. Graphical symbols of 
significant difference were identified as (*) p < 0.05, (**) p < 0.01, (***) p < 0.001, (****) 































The development of a 3D physiologically relevant model of the BM, which truly reproduces 
the interaction between cellular groups seen in vivo, for use in genotoxicity testing is the 
eventual aim of this research. The complexities seen within the BM, such as the interaction 
between haematopoietic, mesenchymal stem cells and ECM (Jagannathan-Bogdan & Zon, 
2013) isn’t seen in a monolayer 2D environment currently adopted by the pharmaceutical 
industry. This harmonisation between compartments of the BM, discussed within chapter 1, 
has been attributed to changes in compound interaction, stromal mediated protection and 
altered genotoxicity (Torisawa et al., 2014; Ciciarello et al., 2019). However in order to 
evaluate the influence that these cellular interactions might have on a compound’s 
genotoxicity in producing inconsistency between in vitro and in vivo study, the production 
of a 3D BM microenvironment in vitro is required. 
 
The development of a more in vivo relevant, in vitro BM model has been ongoing for the 
past decade, with each model increasing in complexity in order to identify the true response 
and mechanism to new and existing compounds (Ham et al., 2019). The utilisation of culture 
systems (fluidic, bioreactor etc), cells (primary, cell lines) and ECMs (soft, hard etc), each 
with their own advantages and limitations, discussed in chapter 1, has increased our 
understanding of the in vivo response to compounds (Ravi et al., 2015; Hoch et al., 2017). 
However, is this level of complexity required for reproducible testing of compounds for 
genotoxicity, whilst replicating an in vivo environment in vitro?  
 
In brief, three artificial scaffolds were chosen, from those identified in Table 1-5, as potential 
surrogate ECMs for the addition of each cell line. These scaffolds consisted of the 
biocompatible polycarbonate polyurethane-urea scaffold, Biomerix, commercial hydrogel 
scaffold AlgiMatrix™ and in-house alginate hydrogel documented in the Armstrong et al. 





(2016) paper. The Biomerix scaffold was chosen as it was already in use at UWE with 
successful initial seeding of the HS-5 stromal cell line. The commercial scaffold 
AlgiMatrix™ made primarily of crosslinked alginate, was chosen due to its ability to 
encapsulate cells within, which can then be dissolved allowing their retrieval after compound 
dosing. As it was made by a large commercial manufacturer, batch to batch reproducibility 
was granted. Finally, the in-house alginate hydrogel was chosen as, unlike the similar 
AlgiMatrix™ scaffold, it had known components which could be assessed for toxicity and 
influence on scaffold morphology in comparison to the AlgiMatrix™ scaffold. The in-house 
alginate hydrogel could also be used in conjunction with a bioprinter for the production of 
bespoke scaffolds.  
 
The human stromal HS-5 and lymphoblastoid cell line TK6 were chosen for eventual 
addition to each scaffold. The HS-5 cell line was chosen as it is the only non-cancerous 
human BM stromal cell line currently on the market (Adamo et al., 2020). The TK6 cell line 
was chosen as it is routinely used in in vitro genetic toxicology due to its proliferation rate, 
p53 competency and sensitivity to compounds (section 1.3.4). As a protocol was already in 
place at UWE for the seeding of HS-5 cells onto Biomerix scaffolds, the reproducibility of 
this seeding method was first assessed and optimised in an effort to maintain an increased 
density of HS-5 on the scaffold. However, optimisation of the hydrogel scaffolds was 
required before the addition of either cell line. 
 
The hydrogel scaffolds both in-house and commercial (AlgiMatrix™), unlike the pre-
constructed Biomerix, required solidification with either a firming buffer (AlgiMatrix™) or 
CaCl2 solution creating divalent crosslinks. The percentage of either firming buffer (10, 25 
and 50%) or CaCl2 (100 - 1000 mM) would alter the mechanical properties and structure of 
the finalised scaffold. Therefore, increasing concentrations of firming buffer or CaCl2 was 
evaluated for its ability to simulate the mechanical properties and structure of the in vivo 
BM. Each firming concentration was also assessed for cytotoxicity in HS-5 cells, as these 
would be directly exposed when incorporated into the scaffold. As each scaffold could be 
dissolved either with a prediluted dissolving buffer or 55 mM EDTA (Armstrong et al., 
2016), both solutions were evaluated for their ability to dissolve each scaffold and any 
cytotoxicity they may induce. Those concentrations which gave a scaffold with similar 
mechanical and structural properties to the in vivo BM, were then assessed for their effect 
on viability, proliferation and cell cycle for long term culture of HS-5 cells. Once a long 





term culture protocol had been established which supported the primary addition of HS-5 
cells, the addition of TK6 was optimised to maintain them in their exponential phase for the 
addition of compound. The construction of a bioprinter for the extrusion of the in-house 
alginate gel was also conducted in addition to the main body of work. This bioprinter once 
constructed was evaluated for its potential use in the printing of bespoke scaffolds using the 
in-house alginate gel. Finally, in order to identify TK6 from those HS-5 which had not been 
included into the scaffold itself, evaluation of appropriate markers was assessed. 
 
The Biomerix scaffold was evaluated first, with the AlgiMatrix™ and bespoke hydrogel 
scaffold evaluated concurrently for comparison between alginate scaffolds.





3.2. Materials and methods 
 
All reagents and equipment were purchased from Sigma-Aldrich (Poole, UK) unless 
otherwise stated. All reagents were of the correct chemical, molecular and cell culture grade. 
 
3.2.1. Biomerix™ (hard) scaffold seeding development  
 
3.2.1.1. Original seeding of HS-5 onto a Biomerix™ scaffold 
 
Passage 2 - 6 HS-5 cells were grown to confluence and seeded at a density of 5x105 cells in 
20 µl of complete medium directly onto the centre of a sterilised Biomerix™ scaffold 
(Cellon, Edinburgh) within a 12 well plate, made of a biocompatible polycarbonate 
polyurethane-urea compound. Sterilisation of the Biomerix™ scaffolds was achieved by 
several compression-decompression cycles in 70% EtOH to expel all air from the scaffold, 
followed by incubation (20 mins) and 2 x 10 minute washes in PBS. Scaffolds were left for 
2 hours (37oC, 5% CO2) for cells to adhere after which a further 2 ml of complete medium 
was added and baseline counts taken of cells within the medium, scaffold and adhered to the 
plate after this initial incubation. To ascertain cell number within the scaffold and plate, each 
was washed separately with PBS 2 x 10 minute washes, 1 ml of 0.25% trypsin in EDTA 
added, incubated for 5 minutes, collected by centrifugation (300 x g, 7 minutes) and counted 
using the Luna-FL™ Counter as described in section 2.2.1. Remaining wells were incubated 
for a further 72 hours with cell counts of the medium, plate and scaffold taken every 24 
hours. 
 
3.2.1.2. Optimisation of HS-5 initial seeding time and density 
 
HS-5 cells were grown until confluence and seeded at a concentration of 5x105, 1x106 or 
1.5x106 cells/scaffold in 20 µl of complete medium onto the centre of a sterilised Biomerix™ 
scaffold. Each scaffold was either compressed then decompressed, drawing the cell 
suspension into the centre of the scaffold, or left for the cells to find their own way into the 
scaffold. Cells were allowed to adhere for 2, 4, 5 or 24 hours after which 2 ml of complete 
medium was added. Immediately, cell number from the medium, plate and scaffold was 
ascertained as described previously. This experimentation concludes that a cell density of 





1x106, and adherence time of 24 hours was found to be optimal and selected for all future 
experiments. 
 
To assess long term culture within the Biomerix™ scaffolds, 1x106 total HS-5 cells in 20 µl 
complete medium were seeded onto each sterile Biomerix™ scaffold, either left to adhere 
naturally or compressed then decompressed; both conditions incubated for 24 hours at 37oC, 
5% CO2 after which 2 ml of complete medium was added and incubated for a further 72 
hours. Scaffolds and medium were then harvested every 24 hours over the 72 hour period 
for assessment of cell number and viability as described previously in section 2.2.1. 
 
3.2.1.3. Evaluation of trypsinisation efficiency 
 
The RealTime-Glo™ MT assay (Promega, Southampton) determines the number of viable 
cells in a culture through the reduction of a pro-substrate to a substrate, which is converted 
to a luminescent product by a NanoLuc luciferase enzyme, producing a luminescent signal 
relative to cell number, for a maximum of 72 hours. Therefore, HS-5 cells were seeded onto 
sterile Biomerix™ scaffolds at a concentration of 0, 5x105, 1x106 or 1.5x106 cells/scaffold 
in 20 µl of complete medium and maintained for 2, 4, 5 or 24 hours. The RealTime-Glo™ 
MT assay reagent was then added to each condition, following the manufacturer’s protocol, 
before and after trypsinisation. Reagent was also added to a blank scaffold to assess 
background luminescence. Luminescence was then read for each sample on a FLUOstar 
Omega (BMG Labtech, Buckinghamshire) at an integrated time of 0.25 - 1 second per well. 
 
3.2.2. AlgiMatrix™ (gel) model development  
 
3.2.2.1. Identification of AlgiMatrix™ internal structure 
 
Dry AlgiMatrix™ scaffolds (ThermoFisher Scientific, Loughborough) were suspended in 
500 µl of either a 50, 25 or 10 % solution of AlgiMatrix™™ firming buffer: complete 
medium (with/without 2.5 x 105 HS-5 cells/ scaffold) for approximately 5 minutes. The 
rehydrated scaffolds were washed with 1 ml of complete medium before analysis by light 
microscope for cellular distribution and structural arrangement. Rehydrated scaffolds 
without HS-5 cells, were also analysed via scanning electron microscopy (SEM), which was 
conducted by Dr D Patton of UWE, for pore size at differing firming concentrations. In order 





to image via SEM, each scaffold was placed on lint free tissue overnight to draw out any 
moisture within the scaffold. The dehydrated scaffold was then place on a carbon conductive 
tab on pin stubs (TAAB, UK), sputter coated with gold utilising a SC 500 Emscope sputter 
coater (BIO-RAD, Watford). Imagining of pore size was then achieved using a FEI Quanta 
650 field emission SEM. 
 
3.2.2.2. AlgiMatrix™ optimisation of cellular seeding and retrieval  
 
3.2.2.2.1. The effect of 55mM EDTA and dissolving buffer on HS-5 
cells 
 
The AlgiMatrix™ is supplied with a dissolving buffer (ThermoFisher Scientific) which, 
when added to firmed AlgiMatrix™ scaffolds, will dissolve the scaffold allowing the 
collection of cells encapsulated within. An alternative method of dissolving each scaffold 
was identified using 55 mM EDTA as a chelating agent for the divalent ions within the 
AlgiMatrix™ scaffold. To identify if either 55mM EDTA or commercial dissolving buffer 
had a cytotoxic effect on cells, HS-5 cells were grown to confluency in a 75cm2 flask, 
trypsinised and aliquoted at a concentration of 1.5 x 106 cells in 1ml of either 55mM EDTA 
or commercial dissolving buffer. HS-5 cells were left for 0, 10, 20 or 30 minutes within each 
solution, washed and assessed for viability and total cell number utilising the Luna-FL™ 
counter with acridine orange (AO) and propidium iodide (PI) counter stain. 
 
3.2.2.2.2. Proliferation index of HS-5 with/ without an AlgiMatrix™ 
scaffold present 
 
To assess how the size, growth area and medium volume of 25 cm2 flask, 24 or 12 well plate 
affected the growth of HS-5 seeded within, HS-5 cells were grown to confluency, trypsinised 
and counted as previously described in section 2.2.1. HS-5 cells were then seeded at the 
same initial density of 6x103 cells/cm2 into a T25 cm2 flask, 24 and 12 well plate with 10, 2 
and 3 mls of complete medium added respectively. Each condition was incubated for 216 
hours, with 50% medium change every 48 hours and sampled every 24 hours. Separate HS-
5 cells were also seeded into 50% firmed AlgiMatrix™ scaffolds, placed in a 12 well plate, 
at a density of 2.5, 5, 7.5 and 10x105 cells/ scaffold with 3 mls of fresh complete medium 
added. Each condition was incubated for an initial 24 hours, 100% medium change 





conducted and incubated for a further 312 hours. Scaffolds underwent a 50% medium change 
every 48 hours and select scaffolds harvested at 48 hour time points over this 312 hour 
period. 
 
In order to assess the affect each culture vessel had on HS-5 cells each experimental 
condition above was analysed for cell number, viability, presence of Ki67 and stages of cell 
cycle. Each sample, mentioned above, was split into 3, one sample was analysed for cell 
number and viability using the Luna-FL™ counter, samples 2 and 3 were washed and 
resuspended in around 10 µl of medium. A 1 ml working solution of Foxp3 
fixation/permeabilisation solution, using the manufacturer’s instructions, was added to 
samples 2 and 3 and left to incubate on ice for 30 minutes. A 2 ml working stock of 
permeabilization buffer was immediately added to both before centrifugation at 600 x g for 
5 minutes with the supernatant discarded. Samples 2 and 3 were resuspended in 
approximately 100 µls of medium, 5 µl of Ki67 (Table 2-1) was added to sample 2. Samples 
2 and 3 were then vortexed and incubated for 30 minutes at room temperature in the dark. A 
further 2 ml of 1x permeabilization buffer was immediately added to both samples before 
centrifugation at 600 x g for 5 minutes with the supernatant discarded. A 500 µl working 
solution of PI (50 µg/ml PI, 100 µg/ml RNase, 2 mM MgCl2 made up to 1 ml in PBS) was 
added to sample 3 for 20 minutes in the dark to assess stages of cell cycle. A 500 µl aliquot 
of fluorescence-activated cell sorting (FACS) (1% bovine serum albumin (BSA) in PBS) 
buffer was added to sample 2 before both sample 2 and 3 were analysed on the Accuri C6 
Plus flow (BD) cytometer for 50,000 events after initial gating (Figure 2-1).   
 
3.2.2.2.3. Washing regimen for increased cellular viability  
 
HS-5 cells were grown to confluency, trypsinised and counted as previously described in 
section 2.2.1, seeded in either 50, 25 or 10% firming buffer in complete medium, at a 
concentration of 5x105 cells/ml. Dry AlgiMatrix™ scaffolds, in a 24 well plate, were 
rehydrated with 500 µl of each firming condition (50, 25 or 10%), containing a total cell 
number of 2.5x105 cells per scaffold and left for approximately 5 minutes. The rehydrated 
scaffolds were either washed with complete medium or left before being transferred into 12 
well plates, 3 ml of complete medium was then added and scaffolds incubated for an initial 
24 hours, after which, scaffolds underwent either a 100, 50 or 0% complete medium change, 
incubated and process repeated every subsequent 48 hours. At 24 hour intervals, HS-5 





incubated scaffolds were transferred into a 15ml centrifuge tube, 2 ml of AlgiMatrix™ 
dissolving buffer added and left for <30 minutes with gentle agitation every 2 minutes until 
the scaffold had dissolved. Cells were collected by centrifugation (300 x g, 7 minutes), 
supernatant removed, fresh medium added, and an aliquot taken for cell number and viability 
as described in section 2.2.1. This experiment identified, in conjunction with the results 
obtained from section 3.3.3.3, an optimised seeding regime (section 2.3.1) of HS-5 cells 
encapsulated within an AlgiMatrix™ scaffold for the addition of TK6. Therefore, this 
method will be used for further studies.  
 
3.2.2.2.4. Proliferation index of TK6 cells in co-culture with HS-5 
cells. 
 
HS-5 cells were grown to confluency, trypsinised and counted as previously described in 
section 2.2.1 and cultured within AlgiMatrix™ scaffolds as described in section 2.3.1. After 
144 hours, TK6 cells were added directly to the scaffold at 0.5, 1 or 3.5 x 105 cells/ml in 
complete medium, mixed by pipetting and left to incubate for 102 hours. A 50 or 0% medium 
change was conducted every 0, 24 or 48 hours over this 102 hour period. Twice a day, six 
hours apart, cells were collected from the medium and dissolved scaffolds and counted as 
described in section 2.2.1. Cells were then washed with PBS, a 1:20 dilution of CD19 
(section 2.4, Table 2-1) in 100 µl of FACS buffer, mixed and incubated on ice for 45 minutes. 
Following incubation, samples were collected (300 x g for 7 minutes) before the addition of 
500 µl’s of FACS buffer. Flow cytometry of percentage positive cells was assessed after 
initial gating (section 2.4, Figure 2-1). This experiment identified the optimal culture 
conditions for the addition of TK6 outlined in section 2.3.2 and therefore will be used for 
further study. 
 
To identify if the viability of HS-5 increased with the addition of TK6 after the initial 
incubation described in section 2.3.1, the addition of TK6 cells seeded into a 0.25µ well 
inserts, at a concentration of 0.5 x 105 cells/ml, were added into wells containing HS-5 
seeded AlgiMatrix™ scaffolds cultured as described in section 2.3.1. The well insert was 
used to distinguish HS-5 cells from TK6. A 50% medium replacement was then conducted 
at either 24 or 48 hour intervals over the remaining 96 hour period. Well inserts were 
removed, and AlgiMatrix™ scaffold dissolved every 48 hours, HS-5 cells within were 
counted (as desciebed in section 2.2.1) stained with the fixable viability dye, eFluor 520 





(ThermoFisher,), and assessed via flow cytometry for 50,000 events (gating described in 
section 2.4, Figure 2-1). A negative dead (HS-5 incubated at 100oC for 10 minutes), positive 
live (HS-5 cells at a viability of >90%) and 50:50 (positive: negative) control for percentage 
positivity was also assessed. The percentage positive and total cell number was then used to 
calculate the total number of live HS-5 cells. 
 
3.2.3. 3D printing of in-house Alginate scaffolds 
 
3.2.3.1. Modification of a 3D printer for use with bioink and design of an 
in vivo relevant bone marrow scaffold.   
 
To accurately extrude the bioink into a 3D soft hydrogel structure, a Mendlemax 3 3D printer 
(Makers tool works, California) was purchased and constructed according to the 
manufacturer’s guidelines. The Mendlemax is built to extrude a hard plastic (polylactic acid; 
PLA) when heated to 220 oC which is layered to make a structure. To prove that the 
Mendelmax 3 can print accurate 3D scaffolds, SEM images of the BM were converted into 
3D structures using the online software selva 3D. This was then manipulated using the online 
software TinkerCad so that it could be converted into a STL. file (3D file which is recognised 
by the printer) and printed in PLA. 
 
In order for the Mendlemax to extrude unheated bioink, not PLA, the Mendlemax required 
conversion into a ’bioprinter’. The bioprinter uses a needle of differing gauge to guide the 
bioink onto the surface, unlike the heated nozzle currently fitted. The conversion required 
the Mendlemax to first print off its own parts in PLA from donated STL. files; notably the 
syringe driver, motor holder and pusher before the conversion could take place. These files, 
along with new firmware for the Mendlemax were kindly donated by Mr T Richardson 
(University of Bristol). The software Ardunino was used to upload the firmware onto the 
Mendlemax. This firmware would control the rate at which the bioink would be extruded 











3.2.3.2. Experimentation of a non-commercial bespoke hydrogel scaffold 
 
A bespoke hydrogel (60% sodium alginate, 32% pluronic F127 and 8% medium) was 
constructed (to compare with the previously described Biomerix™ solid scaffold) utilising 
the protocol in Armstrong et al. (2016) to create a scaffold with differing pore sizes. A 100 
µl aliquot of bioink (a combination of cells, alginate, pluronic F127 and medium) was 
extruded into a 24-well plate and 1 ml of either 100 mM or 1 M calcium chloride (CaCl2) 
solution (CaCl2 and complete medium) was added at RT to crosslink the gel thus hardening 
it. Visual examination of the structure was conducted every 5 minutes for a total of 30 
minutes. The CaCl2 solution was then removed and replaced with a 5 mM CaCl2 solution 
(CaCl2 and complete medium) to stop the scaffold from degrading over time. The 
crosslinked hydrogel was then examined via SEM for pore size as described in section 
3.2.2.1.   
 
3.2.3.3. The effect of calcium chloride on bioink and HS-5 cells 
 
HS-5 cells were grown to confluence, trypsinised and seeded onto a 12-well plate at a density 
of 1 x 105 cells in 400 µl complete medium and left to adhere for 2 hours (37 oC, 5% CO2). 
Medium was then removed from the cells and 400 µls of either 0, 100, 300, 500, 700 or 1000 
mM CaCl2 solution was added for 10 minutes (37 oC, 5% CO2). After 10 minutes the medium 
was removed, cells were washed with PBS, trypsinised, counted and viability assessed using 
an acridine orange/ proprium iodide stain.  
 
3.2.4. Identification of a single cell type in a co-culture 
 
3.2.4.1. Identification of TK6 within a co-culture system. 
 
Within the model described in section 2.3, cells need to be distinguished from HS-5 in order 
to count micronuclei in the ‘haematopoietic’ compartment of the model. The conventional 
method of AO staining cannot distinguish either cell line morphologically. The staining of 
TK6 only would allow the quantification of MN in the “haematopoietic” element of the 
model whilst allowing both cell types to be in contact with each other.  
 
 





3.2.4.1.1. Use of the nanocrystal technology Qtracker 655 
 
The Qtracker 655 labelling kit (ThermoFisher Scientific) delivers Qdot™ nanocrystals into 
the cytoplasm of living cells which has a stable fluorescence emission of 655 nm over six 
generations. The Qtracker 655 reagents were incubated following the manufacturer’s 
protocol and added to a density of 1 x 106 TK6 cells, incubated at 37 oC for 60 minutes then 
washed twice with complete medium. The stained TK6 were combined with unstained HS-
5 cells at a ratio of 100:0, 75:25, 50:50, 25:75 or 0:100 at a final density of 1x105 cells in 1 
ml of complete medium. Cells were either cytospun onto a glass slides using a utilising a 
Shandon cytospin 3 (ThermoFisher) at 800 rpm for 8 minutes, for identification of TK6 
stained cells by florescent microscopy or pelleted and 500µl of FACS buffer added for flow 
cytometry analysis (section 2.4, Figure 2-1) of 50,000 events. 
 
3.2.4.1.2. Flow cytometry of TK6 specific markers. 
 
According to the European Collection of Authenticated Cell Cultures (ECACC), 100% of 
TK6 cells express the membrane bound cluster of differentiation (CD) marker 19 (B cell 
lineage), 50% express CD20 (pro-B cell stage) and a small population express CD22 (mature 
B cells). HS-5 cells, however, do not express these CD markers as they do not reside within 
the B cell lineage. TK6 and HS-5 cells were grown as described in section 2.2, trypsinised 
(HS-5 cells) and counted as described in section 2.2.1. Cells were mixed in a ratio of 100:0, 
75:25, 50:50, 25:75 and 0:100 TK6:HS-5 cells at a concentration of 1 x 105 cells/ml. Cells 
were washed with PBS, a 1:20 dilution of CD19 or CD20 (section 2.4, Table 2-1) either 
alone or in combination in 100 µl of FACS buffer was added, mixed and incubated on ice 
for 45 minutes. Following incubation, samples were collected (300 x g for 7 minutes), 500 
µl of FACS buffer added before being gated (section 2.4, Figure 2-1)  and analysed for 













3.2.4.1.3. Immunofluorescent differentiation of TK6 from HS-5 cells 
 
TK6 and HS-5 cells were grown as described in Section 2.2, trypsinised (HS-5 cells) and 
counted as described in section 2.2.1. Cells were mixed in a ratio of 100:0, 75:25, 50:50, 
25:75 and 0:100, TK6:HS-5 cells at a total concentration of of 1 x 105 cells/ml. 200 µl of 
each ratio was cytospun onto a glass slide using a Shandon cytospin 3 (ThermoFisher) at 
800 rpm for 8 minutes, and once dry, fixed in 100% methanol (15 minutes, RT). To stain, 
slides were washed once with PBS for 1 minute, 200 µl of blocking buffer (1% BSA in PBS) 
added and slides incubated at room temperature for 30 minutes. The primary antibody for 
CD19 and CD20 (section 2.4, Table 2-1) were then diluted in blocking buffer, 200 µls added 
to each slide and incubated for 1 hour at room temperature. Each slide was washed in PBS 
(3 x 5 minutes), 200 µls of secondary antibody added (section 2.4, Table 2-1) and incubated 
for 1 hour at room temperature in the dark before being washed in PBS (3 x 5 minutes). To 
visualise the nuclear material, 10 µls of DAPI (4’,6-diamidino-2-phenylindole) (2 µg/ml in 
PBS) was added to each slide and incubated for 10 minutes at room temperature in the dark, 
washed in PBS (3x 5 minutes) and left to dry, then 200 µl of Prolong Gold antifade mounting 
medium (ThermoFisher) added to each slide and covered with a cover slip. Each sample was 
analysed on a Leica SP8 confocal microscope (Leica, Newcastle Upon Tyne). This was also 
trialled with primary antibodies conjugated with FITC (CD19) and PerCy5.5 (CD20) 






















3.3.1. Biomerix™ scaffold seeding development  
 
3.3.1.1. The seeding of HS-5 onto Biomerix™ using a previously 
published method 
 
To assess the reproducibility of a previous work conducted within UWE, HS-5 grwon to 
confluence were seeded onto a Biomerix™ scaffold and 2 mls of fresh complete medium 
added. Each scaffold was left for a 96 hour incubation period with scaffolds harvested every 
24 hours (Figure 3-1). The datum shows that following a 2 hour incubation of cells with the 
scaffold, cell counts show 75% of cells reside in the medium or have attached to the plate 
surface, and only 25% have adhered to the scaffold. This finding occurs throughout the 
experiment with a significant increase in cells residing on the plate compared to the scaffold 
occurring at 96 hours. This result shows that HS-5 cells will not adhere to the scaffold in 
large numbers with this seeding density or incubation time, therefore, optimisation of the 
initial seeding density and time should be conducted.  
 
 
Figure 3-1. Growth of HS-5 cells seeded onto Biomerix™ scaffolds at a density of 5x105 cells/ scaffold using a 
previously established method. Cells were added to Biomerix™ scaffolds and incubated for 2 hours. Cells were retrieved 
from the plate and Biomerix™ scaffold via trypsinisation every 24 hours over a 96 hour period. Cell number was established 
using trypan blue. (n=3). Significant differences between samples were calculated using a Two-Way ANOVA followed 
by a Dunnett’s test. The p value is indicated by ** (p <0.01), actual p values can be found in appendix 1. 




























3.3.1.2. Optimisation of initial seeding density  
 
In order to retain a larger proportion of cells within the scaffold compared to the medium 
and /or plate surface, an optimisation of the initial seeding concentration and time were 
conducted. An initial seeding concentration of  5 x 105 (Figure 3-2) and 1x106 (Figure 3-3) 
of HS-5 cells in 20 µls  were added to each scaffold and left to adhere naturally for either 2, 
4 (Figure 3-2 A, Figure 3-3A), 2, 5 or 24 (Figure 3-2B, Figure 3-3B) hours, or scaffolds were 
compressed-decompressed before a 5 or 24 (Figure 3-2C, Figure 3-3C) hour incubation.  In 
both initial seeding concentrations (5 x 105 and 1 x 106), irrespective of compression of the 
scaffold 2, 4 and 5 hour incubations resulted in a significant increase in total cells within the 
medium compared to that of the scaffold. The mean total cell count was also >75% in the 
medium compared to the scaffold.  In both initial seeding concentrations (5 x 105 and 1 x 
106), scaffolds that were not compressed (Figure 3-2 B, Figure 3-3 B) showed no significant 
difference between scaffold and medium at 24 hours.  However, those scaffolds seeded with 
1 x 106 total cells (Figure 3-3 B), were found to have a higher mean total cell number of 3.25 
x 105 cells upon the scaffold, unlike those seeded with 5 x 105, which only reached 2.9 x 105 
cells over the same period.  
 
To ensure that the scaffolds had been fully harvested of cells, RealTime-Glo assay reagents 
were added to loaded scaffolds before and after trypsinisation along with a cell free scaffold 
as a negative control (Figure 3-2D, Figure 3-3D). In each condition the RLU of the scaffold 
containing cells reduced by >98% when compared to trypsinsed scaffold, with the negative 
control giving a consistent result of 0 RLU confirming a complete harvest of the scaffold.  






Figure 3-2. Initial adherence time of HS-5 cells seeded onto Biomerix™ scaffolds at a concentration of 5x105. Biomerix™ were either left to naturally adhere (A+B) or compressed-decompressed (C) before 
addition of 20 µl of cell suspension. Cells were incubated for 2 & 4 (A), 2, 5 & 24 (B) or 5 & 24 hours before trypsinisation and cell count via trypan blue. Confirmation of complete evacuation of cells from the 
scaffold using trypsin was established using the RealTime-Glo assay from Promega (D). (n=3). Significant differences between samples were calculated using a Two-Way ANOVA followed by a Dunnett’s 
test. The p value is indicated by * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001), actual p values can be found in appendix 1. 

















) Scaffold with cells
Scaffold after trypsinisation 














































































Figure 3-3. Initial adherence time of HS-5 cells seeded onto Biomerix™ scaffolds at a concentration of 1 x 106. Biomerix™ were either left to naturally adhere (A+B) or compressed-decompressed (C) before 
addition of  20 µl of cell suspension. Cells were incubated for 2 & 4 (A), 2, 5 & 24 (B) or 5 & 24 hours before trypsinisation and cell count via trypan blue. Confirmation of complete evacuation of cells from the 
scaffold using trypsin was established using the Real Time Glo assay from Promega (D). (n=3). Significant differences between samples were calculated using a Two-Way ANOVA followed by a Dunnett’s 
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As an initial seeding density of 1 x 106 cells in 20 µls of complete medium, added to a sterile 
Biomerix™ scaffold for 24 hours has shown to yield a greater number of cells on the 
scaffold, the effects of long-term culture were investigated using this initial seeding method 
with the addition of compression (Figure 3-4 A) or natural adhesion to the scaffold (Figure 
3-4 B).  It can be seen that in both conditions a statistical increase in cells within the medium 
compared to the scaffold was seen.  However, cells exposed to  an initial compression  
(Figure 3-4 A) had increased cell numbers in the scaffold (2 x 105 – 4 x 105 cells) and 
decreased (9 x 105-  5 x 105 cells) in the medium between the 48 - 96 hour period, with the 
combined number of cells in the scaffold and medium reaching 9 x 105 cells which was 
lower than the initial seeding density of 1 x 106 cells. The results from this section show that 
the HS-5 cell line will not adhere in a high enough density for future culture, therefore new 
scaffold were investigated which encapsulates the HS-5 cells, retaining a larger population. 
  
 
Figure 3-4. Growth of HS-5 cells seeded onto Biomerix™ scaffolds at a concentration of 1x106. Cells were seeded 
onto either compressed (A) or natural Biomerix™ scaffolds (B) and incubated for aninitial 24 hours before the addition of 
medium. Cells were retrieved from the Biomerix™ scaffold via trypsinisation every 24 hours over a 96 hours period. Cell 
number was established using trypan blue. (n=3). Significant differences between samples were calculated using a Two-
Way ANOVA followed by a Dunnett’s test. The p value is indicated by * (p < 0.05), **** (p < 0.000)1, actual p values 
can be found in appendix 1. 
 
3.3.2. AlgiMatrix™ model development  
 
In an effort to maintain a higher proportion of cells within the scaffold compared to that of 
the medium and maintain reproducibility between scaffolds, investigation into the use of a 
new, soft hydrogel instead of Biomerix™ was investigated. The commercial scaffold 
AlgiMatrix™, a hydrogel made of biologically inactive alginate, was used for its ability to 
incorporate and retrieve cells within the scaffold itself. 
 
 














































3.3.2.1. Optimisation of initial solidifying and eventual dissolving of 
AlgiMatrix™ scaffolds. 
 
The commercial AlgiMatrix™ scaffold arrives as a freeze-dried alginate solution, which is 
rehydrated with differing concentrations of firming buffer dependent on the internal 
structure required. AlgiMatrix™ scaffolds were subjected to 10, 25 or 50% firming buffer 
in complete medium with the internal and external structure assessed by light microscopy ( 
Figure 3-5). The internal ( Figure 3-5 B, E and H) and surface structure ( Figure 3-5 C, F 
and I) showed little to no difference in structure using light microscopy in either 10, 25 or 
50% firming conditions. However, the external appearance and mechanical structure of a 
10% scaffold ( Figure 3-5 A) was much more gelatinous than that of 25 ( Figure 3-5 D) or 
50% ( Figure 3-5 G) scaffolds and fell apart when manipulated. The scaffolds solidified with 
25 or 50% firming solution held their shape when manipulated and resembled the 
consistency of the hard Biomerix™ scaffold. 
 
 
 Figure 3-5. Images depicting the physical structural difference seen with increasing firming buffer concentration 
of AlgiMatrix™ scaffolds. A 10, 25 or 50% solution of firming buffer and medium was added to each dry AlgiMatrix™ 
scaffold for >5 minutes for solidification. The external appearance of each scaffold can be seen in A (10%), D (25%) and 
G (50%). Light microscopy (10x magnification) was then used to look at the internal (B, E and H) and surface (C, F and I) 

























Due to the lack of differentiation between internal structures using light microscopy, SEM 
was used to identify structural changes at >150 x magnification (Figure 3-6).  Dried 
AlgiMatrix™ scaffolds were once again solidified with 10, 25 or 50% (Figure 3-6 A, B and 
C) firming solution before being assessed by SEM.  A 10% firming solution (Figure 3-6 A) 
produced a structure with no visible pores.  However, those scaffolds solidified with a 25% 
firming solution (Figure 3-6 B) gave pore sizes of 25 µm and a 50% firming solution (Figure 
3-6 C) gave a uniform pore size of approximately 120 µm.






Figure 3-6. Scanning electron microscopy (SEM) images of AlgiMatrix™ scaffolds hardened with a 10, 25 or 50% firming buffer.  A 10% (A), 25 (B) or 50% (C) solution of firming buffer and medium 
was added to each dry AlgiMatrix™ scaffold for >5 minutes, allowed to air dry for 24 hours before being placed on lint free tissue. Once residual medium had been drawn out, the scaffold was then pressurised 














The AlgiMatrix™ kit was initially chosen as each scaffold, once solidified, can be fully 
dissolved using either the supplied dissolving buffer or 55 mM EDTA, enabling the retrieval 
of the residing cells for cellular assessment.  It can be seen, that neither the 55 mM EDTA 
(Figure 3-7 A) or the commercial dissolving buffer (Figure 3-7 B) had any statistical effect 
on the viability or cell number of HS-5 cells over a 30 minute period.  The viability, 
measured using a PI/AO stain, produced a viability >95% in both cases, with cell number 
consistently producing a mean of approximately 1.3 x 105 cells. These results suggest that 
there is no detrimental effect of using wither 55 mM EDTA or dissolving buffer. 
 
 
Figure 3-7. The effect of 55mM EDTA (A) and commercial dissolving buffer (B) on the viability (line) and total cell 
number (bar) of HS-5 cells. HS-5 cells at a concentration of 1.5 x 106 in either 55 mM EDTA or commercial dissolving 
buffer, incubated for 0, 10, 20 or 30 minutes, washed and assessed for viability and total cell number using an acridine 
orange and propidium iodide stain (n=3). 
The effects of both the 55 mM EDTA and commercial dissolving buffer on Algimatrix™ 
scaffolds, bathed in 50% firming buffer for 5 minutes before being replaced with 55 mM 
EDTA and commercial dissolving buffer, can be seen in Figure 3-8. In both cases 3 mls of 
the dissolving solution was added and incubated for 5 minutes. Light manipulation of the 
scaffolds, to break them up, was carried out every minute with a Pasteur pipette. It can be 
seen that the EDTA (Figure 3-8 B), after a 5 minute incubation, did not dissolve the scaffold 
completely with some residue remaining on the surface. However, the dissolving buffer 
(Figure 3-8 C), after a 5 minute incubation, still has some remnants of the scaffold but less 
than that of the EDTA. This result suggests that a prolonged bathing period of the scaffold 


































































Figure 3-8. The effect of 55mM EDTA (B) and commercial dissolving buffer (C) on an Algimatrix™ 50% scaffold. 
Algimatrix™ scaffolds were solidified in 50% firming solution for <5 minutes (A), washed and then bathed in 3 either 55 
mM EDTA (B) or commercial dissolving buffer (C) for 5 minutes. The scaffolds were gently broken up with a Pasteur 
pipette over the 5 minute period. 
 
3.3.2.2. Effect of firming buffer on incorporated HS-5 cells and 
optimisation of long-term culture conditions 
 
The concentrations of AlgiMatrix™ firming buffer, evaluated for physical structure in 
section 3.3.2.1, was able to accommodate cells for inclusion into each scaffold whilst 
solidification occurred. However, the effect that the firming buffer had on HS-5 cells had 
not yet been evaluated, therefore the effect on viability and cell number of each contraction 
was assessed. This was achieved by introducing firming solution containing HS-5 to the 
freeze-dried scaffold and incubating for <5 minutes. Therefore, the effect of incorporating 
HS-5 cells into the scaffold itself with either a 10, 25 or 50% firming solution was 
investigated (Figure 3-9). Once seeded, each scaffold contained 2.5 x 105 total HS-5 cells 
and had 2 mls of fresh medium added, then were incubated and had either a 0, 50 or 100% 
medium change on day 2, with cell number and viability identified using an AO/PI stain. It 
can be seen, that those scaffolds treated with either 25 or 50% firming buffer resulted in a 
statistically significant decrease in cell number (Figure 3-9 A, C, E) and viability (Figure 
3-9 B, D, F) within the first 24 hours. However, HS-5 incorporated into a 10% scaffold 
remained >90% viable; reductions in cell number can be seen before a 0 or 100% medium 









change had occurred on day 2, the scaffold was incubated for a further 3 days. Those 
scaffolds which hadn’t had a medium change (Figure 3-9 A & B) saw an increase in cell 
number from day 2- 5 in scaffolds treated with a 10, 25 and 50% firming solution. 






Figure 3-9. Cell number and viability of HS-5 cells seeded at a concentration of 2.5 x 105 onto AlgiMatrix™ 
scaffolds. The Cell number (A, E, C) and viability (B, D, F) of HS-5 cells seeded at a concentration of 2.5 x 105 onto 
AlgiMatrix™ scaffolds, incubated for 5 days with a 0% (A, B), 50% (C, D) or 100% (E, F) medium change on day 2. Cell 
number (G) and viability (H) were also taken for cells that underwent a 100% medium change on day 2 and a 50% medium 
change on day 4. In all experiment’s HS-5 cells were seeded in a 10, 25 and 50% solidified AlgiMatrix™ scaffold for <5 
minutes before the addition of fresh medium. At each time point scaffolds were dissolved with viability and cell number 
assessed using an acridine orange and propidium iodide stain. (n=3). Significant differences between samples were 
calculated using a Two-Way ANOVA followed by a Dunnett’s test. The p value is indicated by *(p < 0.05), ** (p < 
0.01), *** (p < 0.001), **** (p < 0.0001), actual p values can be found in appendix 1. 
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However, there was a statistical reduction in viability over the same time period in all 
conditions. Scaffolds which underwent a 50% medium change on day 2 (Figure 3-9 C & D), 
resulted in a statistical increase in cell number within the 10 and 50% firming solution 
groups. However, over the same time period (day 2- 5), there was no statistical increase in 
viability in all firming conditions. Finally, those cells which underwent a 100% medium 
change on day 2 (Figure 3-9 E & F) had statistical increases in cell number in all firming 
conditions over the 3-day period. In the same period, however, no increase in viability was 
seen in any of the firming conditions. This infers that the initial addition of firming buffer 
had detrimental effect on HS-5 viability however, the addition of a medium change on day 
2 reduced this effect. 
 
To increase the longevity and viability of cells within the scaffold the addition of a medium 
change on day 4 was investigated (Figure 3-9 G & H). Scaffolds were treated in the same 
way as described above but on day 4 a further 50% change was performed. This protocol 
produced a statistical increase in cell number of those cells treated with a 25 or 50% firming 
solution between days 2- 5. However, only those cells within 50% treated scaffolds resulted 
in a statistical increase in viability over the same period. 
 
The results from this section identified that a 50% firming solution, 100% medium change 
on day 2 and a 50% change on day 4 gave a robust scaffold with maintenance of total cell 
number >2.5 x 105 and viability >50%. Therefore, this protocol was used to assess the 
optimal initial seeding density of HS-5 onto AlgiMatrix™ scaffold for long term co-culture.  
 
3.3.2.3. Identifying the optimal seeding density of HS-5 cells within 
AlgiMatrix™ scaffolds. 
 
In order to identify the optimum seeding density required for prolonged growth in an 
AlgiMatrix™ scaffold, the growth of HS-5 cells in differing 2D well areas were investigated 
and compared to that of a routinely used 25cm2 flask. The cell number, viability and presence 
of Ki67 (Figure 3-10A, B and C) was assessed in a 25cm2 flask, 24 and 12 well plate at a 
starting seeding concentration of 6 x 103 cells/cm2.  Throughout the 168 hour incubation (7 
days) cell number, viability and Ki67 was significantly reduced in the 24 well plate 
compared to that of both the 25cm2 flask and 12 well plate with a viability constantly <60%. 
The 24 well plate did increase in cell number (4.2 x 104 cells) and Ki67 percentage (41%) at 





168 hours, but not to the level of the 12 well (6.7 x 105 cells and 58%) and 25 cm2 flask (9.2 
x 105 cells and 84%). A significant decrease was seen in the 12 well plate compared to the 
25cm2 flask at 168 hours in both Ki67 percentage and cell number.  Total cell number was 
also reduced between 168 and 216 (6.7 x 105 – 4.8 x 105 total cells) in the 12 well plate, 
however, this did not result in a significant change in viability or Ki67 compared to the 
25cm2 flask. Cell cycle was also assessed for 25cm2 flasks, and 24 and 12 well plates (Figure 
3-10D, E, F) but no significant difference was seen between culture vessels. However, all 
culture vessels maintained a high level of cells with the G0/G1 transition. These results 
indicate that a 12 well plate has comparable growth to a 25cm2 flask, up to 168 hours and 
should be used for AlgiMatrix™ addition. 
 
The growth of differing initial total cells seeded onto an AlgiMatrix™ and their effects on 
long term culture was then investigated. Scaffolds were seeded in a 12 well plate with either 
2.5, 5, 7.5 or 10 x 105 total HS-5 cells and assessed for cell number, viability and the presence 
of Ki67 over a 312 hour period (Figure 3-11 A, B and C). It can be seen that after an initial 
incubation of 24 hours 5, 7.5 and 10 x 105 seeding densities decreased in cell number, 
viability and Ki67 with no significant difference between each. However, those scaffolds 
seeded at 2.5 x 105 total cells, did not have a reduction in cell number but did decrease in 
viability and Ki67 during the same time period.  The following 144 hours saw only a 
statistical increase in viability (42%-70%) and Ki67 (38%-65%) in those cells initially 
seeded at 2.5 x 105 total cells, with total cell number over this period remaining 
approximately 2.5 x 105 total cells. The rise in viability continued in the 2.5 x 105 group but 
coincided with a decrease in Ki67.  Those scaffolds initially seeded at 7.5 x 105 total cells 
did see a spike in cell number (1 x106 cells) at 120 hours, but this decreased over the 
remaining time along with both viability and Ki67. Cell cycle was also assessed for 2.5, 5, 
7.5 and 10 x 105 cells/ scaffold (Figure 3-11, Figure 3-10 D, E, F, G) but no significant 
difference was seen between culture vessels. However, once again as in 2D, all culture 
vessels maintained a high level of cells with the G0/G1 transition. These results indicate that 
a starting seeding density of 2.5 x 105 total HS-5 cells left to incubate over a 168 hour period, 
would be beneficial for the addition of TK6.






Figure 3-10. The growth of HS-5 cells in a 25cm2 flask, 24 and 12 well plate at an initial seeding density of 6x103 cells/cm2. HS-5 cells were seeded at a density of 6 x 103 cells/cm 2 into either a 25 cm2 
flask, 24 or 12 well plate, incubated for 24 hours, complete medium change undertaken, incubated for a further 192 hours with a 50% medium change conducted every 48 hours. At each 48 hour time point, 
cells were harvested and assessed for total cell number (A) viability (B) and the presence of Ki67 (C). Cells within a 25 cm2 flask (D), 24 well plate (E) or 12 well plate (F) were also analysed for cell cycle over 
the same period. (50,000 events) (n=3) Significant differences were calculated using a Two-Way ANOVA followed by a Dunnett’s test. Significant differences between A. 25 vs 24 ****, 12 vs 24 **** 
& 25 vs 12 *** B. 12 vs 24 * & 25 vs 12 ** C. 12 vs 24 *, 25 vs 12 *** & 25 vs 24 **** were * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, actual p values can be found in appendix 1. 
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Figure 3-11. The growth of HS-5 cells seeded at 2.5, 5, 7.5 and 10 x 105 cells onto an AlgiMatrix™ scaffold. HS-5 cells were seeded at a density of 2.5, 5, 7.5 and 10 x 105 cells onto AlgiMatrix™ scaffolds, 
transferred to a 12 well plate, incubated for 24 hours, complete medium change undertaken and incubated for a further 312 hours with a 50% medium change every 48 hours. At each 48 hour time point, cells 
were harvested and assessed for total cell number (A) viability (B) and the presence of Ki67 (C). Cells at a starting seeding density of 2.5 (D), 5 (E), 7.5 (F) and 10 x 105 (G) cells were also analysed for cell cycle 
over the same period. (50,000 events) (n=3). Significant differences were calculated using a Two-Way ANOVA followed by a Dunnett’s test. Significant differences between B. 24 hour 2.5 vs 168 hour 
2.5 **** & 2.5 vs 5 **** C. 24 hour 2.5 vs 168 hour 2.5 **** were **** p < 0.0001, actual p values can be found in appendix 1. 





















































































































































































































































3.3.2.4. Identification of TK6 cells utilising florescent CD markers 
 
In order to identify TK6 from HS-5 in future co-culture experimentation, the use of 
fluorescent antibodies of TK6 specific CD markers was investigated. The CD19 and 20 
membrane markers were investigated for their presence on TK6 and HS-5 cells. It can be 
seen that HS-5 cells stained with each marker only produced one peak with the isotype 
control when analysed via flow cytometry (Figure 3-12 A). However, when TK6 were 
analysed, a sharp peak which has shifted to the right of the isotype control can be identified 
in Figure 3-12 A for CD19, whereas a broader peak can be seen with CD20 as fewer TK6 
cells express this. As the presence of CD19 and 20 can clearly be identified, a total mixture 
of 3 x 105 TK6 and HS-5 cells in ratios of 100:0, 75:25, 50:50, 25:75, 0:100 were stained 
with CD19 and analysed by flow cytometry for the actual number of CD19 positive cells 
and percentage of TK6 vs HS-5 (Figure 3-12 B and C). Utilising percentage positive cells 
and the total cell number counted using trypan blue, the true number of TK6 successfully 
stained in each ratio can be seen compared to HS-5 (Figure 3-12 B). At 100% or 3 x 105 
TK6 cells, 2.9 x 105 cells were stained and detected. At 50% or 1.5x105 TK6 cells, 1.9 x105 
cells were stained and detected with no cells detected at 0% or 0 TK6 cells. These total cell 
numbers were then converted into a percentage compared to the original trypan blue cell 
number. Figure 3-12 C shows the comparison between the original ratio and the actual 
percentage of TK6 in each sample. There is no significant difference between the estimated 
and actual percentage at 100, 75 and 0%. However, the actual percentage was statistically 
decreased compared to the estimated percentage at 50 and 25% TK6.  
 
 






Figure 3-12 Histogram plot of CD19 and CD20 expression in TK6 and HS-5 cell lines. The expression of CD19 and 
CD20 (A) in TK6 and HS5 cells. Bar chart showing the total number (B) and percentage (C) of TK6 cells expressing CD19 
in differing ratios with HS-5 (50,000 events, n=3). Significant differences between samples were calculated using a 
Two-Way ANOVA followed by a Dunnett’s test. The P values are indicated by ** (p <0.01), **** (p <0.0001), actual 
p values can be found in appendix 1. 
 
3.3.2.4.1. Identifying an initial concentration of TK6 and optimal 
long-term co-culture condition. 
 
To investigate the required initial seeding density and exponential phase of TK6 cells for 
dosing of actively proliferating cells, HS-5 cells were seeded onto AlgiMatrix™ and 
incubated using the protocol described in section 2.3.1. TK6 cells were then directly added 
to each scaffold at an initial seeding density of 0.5, 1 and 3.5 x 105 cells/ml. A medium 
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As identified in section 3.3.2.4 TK6 express CD19 unlike HS-5, this marker was used to 
distinguish TK6 from HS-5 in co-culture via flow cytometry, therefore, TK6 will now be 
identified as CD19+ and HS-5 CD19- in Figure 3-13.  
 
Those scaffolds seeded with an initial concentration of 3.5 x 105 cells/ml, saw combined 
CD19+ and CD19- from the scaffold and medium increase over an initial 24 hour period 
(Figure 3-13 C) to a combined density of 2.7 x 106 cells.  However, after a further 6 hours, 
the combined CD19+ cell population decreased whilst CD19- cells surpassed that of CD19+. 
Due to this shift in CD19+ and CD19- cells the experiment was terminated, and a medium 
change was not conducted. This result indicated that a lower seeding density of TK6 was 
required for culture past 24 hours. 
 
A seeding density of 1 x 105 cell/ml was then trialled (Figure 3-13 F), which once again 
showed a steady increase in CD19+ cells, entering into an exponential phase at 24 hour up 
to a total cell number of 1.4 x 106 at 54 hours, over the same time period CD19- cells stayed 
<2.5 x 105. However, after a further 24 hours of culture, the combined CD19- cell population 
increased and surpassed that of a decreasing CD19+ population. The shift in CD19 was seen 
for the remainder of the experiment, with CD19+ cells constantly decreasing from 1.4 x 106- 
5 x 105 cells between 54- 96 hours but CD19- cells remaining approximately 1.3 x 106. As 
this result was also previously identified in Figure 3-13 C and no medium change had 
occurred in either, the introduction of a medium change was then investigated. As an initial 
seeding density of 1 x 105 cell/ml extended the experiment by 30 hours, compared to 3.5 x 
105 cells/ml, this was used as the initial seeding density before a 50% medium change was 
conducted at 24 hours (Figure 3-13 G). This medium change increased the duration that 
CD19+ cells proliferated (0-30 hours), compared to 3.5 x 105 cells/ml (0-24 hours), with 
CD19- remaining <2.5 x 105 and the start of an exponential phase of CD19+ cells identified 
between 6-24 hours. However, a medium change at this time point (24 hours) caused a 
decrease in CD19+ and increase in CD19- cells, at approximately 30-48 hours, a reduction 
from the 54-72 hours seen in Figure 3-13 F. This result seemed to indicate that a lower 
seeding density would be necessary but with added medium changes. 






Figure 3-13. Initial seeding density and long-term culture of TK6 (CD19+) cells, co-cultured with pre-cultured 
AlgiMatrix™ scaffold. HS-5 (CD19-) cells seeded onto AlgiMatrix™ scaffolds at a density of 2.5 x 105, incubated for 24 
hours, complete medium change conducted, incubated for a further 144 hours with a 50% medium change every 48 hours. 
TK6 were then combined at an initial concentration of 3.5 (A, B, C), 1 (D, E, F, G, H, I) or 0.5 x 105 cells/ml (J, K, L, M, 
N, O). A 0% (A, B, C, D, E, F) or 50% (G, H, I, J, K, L, M, N, O) medium change was conducted every 0 (A, B, C, D, E, 
F), 24 (M, N, O) or 48 (G, H, I, J, K, L) hours over a 102 hour period. highlighted with an arrow. Twice over 24 hours, six 
hours apart, cells were collected from the medium (B, E, H, K ,N)  and dissolved scaffold (A, D, G, J, M) , counted and 
stained separately with CD19 antibody. Percentage positive of cells was assessed by flow cytometry for total CD19+ and 











































































































































































































































































































































































































































As 1 x 105 cell/ml increased the longevity of the experiment, compared to 3 x 105 cell/ml, 
an initial seeding density of 0.5 x 105 cell/ml then investigated with a medium change every 
24 hours (Figure 3-13 M). It can be seen that the CD19+ cells remain under 7 x 105 cells 
until hour 54, at this point an exponential phase can be seen between 54- 96 hours (5 x 105 - 
2x106 total cells) with CD19- cells remaining <5 x 105 up to 96 hours. At 102 hours, CD19+ 
cells reduced and CD19- cell increased in cell number, but didn’t surpass. The introduction 
of a medium change every 48, not 24 hours, was also trialed (Figure 3-13L) but once again 
CD19+ cells decreased at 96 hours, surpassed by CD19-. However, it was noted that the start 
of the exponential peak occurred at the same period (54- 96 hours) as a medium change 
every 24 hours. In all cases, before surpassing CD19+ cells, CD19- cells remained >5 x 105 
total cells in the medium and scaffold. The proliferation of TK6, CD19+ cells, in the medium 
and scaffold was at the same rate despite the compartment they resided in. However, an 
increase in TK6 within the scaffold was required before an exponential increase in the 
medium was seen.  Given this result, TK6 seeded at an initial density of 0.5 x 105 cell/ml 
and a 50% medium change every 24 hours identified an exponential peak, fit for compound 
dosing, between 54 and 96 hours (Figure 3-13 O).  
 
 In an effort to ensure that each well had been fully harvested of TK6 and HS-5 cells, light 
microscopy investigation of the well surface before and after TK6 addition was assessed 
(Figure 3-14). It can be seen that after 168 hours of incubation, a small population of HS-5 
cells reside upon the well surface not on the scaffold (Figure 3-14 A). After the addition of 
TK6, and a 24 hour incubation, this small population of HS-5 seem to draw and adhere to 
the TK6 cells causing them to become immobile (Figure 3-14 B). However, after the medium 
and scaffold are removed and well surface washed, only a small population of both TK6 and 
HS-5 cells reside upon the well surface (Figure 3-14 C). This result highlights three cellular 
environments within each well, which includes the scaffold, medium and well surface. The 
role of each of these environments should be considered when administering compound.








Figure 3-14. Light microscopy images of the bottom of a 12 well plate containing a seeded AlgiMatrix™ scaffold. HS-5 cells seeded onto AlgiMatrix™ scaffold at a density of 2.5 x 105, incubated for 24 
hours, complete medium change conducted, incubated for a further 144 hours with a 50% medium change conducted every 48 hours. (A) HS-5 cells residing on the bottom of the 12 well plate after 144 hour 
incubation of the AlgiMatrix™ scaffold, before the addition of TK6 at 0.5 x 105 cells/ml (4x magnification). (B) The bottom of a 12 well 168 hours after initial AlgiMatrix™ seeding and 24 hours after the addition 
of TK6 (10x magnification). (C) The surface of a 12 well plate after the removal of AlgiMatrix™ and TK6, 24 hours after TK6 initial seeding (20x magnification). Green arrows indicate TK6 cells, red arrows 
indicate HS-5 cells. Scale bar A. 100 µm B & C. 50 µm .
A B C





The establishment of an initial seeding density and protocol for the longevity of both cell 
lines, allowed the investigation into the effects of TK6 and medium change on HS-5 viability 
and cell number (Figure 3-15).  It can be seen that after an initial incubation (168 hours) of 
HS-5 onto the AligiMatrix scaffold, the viability, identified by flow cytometry, of HS-5 cells 
remained approximately 80% (Figure 3-15 A). TK6 in a well insert was then added at 5 x 
104 cells/ml and left to incubate. After a 24 hour incubation, a 50% medium change of each 
well was conducted in the 24 hour group. An additional 24 hour incubation resulted in the 
viability dropping within the 48 hour group but staying approximately 80% within the 24, a 
medium change was then conducted in both the 24 and 48 hour groups and incubated for a 
further 24 hours. At this point a third 50% medium change was conducted on the 24 hour 
group and incubated a further 24 hours. Those HS-5 which received a 50% medium wash 
every 24 hours after addition of TK6 within a trans-well insert, remained at approximately 
80% viability. However, the viability of those who received a medium change every 48 hours 
reduced to approximately 50%.  
 
The viability recorded using flow cytometry (Figure 3-15 A), combined with the total cell 
number identified via TB, gave a total live cell figure for each time point (Figure 3-15 B). It 
can be seen that the live cell number did not change between 0 and 168 hours. However, 
after the addition of TK6 and a 24 hour medium change (24 hour group only), cells in both 
the 24 and 48 hour groups increased in live cell number from 1.6 x 105 live cells to 1.7 x 105 
(24 hour group) and 2.4 x 105 (48 hour group). After a further 48 hour incubation, the live 
cell number increased again in the 24 hour group (1.7  x105- 2.2 x 105), however, a decrease 
in live cell can be seen in the 48 hour group below the initial count (2.4 x 105- 1.5 x 105).  
These outcomes reinforce previous results in identifying the need for a medium change every 
24 hours. 







Figure 3-15. Viability of HS-5 cells seeded onto an AlgiMatrix™ scaffold with the addition of TK6. HS-5 cells seeded 
onto AlgiMatrix™ scaffolds at a density of 2.5 x 105, incubated for 24 hours, complete medium change conducted, 
incubated for a further 144 hours with a 50% medium change conducted every 48 hours. At each 48 hour time point, 
scaffolds were harvested and assessed for total cell number (TB) and viability. After 168 hours of incubation, TK6 cells 
were added at a concentration of 5 x 104 cells/ml into a 0.25 µm well insert residing within each scaffold well. A 50% 
medium change conducted ever 24 or 48 hours. Each time point was compared to a dead (HS-5 incubated at 100 oC for 10 
minutes), live (HS-5 cells at a viability of >90%) and 50:50 (dead: live) control for percentage positivity (A). This 
percentage positivity was then used to calculate the total number of live HS-5 cells in each condition (B). (50,000 events) 
(n=3). Significant differences between samples were calculated using a Two-Way ANOVA followed by a Dunnett’s 











































































50% Medium replacment every 48 
hours after the addition of TK6
50% Medium replacment every 24 
hours after the addition of TK6
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3.3.3. 3D printing of an in-house Alginate scaffold 
 
3.3.3.1. Optimisation of a bespoke hydrogel for 3D printing and culture 
 
 
A bespoke hydrogel (60% sodium alginate, 32% pluronic F127 and 8% medium) was 
constructed (to compare with the previously described Biomerix™ and AlgiMatrix™ 
scaffold) utilising the protocol in Armstrong et al. (2016). This hydrogel remains semi-
fluidic at room temperature and partially solidifies at 37 oC, therefore, can be shaped into 
any form chosen. This hydrogel, Like the AlgiMatrix™, can incorporate cells into the 
scaffold itself reducing the need to layer cells upon a solid scaffold. However, once extruded 
into its final shape, this hydrogel must be crosslinked with varying concentration (100-1000 
mM) of CaCl2, dependant on the eventual application, and maintained in 5 mM CaCl2 in 
order to gain the long-term structural integrity seen in the AlgiMatrix™ and BM ECM.  
 
To assess the effect of CaCl2 on viability, HS-5 cells were directly exposed for 10 minutes 
to differing concentrations of CaCl2 (Figure 3-16). The results in Figure 3-16 show that when 
seeded into a 12-well plate, not scaffold, the viability decreases from 95% (0 mM) to 85% 
(100 mM) to 55% (500 mM) to 20% (1000mM) after the 10 minutes of exposure. These 
results infer that 1 M CaCl2 is extremely toxic to cells due to a 65% reduction in viability. 
However, a lower concentration of 100 mM gave a viability >80%. Therefore, a 
concentration of 100 mM was investigated for its use in solidifying each hydrogel.  
 




Figure 3-16. Viability of HS-5 cells after 10 minute exposure to 100, 500, 700 and 1000 mM CaCl2. The graphs show 
HS-5 seeded at 1 x 105 cells into a 12 well plate, incubated for 2 hours before the addition of a concentration of CaCl2 fo 
10 minutes. Each well was washed with PBS before the addition of trypsin. Cell viability was assessed using acridine 
orange / propidium iodide stain (n=3).  
To test this, a hydrogel was recreated using the Armstrong et al. (2016) published protocol. 
These hydrogels were then crosslinked with 100 mM CaCl2 in complete medium for 10, 15, 
20, 25 and 30-minute as seen in Figure 3-17. An additional concentration of 1 M CaCl2 was 
also tested (Figure 3-17). Once the hydrogel had formed the medium was removed and fresh 
5 mM CaCl2 in complete medium was added. This protocol should produce a tight hydrogel 
structure like the ECM of human BM for HS-5 to spread and interact, with uniform pores 
across the hydrogel suitable for cytokines and other cellular signalling molecules to flow.  
As can be seen in Figure 3-17 the 1 M hydrogel has formed a solid, opaque ball which light 
will not pass through. This 1M hydrogel took 10 minutes to develop, which when taken out 
of the medium and squeezed with tweezers sprang back to its initial structure. The addition 
of 100 mM, as seen in Figure 3-17 for 10, 15, 20 and 25 minutes gave a slightly transparent 
hydrogel which disassociated when manipulated with tweezers. It wasn’t until 30 minutes 
of incubation that the hydrogel represented the mechanical properties of that seen with 1M. 
Due to the similar mechanical properties of the 1 M and 100 mM (30 minutes) hydrogels, 






























Figure 3-17 Image of crosslinked hydrogels after a 30 minute period to 100 mM or 1 M CaCl2 in medium. Image 
shows the hydrogel formed after 10, 15, 20, 25 and 30 minute bioink exposure to 100 mM CaCl2. The image also shows a 
10 minute exposure to 1 M CaCl2. At each time point the 100 mM/1 M CaCl2 was replaced with 5 mM CaCl2 to maintain 
the gel’s structure. 
The hydrogels were subjected to SEM at a magnification of x1000 (Figure 3-18 A) and x600 
(Figure 3-18 B). The 1 M hydrogel can be seen in Figure 3-18 A and shows a very compact, 
uniform construction with pores no bigger than approximately 1 µm being visible through-
out. The 100 mM hydrogel seen in Figure 3-18 B, however, shows a very loose construction 
with varying pore sizes across the area (approximately 1- 50 µm approximately). These 
results show that a concentration of 1 M would be beneficial in the production of a scaffold 
which HS-5 cells could be layered upon, but 100 mM could be used for the inclusion of cells 
into the scaffold itself. This hydrogel, due to it semi-fluidic nature at room temperature, 
could be used within cutting edge 3D biological printers as a bioink which could be extruded 
into any shape necessary. Therefore, the use of this hydrogel as a bioink in a 3D biological 
printer was investigated.  




Figure 3-18 Scanning electron microscope (SEM) images of the bespoke alginate hydrogel. Hydrogels were 
crosslinked with either 1 M (A) or 100 mM (B) CaCl2 until the gel had solidified adequately to undergo SEM. Scaffolds 
were left to dry overnight on lint free tissue before being processed for SEM. A. 1000x magnification of a crosslinked 
hydrogel with 1 M CaCl2 for 10 minutes. B. 600x magnification of a crosslinked hydrogel with 100 mM CaCl2 for 30 
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3.3.3.2. Conversion of a polylactic acid 3D printer to extrude biological 
material 
 
To construct a 3D hydrogel ECM, a personal communication with Richardson and Perriman 
of the University of Bristol led to the idea of converting a conventional 3D printer into a 
biological one which could print bioink. Richardson and Perriman suggested using the 
Mendlemax 3D printer as this could be modified easily with parts printed on the machine 
itself. Richardson and Perriman had used the 3D printer before and agreed to allow UWE 
access to the conversion data required. The converted 3D printer would allow the extrusion 
of bioink forming a bespoke scaffold of varying size and shape produced using online 
software. 
 
Figure 3-19 of the 3D printer shows how it was bolted together (Figure 3-19 A) using an 
online manual from Makertoolbox (the supplier of the printer). The motherboard, motors, 
power supply and fans were then wired into the shell to produce a fully functioning 3D 
printer (Figure 3-19 B). To show that the printer can print a platform of our choice, a bespoke 
scaffold was designed (Figure 3-19 C- G). Firstly, a SEM image of human BM was traced 
in black and white (Figure 3-19 C) so that the online software Selva could differentiate the 
pores from the ECM when converting the 2D trace into a 3D stl. file (Figure 3-19 D). The 
converted, single plain 3D trace was then uploaded into the online software Tinkercad where 
it was duplicated, turned on its axis and collated to form a completed bespoke scaffold 
(Figure 3-19 E). This completed scaffold was then uploaded to the 3D printer software 
Mattercontrol (Figure 3-19 F) and printed in PLA thermoplastic. The resulting successfully 
printed scaffold (G) showed that it was possible to print a scaffold of our choice, thus the 
conversion into a 3D bioprinter began. The 3D stl. conversion files (pusher, motor holder 
and mounting bracket) were kindly donated by Richardson and printed out in PLA using the 
Mendlemax 3D printer (Figure 3-19 H). Due to the differing constraints the bioink, but not 
the solid PLA, would have on the printer, firmware (computer code) was uploaded to the 
Mendlemax using the programme Arduino (Figure 3-19 I). The printer was then ready for 
the extrusion of the hydrogel bioink in a constant, uniform pattern as seen in Figure 3-19 J. 
However, the inclusion of cells into the bioink before extrusion was unmanageable due to 
long printing times and lack of sterility. The printing time was reduced with optimisation, 
but due the sheer force on the pump motors, produced from printing a viscous fluid, this time 
could not be reduced to <1 hour for the simple structure seen in Figure 3-19 J. The issue of 
time was not a problem with structures printed without HS-5 inclusion, but a scaffold that 
Chapter Three: Developing a 3D model of the BM using commercial cell lines 
 
 87 
could retain these cells was ultimately required. Due to time restraints caused by increased 
printing times and further optimisation of the gel itself, which had already been conducted 
with the similar commercial AlgiMatrix™ scaffold, this hydrogel was side-lined for future 
work in favour of the AlgiMatrix™ scaffold. 
 




Figure 3-19 Process of building and converting a 3D printer whilst also creating a bespoke scaffold from scratch. The process follows the chronological order as depicted by A, B, C, D, E, F, G, H, I and J 
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3.3.4. Identification of a single cell type within a co-culture  
 
3.3.4.1. Identification of TK6 cells from HS-5 
 
In order to identify micronuclei within either the HS-5 or TK6 co-cultured population, the 
nanocrystal dye, Qtracker, was evaluated. The Qtracker dye, using manufactures guidance, 
was added to TK6 and mixed with unstained HS-5 cells in ratios of 0:100, 25:75, 50:50, 
75:25, 100:0 (Figure 3-20 A-E respectively). It can be seen, under fluorescent microscope, 
that as the ratio of TK6 to HS-5 increases, the Qtracker dye also is seen to increase. These 
seeding ratios were also analysed using flow cytometry (gating strategy Figure 2-1) (Figure 
3-20 H), with percentage Qtracker stained cells vs percentage positive events equating to 
100% = 91%, 75% = 67%, 50% = 49%, 25% = 20 and 0% = 0%. However, when TK6 cells 
in isolation were counterstained with either DAPI (Figure 3-20 F) or Hoescht (Figure 3-20 
G), the Qtracker dye was unable to identify individual cellular membrane boundaries for the 
detection of micronucli.  
 
 
Figure 3-20 Fluorescent microscopy images of TK6 cells stained with Qtracker combined in differing ratios with 
unstained HS-5 cells TK6 cells were incubated with Qtracker dye (10 nM). The stained TK6 cells were then mixed in 
differing ratios with unstained HS-5 cells A: 0:100, B: 25:75, C: 50:50, D: 75:25, E: 100:0 (40x magnification). The nucleic 
stains DAPI (F) and Hoescht (G) were then added to Qtracker stained TK6. Bar chart (H) showing the number of events 
positive for Qtracker when analysed via flow cytometer (50,000 events) (n=3). Scale bars indicate 50 µm. 































Chapter Three: Developing a 3D model of the BM using commercial cell lines 
 
 90 
The use of CD19 and 20, identified in section 3.3.2.4, were evaluated for their use as a 
membrane marker for the identification of micronuclei in TK6 cells (Figure 3-21). A ratio 
of TK6 to HS-5 cells (total cell number of 3 x 105 total cells) at 100:0, 50:50 and 0:100 were 
first stained with CD19 and 20 conjugated antibodies (FITC and PerCy5.5) and subsequently 
counterstained with DAPI (Figure 3-21 A, B and C). The combination of antibodies and 
DAPI produced an image which was unable to differentiate TK6 from HS-5 cells or clearly 
identify nucleic acid material. Utilising the same ratio of cells, a primary, unconjugated 
antibody of CD19 and 20 was first incubated with each culture, a secondary Alexa Fluor 488 
fluorophore was then incubated before the addition DAPI. This staining combination 
produced images in which the ratio of TK6 to HS-5, membrane and nucleic acid material 
can be clearly seen (Figure 3-21D, E and F) and would be used in further studies. 




Figure 3-21 Fluorescent confocal microscopy images of TK6 and HS-5 cells stained with CD19, CD20 and DAPI in differing ratios. TK6 and HS-5 were combined in differing ratios A, D: 0:100, B, E: 
50:50, C, F: 100:0 before being spun down onto slides for staining. Cells were either stained with conjugated CD19, CD20 (A, B, C) or unconjugated CD19 and CD20 with an Alexa Fluor 488 secondary (D, E, 
F) before the addition of DAPI and progold antifade. A, B, C 40x magnification D, E, F 60x magnification. Scale bars indicate 50 µm.
D E F
A B C





The aim of this chapter was to establish an in vitro model of the BM, which simulated the 
in vivo environment, for the proliferation and expansion of co-cultured cells for the future 
addition of compound. The results presented within this chapter show the successful 
selection, optimisation and long-term culture of a simple, reproducible, in vitro 3D model 
of the BM, utilising cell lines and a static dissolvable ECM which simulated the structure 
of the in vivo environment. This model was also able to maintain the TK6 cell line in its 
exponential phase.  
 
3.4.1. 3D Scaffold assessment  
 
3.4.1.1. The Biomerix™ hard scaffold already in use at UWE 
 
A model already in development at UWE was first trialled for its ability to simulate the 
microenvironment of the BM. This model utilised the commercially manufactured, hard, 
polyurethane based Biomerix™ scaffold. This scaffold was initially identified as a candidate 
as it has been used in regenerative medicine, in combination with primary MSCs, due to its 
biocompatibility and interconnecting pores, of around 100 to 250 µm, which closely 
corresponded with the structure of the in vivo BM (Gniesmer et al., 2019; Encalada-Diaz et 
al., 2011). These matrices were then cultured with an initial layer of the cell line, HS-5. The 
HS-5 cell line has a fibroblast morphology which is used as a stromal layer due to its 
secretion of large quantities of cytokines. The cytokines released imitated that seen in the 
human BM, driving differentiation of haematopoietic stem cells to maturation 
(Ramakrishnan et al., 2013; Aqmasheh et al., 2017). The HS-5 cell line differs however, 
from the primary MSCs within the human BM as they are less adherent which could explain 
the lack adherence to the Biomerix scaffold seen in Figure 3-1, 3-2, 3-3 and 3-4 (Adamo et 
al., 2020).  
 
The results from Figure 3-1 show that after using the original seeding protocol of a 2 hour 
incubation of 5 x 105 cells upon the Biomerix™ scaffold, before the addition of fresh 
medium, cells evacuated the scaffold and adhered to the surrounding plate. This result can 
be justified primarily via adherence time, cell-cell contact and surface area. Work conducted 
by Salzig et al. (2016) found that primary MSCs adhered within 4 hours when seeded at a 
concentration of 7 x 103- 1 x 104 cells cm2 in a six-well plate. However, work by Vasibuh et 
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al. (2010) found that when utilising at a seeding density of 1 x 106 cells per scaffold, primary 
cells needed 24-48 hours to adhere with cells still leaving the scaffold when flushed. The 
work conducted on HS-5 cells by Wang et al. (2007) and Mraz et al. (2011), found that at a 
seeding concentration of 5 x 104 cells per well 24-48 hours was the minimum time needed 
for successful adhesion to a 96/24 well plate. The first conclusions made from this evidence 
is that a lower seeding density is needed when seeding in plates (7 x 103 – 5 x 104 cells), 
compared to Biomerix™ (1 x 106), due to the maximum surface area available to the cells 
in the latter. The Biomerix™ has a greater surface area, so required a greater initial seeding 
density for close cell-cell communication when adhering. The initial seeding density of 5 x 
105 cells used in Figure 3-1 was thus too low, and cells evacuated the scaffold to adhere on 
the plate where there was less surface area. The second conclusion that can be drawn from 
the evidence above is that primary MSCs, which are more adherent than HS-5, need around 
4-24 hours incubation, with HS-5 needing at least 24 hours (Adamo et al., 2020). The initial 
2 hour incubation utilised in Figure 3-1 thus was too short.  
 
The conclusion, that an initial 2 hour incubation was too short for successful adherence, were 
then rectified using time lines within the literature. The initial adherence time was increased 
to 4, 5 and 24 hours, with initial seeding densities of 5 x 105 and 1 x 106 cells/ scaffold tested. 
Scaffolds were left for cells to adhere naturally, or scaffolds were compressed- 
decompressed after addition of cells, as this was hypothesised to bring a higher proportion 
of cells to the centre of the scaffold increasing cell-cell contact. In line with the previously 
mentioned literature, a higher seeding density of HS-5 (1 x 106 cells/ scaffold) combined 
with a prolonged initial seeding time of 24 hours, increased the cells remaining within the 
scaffold. Conversely, scaffolds that were compressed-decompressed retained less HS-5 than 
those left to adhere naturally. This finding suggests that the internal surface area of the 
Biomerix™ was still too large, even with increased cell number, and that cells that naturally 
adhered to the external structure of the Biomerix™ were in closer proximity and thus 
remained attached. However, even when using the increased initial seeding time (24 hours) 
and cell number (1 x 106 cells/scaffold), regardless of the manipulation of the scaffold, HS-
5 cells still evacuated the scaffold during long term culture as can be seen in Figure 3-4. This 
finding could, in part, be due to the small amount of medium used to initially adhere the HS-
5 onto the scaffold. In all experimentation, HS-5 were added to scaffolds in 20 µls of medium 
before a 2, 4, 5 or 24 hour incubation. This amount of medium was seen as sufficient initially, 
due to a 48 hour doubling time of HS-5. but work by Kosol et al. (2019) found that a 
reduction in medium supplementation caused a considerable reduction in cellular processes, 
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such as adherence of stromal cells similar to HS-5. However, the study also suggested that 
even with larger volumes of medium, cells still may not adhere and instead prefer to reside 
in the medium or plate due to cell-cell contact, and surface area described previously. Work 
by Bruce et al. (2015) found that in human BM stromal cells, the use of microfluidic systems 
increased cells residing within the scaffold. It was suggested that the constant sheer force 
and circuit of flow, reduced the adherence to the plate, thus cells remained in the medium. 
This medium was then constantly forced through the scaffold allowing cells to only adhere 
to the scaffold itself. It was concluded from this evidence, that the Biomerix culture protocol 
could work in a microfluidic system. However, due to the increased cost and complexity of 
microfluidics, which was beyond the scope of the project, investigation into an alternative 
scaffold, which would encapsulate and or adhere the HS-5 in place in a static system, would 
be more beneficial in developing a cheap, reliable, easy to use assay in any laboratory.  
 
3.4.1.2. Establishing a new model for 3D co-culture  
 
Reviewing the current literature and conversing with collaborators at University of Bristol 
and AstraZeneca, it was decided that an alginate hydrogel model would best suit the needs 
of this research, as they have been used in regenerative and tissue engineering of the BM 
due to its bio-mechanical properties (Hernández-González et al., 2020). Alginate, a lineal 
hydrophilic polysaccharide, can be dissolved into complete medium, with/ without cells, to 
make a thick honey-like liquid. This can then be crosslinked with a divalent cation, such as 
CaCl2, to form a rigid hydrogel with pores of differing sizes depending on the concentration 
of the divalent cation, encapsulating cells within. The alginate hydrogel can then be 
dissolved using a chelating agent such as EDTA for retrieving the cells within (Stagnaro et 
al., 2018). The Algimatrix™ scaffold, once solidified, can also be dissociated using the 
dissolving buffer supplied by the manufacturer. As this category of hydrogel would negate 
the issues seen with the Biomerix™, as cells would be encapsulated into the hydrogel, two 
differing alginate hydrogels were selected, including the commercial Algimatrix™ and 
hybrid  in-house hydrogel constructed by Armstrong et al. (2016). The Algimatrix™ system 
consists of a freeze-dried scaffold, containing alginate, which is then rehydrated with a 
firming buffer with/ without cells (Godugu & Singh, 2016). However, the in-house hybrid 
gel required the combination of alginate, pluronic F127 and medium, with/ without cells, 
which was then bathed in CaCl2 to form a rigid structure. This selection allowed the 
comparisons between a hydrogel with known constituents (hybrid), versus one that we did 
not (Algimatrix™), for the ability to create an in vitro environment similar to that of the in 
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vivo BM. In both cases, a solution of either CaCl2/ firming buffer was needed to solidify 
either the hybrid gel or freeze-dried scaffold, the concentration of which, in either case, 
determined the pore size and mechanical properties of the final structure. 
 
The Algimatrix™ firming buffer was investigated for its effect on HS-5 cells. A firming 
solution of either 10, 25 or 50%, firming solution: medium, was added to the freeze-dried 
scaffold and incubated for 5 minutes before fresh medium added. It can be seen in  Figure 
3-5 B, C, E, F, H and I that there is no difference in internal or surface structure under light 
microscopy. However, the overall mechanical structure differs greatly. Those scaffolds 
solidified in 10% firming buffer ( Figure 3-5 A) fell apart under light manipulation, whereas 
25 and 50% ( Figure 3-5 B & C) retained its structure when manipulated. As there wasn’t 
any visible alteration in the internal or external structure of each scaffold, SEM was 
conducted. The SEM images (Figure 3-6) show that at concentrations of 10%, no pores were 
seen, at 25% pores of 25 µm were seen and at 50% pores of 100-150 µm were seen. The 
mechanical and internal structure is as a result of diluted cation within the firming buffer. 
Studies such as Zhang et al, (2020), Watanabe et al, (2019), Çelik et al, (2016) and Agulhon 
et al, (2014) found similar results when setting alginate scaffolds. These studies found that 
at lower concentrations of cations such as Mn2+ Co2+, Cu2+, Ca2+, Mg2+ and Sr2+, penetration 
to the centre of the scaffold was not achieved, leaving an alginate hydrogel of poor 
mechanical structure and smaller internal pore size, similar to the scaffold seen at 10 and 
25%. At low concentration, the cation solution is depleted through chelation with (1-4)-ß-
D- mannuronic acid and α-L-guluronic acid subunits, before it can reach the centre. 
Therefore, this was overcome by saturating the scaffold in a high level of cation solution, 
similar to solidifying each scaffold in 50% firming buffer, so that crosslinking can occur 
throughout the entire scaffold.  This same observation was also seen with the in-house hybrid 
gel. The protocol set out in the Armstrong et al. (2016) paper required the alginate, pluronic 
F127 and medium solution to be crosslinked with 100 mM CaCl2 for 10 minutes. However, 
as Figure 3-17 shows the hydrogel did not solidify and instead fell apart. If the gel was 
solidified in 100 mM for 30 minutes a structure which could be manipulated was achieved. 
If the concentration of CaCl2 was increased to 1 M, scaffolds became solidified in only 10 
minutes, to the same degree as 100 mM for 30 minutes. Once again, SEM was conducted on 
both 1 M scaffolds (10 minute incubation) and 100 mM (30 minute incubation) (Figure 
3-18), in line with the literature and the Algimatrix™ scaffold result, small pores of around 
1 µm, with a 100 mM solution, and larger 25 µm, with 1 M CaCl2 were achieved. As 
previously stated in section 4.1.1, the human BM consists of pores around 100 to 250 µm, 
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and it has been found that pore size has a considerable impact on cellular differentiation and 
proliferation of the cellular compartments within the BM (Chen et al., 2020). A study by 
Gupte et al. (2018) identified that smaller pore sizes (<50 µm) would enhance differentiation 
of human BM stromal cells down the chondrogenic lineage compared to large pore scaffolds. 
It was also found that a small pore size reduced interconnectivity and medium flow, 
therefore, promoting capillary formation to enhance this. Conversely, Brennan & Hoey, 
(2019) found that pores of 100- 200 µm was beneficial for cellular morphology, proliferation 
and osteogenic differentiation of human MSCs, signifying that the pore size produced within 
a 50% solidified scaffold of 100 and 150 µm, would be in vivo relevant. 
 
 It can be concluded from these results, a CaCl2 solution of 1 M (hybrid) or a firming solution 
of 25 or 50% (AlgiMatrix™) is required to produce pores which will aid in proliferation, 
differentiation and morphology similar to the in vivo environment. However, does this level 
of CaCl2 or firming buffer cause detrimental effects to the cells which require incorporation 
into the hydrogel or scaffold? 
 
Calcium is fundamental to controlling cell life, hormone secretion, gene expression, immune 
response and apoptosis (Rimessi et al., 2008). As calcium is fundamental to cell life/death, 
Armstrong et al. (2016) utilised a very small dose (100 mM) to set the hydrogel for 10 
minutes with little detriment to the human MSCs within. However, as previous 
experimentation has shown, a concentration of 1 M CaCl2 is necessary for adequate pore 
size and mechanical structure. The results in Figure 3-16 show that when HS-5 cells were 
directly exposed to 1 M CaCl2, viability dropped by 80% with a concentration of 500 mM 
reducing viability by around 50%. Work by Cao et al. (2012) on Schwann cells, with reduced 
susceptibility to calcium compared to BM, looked at crosslinking hydrogels with 100 mM, 
500 mM and 1 M CaCl2 for 5, 10 and 30 minutes. They found that in all cases, direct exposure 
to calcium had triggered an apoptotic response which had reduced the cell viability by 50% 
compared with that of the control. Cao et al. (2012) noted that when cells were indirectly 
(within the hydrogel) exposed to levels of CaCl2, the cell viability was >60% even at a 1 M 
concentration. The cells within the hydrogel seem to be protected from the CaCl2 thus a 
higher concentration had a reduced effect on the cells. Similar work by Acri et al. (2019), 
found that a concentration of 20 mM CaCl2 or below, added directly to human BM MSCs, 
was required for a reduction in toxicity and unaltered gene expression.  
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In conclusion, given the viability and structural data produced with CaCl2, it is not possible 
to incorporate cells into this hybrid alginate hydrogel. This protocol would be beneficial if 
the hydrogel was extruded from a biological printer, seen in Figure 3-19, to form a specific 
structure, crosslinked followed by the addition of HS-5 cells; however, the lack of adherence 
may occur as seen with the Biomerix™. Due to these complications, the use of the hybrid 
alginate scaffold was ceased in favour of the Algimatrix™ system.  
 
The solidified Algimatrix™, as mentioned previously, can be dissociated with the supplied 
dissolving buffer.  The constituents of this buffer are unknown, therefore, the toxicity to HS-
5 was conducted, in parallel with an investigation into similar dissolving solutions. As seen 
in the hybrid gel, a divalent cation was used to crosslink alginate subunits to create a 
solidified structure. When mechanical and structural properties were compared to that of the 
solidified AlgiMatrix™ scaffold, several similarities were seen. Since both scaffolds seem 
to be constructed using a divalent cation, a chelating agent such as EDTA could be the main 
component of this commercial dissolving buffer, and therefore would be used as a 
comparison. The AlgiMatrix™ protocol for dissolving buffer requires bathing each 
solidified scaffold in 3 mls of solution for 5-10 minutes, depending on the percentage firming 
buffer used, with manipulation to break up the scaffold entirely. The firming buffer, with 
increased percentage, introduces more of these crosslinks which require a longer period of 
time to chelate (Grijalvo et al., 2019).    
 
As can be seen in Figure 3-7, when 3 mls of 55 mM EDTA or dissolving buffer was added 
directly to HS-5 cells, there was no difference between solutions in cell number or viability 
over the initial 5-10 minute period required within the protocol. The experiment was 
extended to 30 minutes as this was the maximum time, indicated by the manufacture, needed 
to dissolve an AlgiMatrix™ scaffold with dissolving buffer therefore, if there was no 
detrimental effects up to this point then solutions were determined as non-toxic and, as 
shown, there was no reduction in viability or cell number over this time period. As the time 
required for dissolving was dependent on the firming buffer percentage used, a 50% scaffold 
was bathed in each solution for 5 minutes. A 50% AlgiMatrix™ scaffold was included as 
firming with this solution, which provided the required pore size and mechanical structure 
identified in vivo have the maximum subunits to chelate, therefore should require an 
increased time to dissociate. As can be seen in Figure 3-8, after a 5 minute incubation, in 
either solution, the scaffold hasn’t dissolved, with more remnants within the EDTA solution 
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than dissolving buffer, therefore, a >5 minute incubation in either solution would dissolve a 
scaffold solidified with a firming solution <50%.  
 
Given the results obtained, it can be concluded that both the dissolving buffer and 55 mM 
EDTA are non-toxic to HS-5 cells and that the dissolving buffer’s main constituent appears 
to be a chelating agent similar to EDTA, but possibly more concentrated, as AlgiMatrix™ 
scaffolds were dissolved more rapidly in the dissolving buffer. Now that the dissolving 
buffer has been seen as non-toxic and requires >5 <30 minutes to dissolve a scaffold, the 
successful retrieval of cells, without loss of viability, can be conducted, and the effects of 
the firming buffer on HS-5 seeded within the scaffold was investigated. 
 
The Algimatrix™ firming buffer produced scaffolds which, when compared to the hybrid 
alginate gel, seemed to resemble structures created by a divalent cation such as CaCl2. As 
seen with previous work within section 3.3.3.1, CaCl2 had a detrimental effect on directly 
treated HS-5 cells, however, it seemed from the literature, that cells within a scaffold are 
less affected by the cation compared to those treated with a direct dose. Since the firming 
buffer appeared to include a divalent cation, the toxicity of this buffer was investigated. 
Utilising the protocol put forward by the manufacturer, HS-5 cells were seeded in 10, 25 or 
50% firming buffer, at a total count of 2.5 x 105 cells/scaffold into dry Algimatrix™ 
scaffolds; once set new complete medium was added and then scaffolds left to incubate. 
Even though results in Figure 3-6  showed that a 10% scaffold did not produce a structure 
that simulated the in vivo setting, it was still included for comparison of toxicity with dose 
escalation conducted with CaCl2.  It can be seen from Figure 3-9 B, that after a 24 hour 
period the viability of HS-5 cells fell below 50% in the scaffolds treated with 25 and 50% 
firming buffer, but not with an initial 10%. However, over the remaining period, viability 
continued to drop in the 25 and 50% scaffold and began to decrease steadily in the 10% 
group. Once again, this result reinforced the use of a cation, like CaCl2, within the firming 
buffer as at 100 mM, in a similar manner to a 10% firming solution, HS-5 did not reduce in 
viability. However, when a 500 mM solution of CaCl2 was added to HS-5 cells, viability 
dropped to around 50% when compared to the control, similar to the results seen with a 50% 
firming buffer solution. The continuous drop in viability over the remaining time period can 
be explained, in part, by the paper produced by Armstrong et al. (2016). In this paper it is 
concluded that a small level of divalent cation (5 mM CaCl2) is required to stay within the 
medium to maintain the long-term structure of an alginate scaffold. However, at low levels, 
( <5 mM in the case of CaCl2), human or rat MSCs do not turn on their respective ion pumps, 
Chapter Three: Developing a 3D model of the BM using commercial cell lines 
 
 99 
therefore an accumulation of compound occurs, causing apoptosis and loss of viability 
(Yener. 2013; Scherzad et al., 2016; Leonard et al., 2019). These data suggest, that even 
with a direct, acute, low dose of divalent cation (20-100 mM), further dilution is required 
for long term culture of HS-5. As the level of divalent cation perceived to be the main 
component of the firming buffer is unknown, an investigation into the level of dilution, 
whilst still maintaining scaffold structure and HS-5 viability, was conducted. It was found, 
that if a 50% medium change was conducted on day 2 (Figure 3-9 C and D), hence diluting 
the cation solution by 50%, an initial decrease in total cell number and viability was still 
seen in all three concentrations (10, 25 and 50%). However, if a 100% medium change 
(Figure 3-9E and F), hence diluting the cation solution by ~90% as some residual medium 
remained in the scaffold, no initial dip in viability was seen at day 3, whilst maintaining the 
structure. Conversely, at day 4, 10% and 50% scaffold viability levelled off and 25% reduced 
in viability. This result was not due to the level of cation in the solution but instead the 
supplementation in the medium. As previously mentioned, HS-5 have a doubling rate of 48 
hours in 2D flasks and it can be seen in Figure 3-9 E and G that over the same time period, 
HS-5 cell numbers are increased within the 25% group, after an initial reduction on day 2, 
back to 2.5 x 105 total cells. At this cell number, the supplementation with the 3 mls of 
medium within the well may not be adequate, therefore, a 50% medium change was added 
on day 4 to accommodate this higher number.  This increase in HS-5 number appeared to be 
the cause of the lowered viability as, when this medium change was added, viability (Figure 
3-9H) continued to increase in a 50% scaffold between day 4 and 5 instead of plateauing.  It 
can also be seen that cell number (Figure 3-9G) seems to plateau at 2.5x105 total cells in the 
50% scaffold at day 3, whereas 10 and 25% scaffolds only reach half this total number at 
day 4. Given the previous evidence on cell-cell contact and the surface area’s impact on 
viability within the Biomerix™ scaffold, the reduction in cell number on day 2 of the 10 and 
25% is too large, creating a greater space around cells, even with the optimised medium 
regime. This reduction is not as apparent within the 50% AlgiMatrix™ scaffolds on day 2 
and hence a greater increase in cell number and viability occurs, until it appears, the surface 
area is entirely accommodated with a total cell number of <5 x 105, allowing cells to continue 
to increase in viability. This low density of cells residing on the scaffold, does concur with 
the literature, as it can be seen in vivo that BM stomal MSCs make up 1 in every 3  x104 
cells (Wexler et al., 2003). 
 
The conclusions that can be drawn from these results are that, even though a preliminary 
drop in viability associated with the concentration of CaCl2, is seen after initial seeding, this 
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can be increased by diluting the firming solution by 90% on day 2 combined with a medium 
change 48 hours later to accommodate the expanding cell number. However, over the 5 day 
period, viability only reached between 60-70% which infers a increased incubation period 
of initial HS-5 culture on the scaffold is required. Given the evidence put forward in this 
chapter on increased number, viability, pore size and bio-mechanical structure of the 
differing scaffolds, it was decided that a 50% AlgiMatrix™ scaffold simulated the in vivo 
ECM more closely, and therefore was utilised for further study.  
 
The initial reduction in HS-5 cell number and viability seen in Figure 3-9 G and H, even 
with an optimised medium regime, was still disconcerting with a drop of 50% seen in both 
cell number and viability in the 50% scaffold. The starting seeding density used in this study 
was 2.5 x 105 total cells/ scaffold in a 24 well plate, therefore, an investigation into the 
seeding density and vessel of initial HS-5 culture on an 50% AlgiMatrix™ scaffold was 
assessed. Firstly, HS-5 cells were seeded in a 25 cm2 flask, 24 and 12 well plate at the same 
starting seeding density, to assess the initial growth parameters of HS-5 without an 
AlgiMatrix™ present.  The HS-5 cell line is routinely cultured for 7-8 days at starting 
concentration of 6 x 103 cells/cm2 in a 25 cm2 flask before use in further assays. It can be 
seen in Figure 3-10 that HS-5 seeded in a 25 cm2 flask, increased in cell number (A) and 
viability (B) over this period, therefore, would act as the control to assess other culture 
vessels. The freeze-dried AlgiMatrix™ scaffolds arrive in a 24 well plate which, when cells 
are seeded on the AlgiMatrix™, only allow for the addition of 2-3 mls of fresh culture 
medium, with the latter reaching the vessel lid which could introduce contamination. As 
previous study had been conducted within the 24 well plate, an empty 24 well plate was used 
to assess how the HS-5 would react to this reduction in medium. As illustrated in section 
3.3.2.3, a medium volume of 3 mls is required for long-term culture and increased viability 
of HS-5 upon an AlgiMatrix™ scaffold, therefore, a 12 well plate, which can accommodate 
3 mls was also seeded with HS-5. The same culture protocol outline in section 3.3.2.2, for 
3D culture, was used for this 2D experiment, with HS-5 in separate wells, trypsinised every 
48 hour and assessed for cell number, viability, cell cycle and the presence of Ki67. The 
nuclear protein, Ki67, was used as it is routinely deemed as a marker of proliferation. When 
the cell is proliferating, the marker is transferred from the internal nuclear membrane to the 
outer nuclear membrane and is present in all phases of cell cycle apart from G0 or quiescence 
(Sun & Kaufman 2018; Yang et al., 2018; Menon et al., 2019; Bosch). This can then be 
correlated with viability and cell cycle to gain an indication of cell health and indicate the 
optimal time for seeding of a secondary cell line. However, as can be seen in Figure 3-10, 
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the viability of the 25cm2 and 12 well are maintained above 50% viability after an initial 
drop at 24 hours. This level of viable cells and steady increase in cell number, over this time, 
would indicate that cells were proliferating, conversely, the presence of Ki67 doesn’t 
increase at the same rate. This could be explained utilising the cell cycle analysis seen in 
Figure 3-10D, E and F, as in all culture vessels, cells appear to gather in the G0 or quiescence 
stage of cell cycle, which would infer that cells were not proliferating even with the cell 
number and viability data.  Work by Miller et al. (2018) confirmed the Ki67 finding, as they 
found that the longer cells are in G0, regardless of the cause of entry, Ki67 would degrade 
and is highly heterogeneous between cell cultures. However, work by Rumman et al, (2018), 
Cherry et al, (2014) and Morikawa et al, (2009) found that primary BM stromal stem cells, 
even though viable, remain in G0 in the in vivo BM to enhance self-renewal and wouldn’t 
pass into G1 routinely until HSCs were present. If BM stromal stem cells don’t have contact 
with HSCs, they will begin to reduce in viability and cell number to conserve a small 
population. This finding suggests that even without an AlgiMatrix™ scaffold, the HS-5 cell 
line may be simulating the BM stromal stem cell population not previously seen in the 
literature. It was concluded by using these makers of cell cycle, viability and cell number, 
the change in Ki67 expressions were true and comparable between all samples, therefore, 
taking this into account, along with medium and space required for the AlgiMatrix™ 
scaffold, a 12 well plate overall maintained HS-5 cells similar to that of the routinely used 
25 cm2 flask, and therefore was used in future AlgiMatrix™ study.   
 
Now that an appropriate culture vessel had been identified, the required total cell seeded 
onto the AlgiMatrix™ was investigated. Hence cells were seeded at a total density of 2.5, 5, 
7.5 and 10 x 105 cells/scaffold before being transferred to a 12 well plate. The seeding 
densities were chosen because, as previously mentioned in section 3.3.2.3, the AlgiMatrix™ 
scaffold seems to hold <5  x 105 total cells, which correlated with the in vivo literature. 
However, at this density the firming buffer had a detrimental effect on the HS-5 cells and as 
noted with the bespoke hydrogel scaffold, a higher number of cells seemed to dilute the 
effects of the firming buffer, therefore a higher seeding density was also chosen. The results 
seen in  Figure 3-11 A reinforce this result, as there is a sudden drop in cell number between 
0 and 24 hours in the 7.5 and 10 x 105 samples, to around 5 x 105, but not 2.5 or 5 x 105 
which remain at the same density throughout the experiment, inferring that the scaffold can 
only hold a maximum of 5 x 105 total cells. Unfortunately, as previously mentioned, the 
freeze-dried scaffold arrives in a 24 well plate and cannot be removed until firming has 
occurred. This movement from one vessel to the next could explain this initial loss, as too 
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high a density of cells were initially seeded and couldn’t reside within the scaffold, therefore, 
the excess may be lost to the medium when transferring across to the 12 well plate.  
 
However, unlike in 2D, Ki67 does correlate with viability over a 168 hour period, although 
a high proportion of cells were still remaining in the G0 stage of cell cycle throughout. 
Within the previous 2D experiment each well was trypsinised; trypsinisation has been seen 
to be detrimental to cells, altering cell size, shape, markers (such as Ki67) and gene 
expression which has not been seen or noted in the literature when using the AlgiMatrix™ 
firming buffer (Shin et al., 2017). This change in retrieval of cells, therefore, seems to also 
have an impact on the final result, with a firming buffer allowing cells to maintain their 3D 
morphology. Conversely, each density, after a 168 hour period, increased cell number, 
plateaued/ decreased viability and decreased Ki67 expression. As previous literature has 
highlighted, regarding the stall of BM cells within G0, if BM stromal cells don’t have contact 
with HSCs for an extended period, they will reduce in viability and cell number to conserve 
cellular numbers in dwindling supplementation. In conclusion, the original, lower seeding 
density of 2.5 x 105 total cells seeded onto an AlgiMatrix™, seems to correlate with the 
current in vivo BM literature, with a maximum seeding time of 168 hours before the 
introduction of a secondary HSC cell line. 
 
The human B lymphoblastoid cell line, TK6, is used routinely in 2D genotoxicity studies 
within the pharmaceutical industry. This cell line is used due to its proliferation index (12-
15 hour doubling time), p53 competency, human origin and ease of culture allowing a rapid 
7 day analysis of potential therapeutic compounds (Hintzsche et al., 2018). This cell line is 
used in the single culture 2D MN assay, as a predictor of the potential genotoxic damage 
that could occur in erythroblasts in vivo (Hayashi et al., 2016).  As this cell line is routinely 
used within the pharmaceutical industry, it was decided that due to its ease of use and ability 
to compare between MN induction in 2D, our 3D model and the in vivo result, this would be 
the best candidate for addition to the AlgiMatrix™ cultured HS-5. 
 
 As mentioned previously, work by Rumman et al., (2018), Cherry et al. (2014) and 
Morikawa et al. (2009) found that BM stromal stem cells remained in a quiescent state until 
the addition of HSCs which then increased the MSC’s viability, proliferation and cell 
number. The model’s ability to simulate this in vivo behaviour, was once again reinforced 
with the addition of TK6, in a 0.2 µm pore culture insert, to HS-5 seeded onto AlgiMatrix™ 
scaffolds for seven days as seen in Figure 3-15. This result infers that just the addition of 
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soluble factors, not just cell-cell contact, induces an increase in HS-5 similar to the in vivo 
literature. A 0.2 µm pore insert was used to separate cell lines as literature by Ngo et al. 
(2019) and Cardoso et al. (2015) had found that a 15 µm TK6 or HS-5 could not pass through 
a 0.4 µm pore, therefore, a 0.2 µm pore would ensure that only the HS-5 were counted when 
analysing cells residing on the scaffold. However, both cell lines were cultured in RPMI-
1640, as mentioned in chapter 2 section 2.2.1, but HS-5 have been routinely cultured in 
Dulbecco’s modified Eagle’s medium. Nevertheless, a study by Deynoux et al. (2020) found 
that RPMI-1640 had no effect on HS-5 cells and conversely produced a HS-5 cell more 
morphologically similar to the in vivo BM fibroblast.  
 
The in vitro and in vivo MN assay requires the active proliferation of the HSC compartment 
for the formation of micronuclei. Therefore, a method of differentiating cell lines from each 
other must be established, so that the proliferation and initial seeding density of TK6 can be 
established for future compound addition. The results in Figure 3-12 show that TK6 cells, 
unlike HS-5, are CD19 positive which aligns with the literature (Krüger et al., 2014) and can 
be used to differentiate TK6 via flow cytometry for proliferation, and confocal microscopy 
for identification of MN (Figure 3-21). A marker for TK6 only was selected as, mentioned 
in section 3.3.2.4, the harvest of HS-5 seems to alter their surface markers, and this study is 
especially interested in the genotoxic events occurring in the TK6 for comparison to the 2D 
and in vivo setting. As CD19 was found to be present in >98% of cells this was used to assess 
the proliferation and optimal initial seeding density of TK6 onto AlgiMatrix™ cultured HS-
5. 
 
Utilising this CD marker, TK6 were added to AlgiMatrix™ cultured HS-5 and assessed for 
their ability to proliferate over a 5 day period, similar to that of the in vitro MN. As can be 
seen in Figure 3-13, regular medium changes were needed every 24 hours to accommodate 
the increasing number of cells within the well, concurrent with previous evidence on medium 
supplementation in section 3.3.2.2. An exponential phase, without the loss of CD19, can be 
seen in Figure 3-13 D between 54 and 96 hours, which closely corresponds with the 
timeframe seen in the in vitro MN assay, allowing for the comparison between 2D and 3D 
MN induction in vitro. The loss of CD markers indicates membrane degradation of dead or 
dying cells through reduction in medium supplementation not necessarily an increase in 
CD19- HS-5 cells (Lin et al., 2013). 
 
Chapter Three: Developing a 3D model of the BM using commercial cell lines 
 
 104 
The initial lack of proliferation of TK6 between hour 0-54 (Figure 3-13) is indicative of the 
cell-cell interaction seen in vivo.  As previously stated, HS-5 begin to increase in cell number 
when TK6 are added in a well insert. This expansion in vivo, facilitates the release of 
chemokines into the surrounding medium, such as SDF-1, homing the HSCs to the stromal 
MSCs, which will slowly proliferate until they are in cell-cell contact, and lineage defined 
(Wei & Frenette, 2018; Emmons et al., 2016). Hence, this apparent lack of proliferation 
could indicate TK6 cells homing from the medium into the scaffold, before increased 
expansion of the TK6 can occur. This change can be seen in Figure 3-13, as TK6 cells within 
the scaffold are required to increase before an exponential increase of those in the medium. 
The introduction of a medium change also influenced this initial lack of proliferation, as 
50% of the medium is discarded every 24 hours, reducing cells within and reducing the 
accumulating cellular signalling molecules. Additionally, the initial low seeding density 
would have an effect on proliferation as mentioned previously with HS-5 proliferation in 
3D.  Therefore, a 0.5 x 105 total initial seeding density of TK6 cells onto AlgiMatrix™ 
cultured HS-5, produced a finalised model which simulates the in vivo environment within 




























A co-culture model of HS-5 and TK6 has been developed, with optimised conditions for the 
long-term (270 hour) in vitro culture of both cell types, which closely simulates the in vivo 
BM stromal and haematopoietic compartments closely, whilst being able to discriminate cell 
lines from each other. The in vitro model developed, provides a physiologically relevant 
platform to investigate the effects of new and existing compounds in a more in vivo relevant 
setting, for genotoxicity and changes in gene expression. 
 
These data clearly demonstrate the importance of selecting an optimal initial seeding density, 
medium change, culture vessel and ECM for the co-culture of two diverse cell lines. These 
results have shown that HS-5 stromal cells are not able to adhere fully to Biomerix™ 
scaffolds. However, by incorporating 2.5 x 105 total cells into a solidified Algimatrix™ 
scaffold, using a 50% firming buffer, HS-5 proliferated and expanded in a similar manner to 
human primary in vivo stromal cells. The addition of TK6 at 0.5 x 105 cells/ml, at day seven, 
continued to closely replicate the expansion and environment mentioned within the in vivo 
BM literature. Therefore, in all subsequent experiments, the optimised in vitro co-culture 
model described in this chapter (outlined in section 2.3.1) was used.  




4. Screening of positive, negative and potential genotoxic 




Genetic toxicology testing is routinely performed by pharmaceutical companies on 
therapeutic compounds to identify potential carcinogens. A battery of assays is 
recommended by the ICH, so that a compound will meet the criteria set out by the regulatory 
body of that region, such as the Food and Drug Administration (FDA) in America and the 
European Medicines Agency (EMA) in Europe (Koutsilieri et al., 2020). The ICH 
recommends a battery of assays, described in section 1.2.2, with the pharmaceutical 
company AZ including in their battery, the Ames and in vitro MN assay before moving the 
compound into animals utilising the in vivo BM MN assay.  
 
The compound’s interaction within the in vitro MN assay, is meant to be predictive of the in 
vivo BM environment. However, the complexities described previously with the differing 
compartments of the BM, cannot truly be represented with the single cell culture used in 
vitro. This has led to compounds (termed pharmacological positives), known to be non-
genotoxic in the clinic, showing a positive result in the in vivo but not the in vitro MN assays 
(Hayes et al. 2013). Therefore, new compounds may infer a negative result in vitro, which 
are then positive in vivo wasting time, money, animal life with an uncertainty which 
compound is a true positive/ negative for genotoxicity. Conversely, the stromal layer of the 
BM, has been seen to provide protection to the haematopoietic cells through metabolism and 
absorption, reducing the genotoxicity of compounds, giving a negative result in vivo but 
positive in vitro (Jaroch et al., 2018). These problems highlight the need for a more in vivo 
relevant multicellular model in vitro, to isolate these compounds and identify their 
mechanism before being assessed in vivo. 
 
Work in the previous chapter has demonstrated a simple, optimised, in vitro, co-culture 
model of cell lines, upon an ECM, which aligns with the BM in vivo environment noted in 
the literature. The aim of this chapter was to evaluate the outcome of known positive, 
negative and pharmacological positive compounds for genotoxicity, within this developed 
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model, and compare these results to those seen within the regulatory in vitro and in vivo MN 
assay. To achieve this aim, three stages were conducted: (1) A series of baseline 2D in vitro 
MN assays were then conducted, on known compounds which induce genotoxicity, to 
standardise the scoring of MN between AZ and UWE. (2) A secondary 2D in vitro MN assay 
was then conducted, solely at UWE, of known positive, negative and pharmacological 
positive compounds which induced cytotoxicity (RPD) <50% ± 5% or reached a 1 mM 
concentration, which is noted as the highest dose necessary without genotoxicity to call a 
compound non-genotoxic. This increase in dose was essential, as in vivo a higher 
concentration of compound is required due to a reduction in bioavailability and 
detoxification (Shan et al., 2018). (3) Finally, a range of doses from each compound tested 
within the 2D in vitro MN assays, were then assessed using the 3D model optimised in 






























4.2.1. Identification of the exponential phase of TK6 cells in 2D culture 
 
Identification of the exponential phase in TK6 cells was conducted at UWE utilising the 
method described in section 2.2.2. 
 
4.2.2. The regulatory in vitro 2D micronucleus assay 
 
The 2D in vitro MN assay was conducted for the initial baseline doses of MMC, 4NQO, 
etoposide and paclitaxel at UWE and AZ. Those slides scored at AZ were then scored at 
UWE to ensure that scoring was comparable between each laboratory. Additional doses, for 
use in future 3D analysis, of MMC, 4NQO, etoposide and paclitaxel were then tested at 
UWE, with relevant doses of dexamethasone, prednisolone and caffeine also identified. All 
2D in vitro MN assay were performed as previously described in section 2.6 whilst satisfying 
the criteria laid out within the section 2.6.1. All assays for each compound, except MMC, 
included a positive control of MMC at 30 and 40 nMol/L. 
 
4.2.3. Selection and concentration of known positive, negative and 
pharmacological positive compounds. 
 
The final concentrations, added to TK6 within the regulatory in vitro 2D MN assay, of 
known positive (MMC, 4NQO, etoposide and paclitaxel), pharmacological positives 
(dexamethasone and prednisolone) and non-genotoxicant (caffeine) can be seen in Table 
4-1, Table 4-2, Table 4-3 respectively with those inducing an RPD score <50% ± 5% 
highlighted. A range of doses for each compound was initially tested for induction of a 50% 
± 5% RPD, this range was then increased to identify doses which gave an RPD <50%. Those 
compounds that did not reach an RPD of 50% ± 5% at a dose of 1 mM, were deemed as non-
genotoxic and dose ranges were terminated at this point. The final concentrations identified 
and tested within the multicellular 3D model, of known positive (MMC, etoposide and 
paclitaxel), pharmacological positives (dexamethasone and prednisolone) and non-
genotoxicant (caffeine) can be seen in Table 4-4, Table 4-5, Table 4-3 respectively. 
However, doses of 4NQO were not advanced to the 3D MN assay.   
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Table 4-1. Concentration of known genotoxic compounds used in the 2D in vitro micronucleus assay in assessing the correct dose to induce a <50% RPD score in TK6 cells. Concentrations are given in 
both ng/ml and nmol/L as stipulated in OECD guideline 487 (2016) in section 2.6.1. Those concentrations highlighted in yellow gave an RPD <50%.  
4-nitroquinoline-N-oxide (4NQO) 
Vehicle control <1% DMSO 
Etoposide 
Vehicle control <1% DMSO 
Mitomycin C (MMC) 
Vehicle control <1% DMSO 
Paclitaxel 
Vehicle control <1% DMSO 
ng/ml nmol/L ng/ml nmol/L ng/ml nmol/L ng/ml nmol/L 
0.01 0.06 0.1 0.2 1.7 5 0.3 0.4 
0.02 0.13 0.3 0.5 2.3 7 0.7 0.8 
0.04 0.19 0.6 1 3.3 10 0.9 1 
0.21 1.1 2.9 5 6.7 20 3.4 4 
0.4 2.09 6 10 10 30 6.8 8 
0.68 3.59 12 20.4 11.7 35 8.5 10 
0.83 4.39 14.9 25.4 13.4 40 14.5 17 
0.93 4.91 18 30.6 16.7 50 17.1 20 
1.08 5.7 24 40.8 20.1 60 17.9 21 
1.2 6.29 29 49.3 23.4 70 20.5 24 
1.45 7.61 35 59.5 26.7 80 22.2 26 
1.64 8.6 38 64.5 30.1 90 28.2 33 
1.81 9.51 41 69.7 33.4 100 30.7 36 
1.9 10 47 79.9 40.1 120 38.4 45 
2.09 11 53 90.1 46.8 140 47 55 
2.47 13.01 59 100.2 53.5 160 
5 26.3 72.9 123.9 60.2 180 
7.4 38.9 88 149.5 66.9 200 
10 52.6 120 203.9 73.6 220 
15 78.9 150 254.9 80.2 240 
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Table 4-2. Concentration of pharmacological positive compounds used in the 2D in vitro micronucleus assay in 
assessing genotoxicity of TK6 cells in 2D. Concentrations are given in both ng/ml and nmol/L as stipulated in OECD 
guideline 487 (2016). Concentrations are quoted as per the OECD guidelines in section 2.6.1. Doses with these compounds 
did not induce an RPD score of <50% in the 2D in vitro MN assay. Therefore, testing with doses higher than 1 mM was 
not undertaken. 
Dexamethasone 
Vehicle control <1% DMSO 
Prednisolone 
Vehicle control <1% DMSO 
ng/ml nmol/L ng/ml nmol/L 
2.4 x1 04 6 x 104 1.8 x 104 5 x 104 
3.9 x 104 1 x 105 4.5 x 104 1.25 x 105 
1.2 x 105 3 x 105 9 x 104 2.5 x 105 
2 x 105 5 x 105 1.8 x 105 5 x 105 
3.1 x 105 8 x 105 2.7 x 105 7.5 x 105 
3.9 x 105 1 x 106 3.6 x 105 1 x 106 
 
Table 4-3 Concentration of a negative genotoxic compound used in the 2D and 3D in vitro micronucleus (MN) assay 
in assessing genotoxicity of TK6 cells. Concentrations are given in both ng/ml and nmol/L as stipulated in OECD 
guideline 487 (2016). Concentrations are quoted as per the OECD guidelines in section 2.6.1 Doses with these compounds 
did not induce an RPD score of <50% in the 2D in vitro MN assay. Therefore, testing with doses higher than 1 mM was 
not undertaken, with all 2D doses utilised in 3D. 
Caffeine 
Regulatory 2D MN assay 
Vehicle control sterile H2O 
The multicellular 3D MN assay 
Vehicle control sterile H2O 
ng/ml nmol/L ng/ml nmol/L 
97 5 x 102 97 5 x 102 
9.71 x 102 5 x 103 9.71 x 102 5 x 103 
9.710 x 103 5 x 104 9.710 x 103 5 x 104 
9.7 x 104 5 x 105 9.7 x 104 5 x 105 
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Table 4-4 Concentration of known genotoxic compounds used in the 3D in vitro micronucleus assay in assessing 
genotoxicity of TK6 cells  within the model. Concentrations are given in both ng/ml and nmol/L as stipulated in OECD 
guideline 487 (2016). Concentrations are quoted as per the OECD guidelines in section 2.6.1. Those concentrations 
highlighted in yellow gave an RPD <50% in the 2D in vitro micronucleus (MN) assay.  
Mitomycin C (MMC) 
Vehicle control <1% DMSO 
Etoposide 
Vehicle control <1% DMSO 
Paclitaxel 
Vehicle control <1% DMSO 
ng/ml nmol/L ng/ml nmol/L ng/ml nmol/L 
2.3 7 0.6 1 0.9 1 
11.7 35 24 40.8 14.5 17 
20.1 60 38 64.5 17.9 21 
30.1 90 59 100.2 28.2 33 
46.8 140 120 203.9 38.4 45 
 
Table 4-5. Concentration of pharmacological positive compounds used in the 3D in vitro micronucleus (MN) assay 
in assessing genotoxicity of TK6 cells  within the model. Concentrations are given in both ng/ml and nmol/L as stipulated 
in OECD guideline 487 (2016). Concentrations are quoted as per the OECD guidelines in section 2.6.1. Doses with these 
compounds did not induce an RPD score of <50% in the 2D in vitro micronucleus (MN) assay. Therefore, testing with 
doses higher than 1 mM was not undertaken. 
Dexamethasone 
Vehicle control <1% DMSO 
Prednisolone 
Vehicle control <1% DMSO 
ng/ml nmol/L ng/ml nmol/L 
3.9 x 104 1 x 105 1.8 x 104 5 x 104 
1.2 x 105 3 x 105 9 x 104 2.5 x 105 
2 x 105 5 x 105 1.8 x 105 5 x 105 
3.1 x 105 8 x 105 2.7 x 105 7.5 x 105 
3.9 x 105 1 x 106 3.6 x 105 1 x 106 
 
4.2.4. Genotoxicity and cytotoxicity of known positive, negative and 
pharmacological positive compounds within a 3D multicellular model.  
 
The HS-5 cell line was initially seeded onto an AlgiMatrix scaffold™ for 7 days before the 
addition of the TK6 cell line. The TK6 cell line was then allowed to proliferate in contact 
with HS-5 for a further 54 hours, in accordance with the method described in section 2.3.2 
before MN assessment was carried out (Figure 4-1.).  




Figure 4-1. Planned protocol, utilising the proliferation of cells in 3D, for micronucleus assessment of known 
positive, negative and pharmacological positive genotoxicants. HS5 (CD19-) cells were incubated on AlgiMatrix™ 
scaffolds for 168 hours before the addition of TK6 (1). After a 72 hour incubation, scaffolds were dosed with compound 
(2), incubated, cells washed of compound (3), cells reseed onto the scaffold (4), incubated for a further 24 hours and 
harvested for MN and cell number assessment. 
At the 54 hour time point (-24 hours before dosing), baseline seeded scaffolds (4 technical 
repeats) were harvested for cell number within the medium and scaffold, with the remaining 
treatment scaffolds, left to incubate for an additional 24 hours. At hour 72 (0 hours), a further 
4 baseline seeded scaffolds were harvested for cell number within the medium and scaffold, 
with the remaining treatment scaffolds undergoing a 50% depletion (1.5 mls) of medium. 
Each compound was then added directly in 1.5 mls of medium to the scaffold according to 
the schematic seen in Figure 4-2, including a positive and vehicle control evenly spaced 
across each plate reducing plate location bias, mixed using a 1 ml pipette and left to incubate 
for a further 24 hours. After a 24 hour (+24 hours after dosing) incubation, medium from 
each scaffold and well was mixed with a 1 ml pipette, collected, washed and counted. 
Scaffolds still containing low amounts of medium, were moved to fresh 12 well plates whilst 
their original well was washed with 3 mls of PBS.   
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Figure 4-2. Schematic representation of the plate layout of AlgiMatrix™ scaffolds for 3 biological repeats of 
compound dosing. Each plate consisted of one positive, negative, pharmaceutical genotoxicant, and a vehicle control 
evenly spaced across the plate. Each sample location was altered with each biological repeat to reduce location bias. 
 
Scaffolds were then placed back into their original, now washed wells, for the addition of 
their corresponding cells from the medium, seeded at the density at which they were dosed, 
mixed with a 1 ml pipette and left to incubate for an additional 24 hours. After this incubation 
(+48 hours after dosing), the medium for each well was mixed with a 1 ml pipette, collected, 
scaffolds harvested, both well and scaffold assessed for cell number using TB and MN 
assessed individually for each scaffold and corresponding well using the protocol described 
in section 2.6.2. This was then compared to the results seen in the regulatory 2D MN assay 
for each corresponding compound. The percentage increase from 2D to 3D MN induction, 
was then conducted using the following calculation where V2 equals the final value and V1 
equals the initial value: 
 
("2 − "1)

































































































Biological repeat 1 Biological repeat 2
Biological repeat 3





4.3.1. Identifying the exponential phase of TK6 at UWE 
 
The MN assay assesses the genotoxic potential of a compound and requires the cells to be 
actively turning over. Cells which are not actively turning over (in lag phase) will not take 
the compound up and thus no genotoxic event will occur. To assess the optimal times to dose 
TK6 cells (exponential phase) a growth curve was performed on differing starting 
concentrations. Cells were sampled at 11am and 5pm for 102 hours on an automated Luna 
counter. The initial seeding density differed, starting at 5 x 104 and 1 x 105 cells/ml (Figure 
4-3). 
 
The results seen in Figure 4-3 shows the exponential phase for both seeding densities starts 
at around 3 x 105 - 3.5 x 105 at around 24-30 hours into the 102 hour period. The exponential 
phase then reaches a plateau between 1.3 x 106- 1.4 x 106 at around 100-102 hours. A PD 
time was calculated for both seeding densities to be 14.57 hours. These results conclude that 
TK6 cells should be allowed to proliferate for around 24 hours after seeding before being 
dosed. The cell count at this stage should be at around 3 x 105 cells/ml which suggests that 
the cells are actively turning over and taking up the drug. The exponential phase lasts for a 
period of 78 hours thus encompasses the 48 hour treatment period needed for the MN assay. 
 
 
Figure 4-3. TK6 growth curve over 102 hour period. The graph illustrates the lag and exponential phase of two differing 
starting seeding densities (5x104 and 1x105 cells/ml) in the TK6 cell line. Cell counts were taken at 11am and 5pm every 
day for a five-day period. The cell doubling time was calculated at 14.57 hours for both (n=3) 
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4.3.2. An initial dose range of known genotoxic positive compounds conducted 
at AZ 
 
The following MN assays (Figure 4-4) were conducted at AZ with MMC, etoposide, 4NQO 
and paclitaxel for alignment of scoring and expansion of dose concentration at UWE. The 
criteria set out in section 2.6 were followed so that alignment can take place once testing has 
been re-conducted at UWE. Where the toxicity meant RPD exceeded 50% ±5%, experiments 
were repeated to ensure enough doses were available to demonstrate 50% cytotoxicity, as 
well as have 4 doses for scoring MN. This set of experiments was utilised as a dose range 
finder, to glean an RPD of 50% ± 5% testing the compound to its limits. Each experiment 
consisted of a 48hr treatment (24 hour with drug, 24 hour recovery without drug) to allow 
the completion of cell cycle. Further to the data in section 4.3.1, cells were dosed 24 hours 
after seeding at a density of around 3 x 105 cells/ml. All compounds were tested with a 
negative (vehicle control), and the assays for etoposide, 4NQO and paclitaxel utilised MMC 
as a positive control. 
 
The results in Figure 4-4 A show that MMC induced an RPD of 53% and 46% at 50 nmol/L 
and 70 nmol/L respectively. MN induction was found to be 81 and 55 MN/ 1000 
mononucleated cells for these doses. However, it can also be seen that the RPD progresses 
from 53% at 50 nmol/L to 58% at 60 nmol/L then to 46% at 70 nmol/L. As the 50 nmol/L 
and 70 nmol/L have an RPD nearer to the 50% ± 5% criterion we have to reject the result 
obtained at 60 nmol/L. These results conclude that, 50 nmol/L gave the highest, scorable 
induction of MN during dose finding at AZ for future validation at UWE. The results also 
showed that 30 nmol/L and 40 nmol/L gave an RPD of 74% and 62%. Since these scores 
show a cytotoxic affect, at an RPD >50% ± 5%, they will be used as the positive in the 
following experiments. 
 
The results in Figure 4-4 B show that etoposide induced an RPD of 52% and 44% at 69.7 
nmol/L and 79.9 nmol/L respectively. MN induction was found to be 97 MN/ 1000 
mononucleated cells for 69.7 nmol/L but was not scored at 79.9 nmol/L due to high 
cytotoxicity. This result concludes, that 69.7 nmol/L gave the highest, scorable induction of 
MN during dose finding at AZ for future validation at UWE. Additionally, the positive 
control (MMC) has exceeded more than double that of the negative with around 50 MN/ 
1000 mononucleated cells, so can be confirmed as positive.




Figure 4-4. Baseline relative PD (RPD) and MN induction following 24 hour treatment with mitomycin C, etoposide, paclitaxel and 4-nitroquinolone-N-oxide at AstraZeneca for initial dose discovery. 
The total number of MN scored per 1000 mononucleated cells and RPD induced over a 48 hour period (24 hour treatment + 24 hour recovery) by mitomycin C (A), etoposide (B), paclitaxel (C) and 4-
nitroquinolone-N-oxide (D). Those concentrations without a result for MN were not scored as they passed below the 50% ± 5% RPD regulatory guidelines (2.6.1). A positive mitomycin C control was run 
alongside etoposide (B), paclitaxel (C) and 4-nitroquinolone-N-oxide (D) to ensure that the assay had successfully worked. A minimum of 2000 mononucleated cells were scored (n=1).
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The results seen in Figure 4-4 C shows that paclitaxel induced an RPD of 57 % at a 
concentration of 26 nmol/L. MN induction at this dose was found to be 40 MN/ 1000 
mononucleated cells more than twice the negative which only gained 6 MN/ 1000 
mononucleated cells. The MMC controls can also be called positive as they are twice the 
negative at 50 and 64 MN/ 1000 mononucleated cells. These results conclude that a dose of 
26 nmol/L paclitaxel has an induction of MN twice that of the negative, so can be called 
positive. However, since an RPD of 50% ± 5% wasn’t identified, a further extension of the 
dose range will be required at UWE to identify its cytotoxic limit. 
 
The results seen in Figure 4-4 D show that 4NQO induced an RPD >80% at every dose 
tested. The last concentration of 13.01 nmol/L gave an RPD of 84% which was the closest 
dose to 50% tested. The MN score at this dose was 16 MN/ 1000 mononucleated cells, more 
than twice the negative control which produced only 7. The results conclude that since 13.01 
nmol/L showed an induction of MN twice that of the negative, in conjunction with a positive 
MMC induction of MN, it can be called a positive genetoxic dose. However, since an RPD 
of 50% ± 5% wasn’t identified, not meeting the criteria in section 2.6.1,  once again a further 
dose range will be required at UWE to identify its cytotoxic limit. 
 
4.3.3. Comparison of micronucleus induction at AZ and UWE for alignment 
of scoring 
 
To assess if scoring of MN was comparative between AZ and UWE for validation of future 
2D and 3D study, the regulatory 2D MN assay was conducted at AZ for MMC, etoposide, 
4NQO and paclitaxel as described in section 2.6, spun onto slides and counted for MN at 
AZ. Each slide was counted blind at AZ using a coding system to reduce experimenter bias, 
with dose and compound not revealed until after counting. These slides were then 
transported to UWE, re-coded and scored again to ensure that counting was reproducible 
between laboratories of the same sample.  
 
The results seen in Figure 4-5 show that, for these compounds and doses, the number of MN 
in each sample were comparable between the two laboratories. These results conclude that 
scoring between the two laboratories is comparable, therefore an increase in range finding 
of doses for each compound can be conducted utilising the baseline counts identified at AZ. 




Figure 4-5. Comparison of micronucleus scoring between AZ and UWE, utilising the same individual scoring, within 
TK6 cells dosed with mitomycin C (A), etoposide (B), paclitaxel (C) and 4-nitroquinolone-N-oxide (D). The original 
in vitro micronucleus assay and initial scoring was conducted at AZ by Mr A Vernon. These slides were then transported 
to UWE and scored again by Mr A Vernon for comparison of scoring at the two laboratories. Each slide was coded to 























































































































































































































































































































































4.3.4. Extended dose range of known positive genotoxicants conducted at 
UWE, utilising an initial range from AZ 
 
The following MN assays (Figure 4-6) were conducted at UWE with MMC, etoposide, 
4NQO and paclitaxel for alignment with the baseline dose range identified at AZ and 
expansion into a range which gave an RPD of <50%. Once again, the regulatory MN assay, 
set out in section 2.6, was followed so that alignment can take place once re-testing has been 
conducted. Each experiment consisted of a 48 hour treatment (24 hour with drug, 24 hour 
recovery without drug) to allow the completion of cell cycle. Further to the data in section 
4.3.1, cells were dosed 24 hours after an intial seeding concentration of around 3x105 
cells/ml. All compounds were tested with a negative (vehicle control), with the assays for 
etoposide, 4NQO and paclitaxel utilising MMC as a positive control. The results of the 
expansion of dose concentration to identify an RPD <50%, would allow a wide range of 
doses for use in a 3D multicellular culture system,  in case of possible increases/ decreases 
in cytotoxicity occuring in 3D culture systems. 





Figure 4-6. Extended dose range finder at UWE, identifying the relative PD (RPD) and micronucleus induction, of TK6, following a 24 hour treatment with mitomycin C, etoposide, paclitaxel and 4-
nitroquinolone-N-oxide. The dose range included those doses which were identified at AZ as well as those which exceeded the regulatory guidelines. The total number of MN scored per 1000 mononucleated 
cells and RPD induced over a 48 hour period (24 hour treatment + 24 hour recovery) by mitomycin C (A), etoposide (B), paclitaxel (C) and 4-nitroquinolone-N-oxide (D). Those concentrations without a result 
for MN were not scored as they passed below the 50% ± 5% RPD regulatory guidelines (2.6.1). A positive mitomycin C control was run alongside etoposide (B), paclitaxel (C) and 4-nitroquinolone-N-oxide (D). 
A minimum of 2000 mononucleated cells were scored (n=3). Significant differences between samples were calculated using a One-Way ANOVA followed by a Dunnett’s test. The P values are indicated 
by * (p < 0.05), ** (p < 0.01), **** (p < 0.0001), actual p values can be found in appendix 1. 
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The results in Figure 4-6 A show that MMC induced an RPD of 53 and 47% at 60 and 70 
nmol/L respectively. MN induction was found to be 83 and 87 MN/ 1000 mononucleated 
cells for these doses in a clear dose dependent increase. However, during the baseline dose 
range at AZ, an RPD of  53 and 46% were found at 50 and 70 nmol/L respectively with MN 
induction, found to be 81 and 55 MN/ 1000 mononucleated cells for these doses. This result 
shows that even though the baseline range identified at AZ was correct, that 70 nmol/L dose 
induces a RPD around 47%, three biological replicates were needed for accurate assessment 
of the level of cytotoxicity induced by 50 and 60 nmol/L. This result concludes that a dose 
of 70 nmol/L gave the highest, scorable induction of MN. Using 70 nmol/L as a starting 
dose, which gave 50% ± 5% cytotoxicity, the dose range was increased to a maxium dose of 
240 nmol/L. The results show that at an RPD of 36%, 16% and 1.3% was induced with 90, 
140 and 160 nmol/L respectively. MN was not counted at these doses as genotoxicity could 
not be differentiated from cytotoxicity (section 2.6.1).  Further doses did follow a dose 
dependent trend which induced an RPD <0%, however, past this point the RPD calculation 
is inadequate due to ‘minus’ RPD values. It can be suggested from these results that a dose 
range, to be used in 3D culture, should include 7, 35, 60, 90 and 140 nmol/L which induce 
an RPD of around 100-80%, 80-60%, 60-40%, 40-20%, 20-0% providing a wide dose range 
for possible increase/ decrease of cytotoxicity in 3D. 
 
The results in Figure 4-6 B show that etoposide induced an RPD of 49 and 46% at 64.5 and 
69.7 nmol/L respectively. MN induction was found to be 74 and 91 MN/ 1000 
mononucleated cells for these doses in a clear dose dependent increase. However, during the 
baseline dose range finding at AZ, an RPD of 52% was found at 69.7 nmol/L, with MN 
induction found to be 97 MN/ 1000 mononucleated cells cells for this dose. This result shows 
that there was a decrease in cytotoxicity by 6% and increase in MN by 6 MN/ 1000 
mononucleated cells seen at UWE compared to AZ. However, this result still concludes that 
69.7 nmol/L gave the highest, scorable induction of MN at an RPD around 50%. Utilising 
69.7 nmol/L as a starting dose, which gave 50% ± 5% cytotoxicity, the dose range was 
increased to a maximum dose of 271.8 nmol/L. The results show that  an RPD of 35, 11 and 
4% was induced with 100.2, 203.9 and 254.9 nmol/L respectively. MN were not counted at 
these doses as genotoxicity could not be differentiated from cytotoxicity.  A further dose did 
follow which induced an RPD <0%, however, past this point the RPD calculation is 
inadequate due to ‘minus’ RPD values. It can be suggested from these results that a dose 
range, to be used in 3D culture, should include 1, 40.8, 64.5, 100.2 and 203.9 nmol/L which 
induce an RPD of around 100-80%, 80-60%, 60-40%, 40-20%, 20-0% providing a wide 
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dose range for possible increase/ decrease of cytotoxicity in 3D. Additionally, the positive 
control (MMC) has exceeded more than double the MN than that of the negative, so can be 
confirmed as positive and the assay successfully completed. 
 
The results in Figure 4-6 C show that paclitaxel induced an RPD of 53 and 47% at 21 and 
24 nmol/L respectively. MN induction was found to be 36 and 43 MN/ 1000 mononucleated 
cells for these doses in a clear dose dependent increase. However, during the baseline dose 
range finding at AZ, an RPD of 57 % at a concentration of 26 nmol/L with MN induction of 
40 MN/ 1000 mononucleated cells was found for this dose. As 26 nmol/L induced an RPD 
of 44%, below the 50% ± 5% threshold, at UWE it should not be scored, however, given the 
previous score at AZ this dose was scored inducing 50 MN/ 1000 mononucleated cells. This 
result shows that a higher level of cytotoxicity and genotoxicity was seen, with 3 biological 
repeats, at UWE than at AZ. Given these results, it can be concluded that 24 nmol/L gave 
the highest, scorable induction of MN at an RPD around 50%, not 26 nmol/L as first 
suggested at AZ. Utilising 24 nmol/L as a starting dose, which gave 50% ± 5% cytotoxicity, 
the dose range was increased to a maximum dose of 95 nmol/L. The results show that an 
RPD of 30, 20 and 3% was induced with 33, 45 and 65 nmol/L respectively. MN were not 
counted at these doses as genotoxicity could not be differentiated from cytotoxicity.  A 
further dose did follow which induced an RPD <0%, however, past this point the RPD 
calculation is inadequate due to ‘minus’ RPD values. It can be suggested from these results 
that a dose range, to be used in 3D culture, should include 1, 17, 21, 33 and 45 nmol/L which 
induce an RPD of around 100-80%, 80-60%, 60-40%, 40-20%, 20-0% providing a wide 
dose range for possible increase/ decrease of cytotoxicity in 3D. Additionally, the positive 
control (MMC) has exceeded more than double the MN than that of the negative so can be 
confirmed as positive and the assay successfully completed. 
 
The results in Figure 4-6 D show that 4NQO induced an RPD of 50% at 184.1 nmol/L with 
a MN induction of 23 MN/ 1000 mononucleated cells. However, during the baseline dose 
range finding at AZ, an RPD of 50% ± 5% was not achieved, with the highest dose at AZ of 
13.01 nmol/L giving an RPD of 84%. Given these results it can be suggested that 184.1 
nmol/L is required to give the highest, scorable induction of MN at an RPD of 50%. Utilising 
184.1  nmol/L as a starting dose, which gave 50% cytotoxicity, the dose range was increased 
to a maximum dose of 368.1 nmol/L. The results show that a dose dependent decrease in 
RPD did occur, conversely, over the scorable doses, MN did not increase. The positive 
control (MMC) did exceed more than double the MN than that of the negative so can be 
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confirmed as positive and the assay successfully completed. Due to the lack of MN induction 
within this dose range and the selection of two clastogens (MMC and etoposide) which did 
give a dose dependent increase in MN, 4NQO was not chosen for further study within the 
3D multicellular model.  
 
4.3.5. Dose range of known negative and pharmacological positives conducted 
at UWE.   
 
The use of known negative and pharmacological positive compounds was not assessed at 
AZ. However, as the regulatory 2D MN assay was comparable between UWE and AZ for 
the known positives (section 4.3.3), this assessment was only carried out at UWE. To assess 
a dose of each compound which gave an RPD of 50% ± 5% or, as these were known non-
genotoxicants, a maximum dose of 1 x 10
6
 nmol/L without an RPD of 50% ± 5% at these 
concentrations, to use in the 3D multicellular model the following MN assays (Figure 
4-7Figure 4-8) were conducted. Once again, the regulatory MN assay, set out in section 2.6, 
was followed so that alignment can take place with both an MMC positive and vehicle 
control.   
 
The results in Figure 4-7 A show that the pharmacological positive compound, 
dexamethasone, did not induce an RPD of 50% ± 5% at the top dose of 1 x 10
6
 nmol/L, with 
an actual RPD of 60%. A dose dependent increase in cytotoxicity can be seen with 
dexamethasone but MN induction remained around 18 MN/ 1000 mononucleated cells. This 
induction of MN was not twice that of the vehicle control of 10 MN/ 1000 mononucleated 
cells; therefore, can be classed as negative. The positive control of MMC did induce more 
than twice as many MN than that of the negative control and ensures that the negative result 
is true. In conclusion, the results suggest that all concentrations tested within the regulatory 
MN should be taken forward into the 3D multicellular system.   




Figure 4-7. Dose range finder of pharmacological positive compounds at UWE, identifying the relative PD (RPD) and micronucleus induction, of TK6, following a 24 hour treatment with 
dexamethasone and prednisolone. The graphs illustrate the total number of MN scored per 1000 mononucleated cells and RPD induced over a 48-hour period (24 hour treatment + 24 hour recovery) by 
dexamethasone (A) and prednisolone (B). The dose range didn’t induce an RPD score <50%, up to and including 1 x 106 nMol/l (1 mM) therefore, was identified as non-genotoxic as stated in section 2.6.1. A 
positive mitomycin C control was run alongside dexamethasone (A) and prednisolone (B). A minimum of 2000 mononucleated cells were scored (n=3). Significant differences between samples were calculated 


































































































































Figure 4-8. Dose range finder of a known negative compound at UWE, identifying the relative PD (RPD) and micronucleus induction, of TK6, following a 24 hour treatment with caffeine. The graph 
illustrates the total number of MN scored per 1000 mononucleated cells and RPD induced over a 48-hour period (24 hour treatment + 24 hour recovery). The dose range didn’t induce an RPD score <50%, up to 
and including the maximum soluble concentration of 7.7 x 105 nMol/l, therefore, was identified as non-genotoxic as stated in section 2.6.1. A positive mitomycin C control was run alongside to ensure that the 
assay had successfully worked. A minimum of 2000 mononucleated cells were scored (n=3). Significant differences between samples were calculated using a One-Way ANOVA followed by a Dunnett’s 
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Unlike dexamethasone, the results shown in Figure 4-7 B for prednisolone, an alternative 
glucocorticoid which has also been classed as a pharmacological positive compound, did 
induce an RPD of 46% at the top dose of 1 x 106 nmol/L. Even though this top dose was 
cytotoxic, (and cytotoxicity increased in a dose dependent manner), the top dose was not 
genotoxic as MN induction did not increase above 14 MN/ 1000 mononucleated cells, less 
than twice the vehicle control; therefore, can be classed as negative. The positive control of 
MMC did induce more than twice as many MN than that of the negative control and ensures 
that the negative genotoxic result is true. In conclusion, the results suggest that all 
concentrations tested within the regulatory MN should be taken forward into the 3D 
multicellular system.  
 
The results in Figure 4-8 show that the known negative compound, caffeine, did not induce 
an RPD of 50% ± 5% at the top dose of 7.7 x 105 nmol/L, with an actual RPD of 60%. 
However, the SD did infer that this level of caffeine can induce an RPD of 44%. The dose 
of caffeine did not reach 1 x 106 nmol/L as it was insoluble at this concentration; therefore 
the top dose used of 7.7 x 105 nmol/L was now used as the maximum dose necessary 
following the guidelines in section 2.6.1. Even though an RPD of 50% ± 5% was only 
reached by the error bars at this dose, a dose dependent decrease can be seen throughout. 
This trend cannot be seen with MN induction with the top dose of 7.7x105 nmol/L inducing 
17 MN/ 1000 mononucleated cells, less than twice the vehicle control at 11 MN/ 1000 
mononucleated cells. The positive control of MMC did induce more than twice as many MN 
than that of the negative control and reinforces the use of caffeine as a known negative 
genotoxic control. In conclusion, the results suggest that all concentrations tested within the 
regulatory MN should be taken forward into the 3D multicellular system.   
 
4.3.6. Genotoxic assessment of positive, negative and pharmacological positive 
compounds within a multicellular, in vitro, 3D model of the bone marrow. 
 
As described in section 1.2.2.1 the HSC compartment or TK6 cells in the developed 3D 
model, is required to be actively proliferating before the addition of compound. The HS-5 
cell line was seeded onto AlgiMatrix™ scaffolds and cultured as described in section 2.3.1, 
TK6 cells were then added to each scaffold and cultured for a 54 hour period. At this point, 
to ensure that the TK6 cells were actively dividing, pre-treatment baseline counts of the 
medium and corresponding AlgiMatrix™ were taken 24 hours before and on the day of 
dosing with compound, counted with TB and compared to the proliferation of cells seen 
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during optimisation of the model seen in Figure 3-13 to assess the alignment between the 
two. 
 
The results in Figure 4-9 show that 24 hours before dosing with compound, cell number 
within the pre-treatment (baseline) medium, scaffold and total for the well were 2.5, 4.6 and 
7.1 x 105 total cells respectively. However, the total cell number of cells seen during 
optimisation of the model (Figure 3-13 M, N and O), were at a lower level than that of the 
medium, scaffold and total for the pre-treatment, baseline wells, gleaning results of 1.4, 3.7 
and 5.1 x 105 total cells, but these results didn’t induce a significant difference. 
 
The results in Figure 4-9 show that on the day of dosing, unlike 24 hours before, total cell 
number within the pre-treatment (baseline) medium, scaffold and well were at 7.3, 7.7 and 
15 x 105 total cells, similar to the proliferation of cells seen within the model optimisation 
(Figure 3-13 M, N and O) at 6.9, 8.1 and 15 x 105 total cells which once again did not produce 
a significant difference between the two samples. Utilising the calculation in section 2.6.1, 
PD between the total cell number in the 24 hour period, in the pre-treatment, baseline group 
was 1.06 compared to the original proliferation of cells within the model (Figure 3-13 M, N 
and O) which was 1.54. The PD within the pre-treatment, baseline medium and scaffold was 
1.54 and 0.65 respectively, with PD of the original proliferation of cells (Figure 3-13 M, N 
and O) in the medium and scaffold being 2.37 and 1.11 respectively. 
 
These results conclude that both the pre-treatment (baseline) and original proliferation of 
cells in the model (Figure 3-13 M, N and O) had successfully gone through at least one PD 
before the addition of compound, inferring that both cultures were proliferating. However, 
it can be seen that the pre-treatment (baseline) group has a lower PD than the original 
proliferation in the model, but this is still above 1 within the combined scaffold and medium. 
Therefore, any addition of compound would induce a response within the exponential phase 
of the cells in co-culture.  





Figure 4-9. Baseline counts taken from the medium and well of TK6 and HS-5 seeded Algimatrix™ scaffolds, 24 hours before and on the day of compound dosing. Pre-treatment baseline counts, were 
then compared to the same parameters previously seen within Figure 3-13 M, N and O, to establish the consistent initial growth between the two studies. HS-5 cells were seeded onto AlgiMatrix™ scaffold, left 
to incubate for 24 hours, complete medium change conducted, incubated for a further 144 hours with a 50% medium change conducted every 48 hours. TK6 were then combined with each scaffold and incubated 
for a further 54 hours. Baseline Algimatrix™ scaffolds (four technical repeats) and corresponding medium were then harvested at -24 hours before and on the day of dosing (0 hour), with total cell number assessed 




















Cells in the Medium pre-treatment (baseline)
Cells in the scaffold pre-treatment (baseline)
Total cell number in the well pre-treatment (baseline)
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Having established a dose range suitable for use in the multicellular model (section 4.3.5, 
4.3.6), a dosing period (Figure 4-1)  confirming that cells within the model are proliferating, 
comparable to previous optimisation, treatment of the AlgiMatrix™ scaffolds was 
conducted. The HS-5 cell line was seeded onto AlgiMatrix™ scaffolds, incubated, TK6 
introduced and the co-culture left to incubate as described in section 2.3. At 0 hour time 
point, compound was added to the centre of the scaffold, mixed and incubated.  After a 24 
hour incubation, cells from the medium were harvested, counted and reseeded at the cell 
density established at time point 0 hour from the baseline counts onto their corresponding 
AlgiMatrix™ scaffold, and the scaffold returned to washed wells, for a further 24 hour 
incubation. Total cell number residing on the AlgiMatrix™ scaffold was not established at 
this point, as to not disturb the cells residing within.   After a period of 48 hours after initial 
dosing, cells were harvested from the AlgiMatrix™ scaffold and medium and counted using 
TB.  The results in Figure 4-10, show the total cell counts for two clastogens (MMC and 
etoposide), one aneugen (paclitaxel), two pharmacological positives (dexamethasone and 




The results in Figure 4-10 A and B show the total cell counts for the two clastogens MMC 
and etoposide.  On the day of dosing (0 hour) both MMC and etoposide wells, have 7.3 x 
105 total cells in the medium and 7.4 x 105 total cells within the AlgiMatrix™ scaffold. After 
a 24 hour incubation, those cells within the medium of MMC treated AlgiMatrix™ scaffolds, 
at all concentrations were 1 x 106 total cells, which were then washed and reseeded onto 
their corresponding AlgiMatrix™ scaffold at 7.3  x105 total cells. However, those cells 
harvested from the etoposide treated AlgiMatrix™ scaffold saw a dose dependent increase 
in total cell number with 1, 40.8, 64.5, 100.2 and 203.9 nMol/L achieving 1, 1.4, 1.4, 1.5 and 
1.9 x 106 total cells respectively but weren’t significant between each concentration. Once 
again, cells were washed and reseeded onto their corresponding AlgiMatrix™ scaffold at 
7.3 x 105 total cells and left to incubate for a further 24 hours. 




Figure 4-10. Total cell number of cells harvested from the medium and Algimatrix™ scaffold after dosing with compound. HS5 cells seeded onto AlgiMatrix™ scaffolds, incubated for 24 hours, complete 
medium change conducted, incubated for a further 144 hours before the addition of TK6 cells. After a 72 hour incubation, concentration of mitomycin C (A), etoposide (B), paclitaxel (C), dexamethasone (D), 
prednisolone (E) and caffeine (F) were added, incubated for 24 hour (+24 hours after initial dosing), medium washed, cells reseeded, incubated for a further 24 hours (+48 hours after initial dosing) before the 
medium and scaffold were harvested and assessed for total cell number via trypan blue (n=3)
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After this second 24 hour incubation, the MMC vehicle control (0 nMol/L) resulted in a total 
cell number within the medium of 8 x 105 and a total cell number of around 26 x 105 in the 
AlgiMatrix™ scaffold. The total cell number within the AlgiMatrix™ scaffold remained 
constant at all concentrations. However, total cell number within the medium increased from 
8 x 105 to around 20 x 105 in all concentrations, inducing a 2.5 fold increase in total cells. 
Etoposide showed a similar result, with cells in the vehicle control (0 nMol/L) resulting in a 
total cell number of 8  x105 within the medium and a total cell number of around 25 x 105 in 
the AlgiMatrix™ scaffold. The total cell number within the AlgiMatrix™ scaffold remained 
constant at all concentrations. However, similar to MMC, the total cell number within the 
medium increased from 8 x105 to around 26 x 105, inducing a 3.3 fold increase in all 
remaining concentrations.  
 
The results in Figure 4-10 C show the total cell counts for the aneugen paclitaxel. On the 
day of dosing (0 hour), in all wells there was a total cell number of 7.3 x 105 in the medium 
and 7.4 x 105 within the AlgiMatrix™ scaffold similar to MMC and etoposide. After a 24 
hour incubation, those cells within the medium of treated AlgiMatrix™ scaffolds, saw an 
increase in total cell number at 17 and 45 nMol/L to around 18 x 105 with the remaining 
concentrations inducing a total cell number of around 12 x 105. Cells within the medium of 
all concentrations were washed and reseeded onto their corresponding AlgiMatrix™ 
scaffold at 7.3 x 105 total cells and left to incubate for a further 24 hours. After this 24 hour 
incubation, similar to MMC and etoposide, the vehicle control (0 nMol/L) resulted in a total 
cell number within the medium of 8 x 105 and a total cell number of around in the 
AlgiMatrix™ scaffold. The AlgiMatrix™ scaffold which had received a dose of compound 
did see an increase in cells within the medium from 8 x 105 to around 15 x 105 total cells, a 
fold increase of 1.9. However, unlike MMC and etoposide, there was no significant 
difference in total cells within the AlgiMatrix™ scaffold or medium within all 
concentrations excluding the vehicle control.  
 
The results in Figure 4-10 D and E show the total cell counts for the pharmacological positive 
compounds dexamethasone and prednisolone. On the day of dosing (0 hour) both 
dexamethasone and prednisolone, in all wells, had 7.3 x 105 total cells in the medium and 
7.4 x 105 total cells within the AlgiMatrix™ scaffold, similar to the known genotoxic 
positives above. After a 24 hour incubation, those cells within the medium of dexamethasone 
treated AlgiMatrix™ scaffolds, saw an increase in total cell number, compared to the vehicle 
control, at 3 x 105 and 10 x 105 nMol/L with 12 and 17 x 105 total cells recorded. However, 
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there was no change in the total cell number residing in the medium of AlgiMatrix™ 
scaffolds treated with concentrations of prednisolone. Cells within both compound dose 
ranges, were washed and reseeded onto their corresponding AlgiMatrix™ scaffold at 7.3 x 
105 total cells and left to incubate for a further 24 hours. 
 
After this second 24 hour incubation, the vehicle control (0 nMol/L) in both dexamethasone 
and prednisolone, resulted in a total cell number within the medium of 8 x 105 and a total 
cell number of around 22 x 105 in the AlgiMatrix™ scaffold. The total cell number within 
the AlgiMatrix™ scaffold, as previously seen in the known genotoxic positives above, 
remained around the cell number identified within the vehicle control, for all concentrations. 
However, the total number of cells within the medium increased from the vehicle control to 
14 x 105 at 5 x 105 and 10 x 105 nMol/L concentrations of dexamethasone, a fold increase of 
1.8. In a similar manner, prednisolone remained at constant total cell number, similar to the 
vehicle control, for all concentrations with an increase only observed at 5 x 105 nMol/L to 
16 x 105 total cells; a fold increase of 2. 
 
The results in Figure 4-10 F show the total cell counts for the known negative caffeine. On 
the day of dosing (0 hour), in all wells, there was a total cell number of 7.3x105 in the medium 
and 7.4x105 within the AlgiMatrix™ scaffold similar to the results seen above. After a 24-
hour incubation with compound, those cells within the medium of treated AlgiMatrix™ 
scaffolds, saw a decrease from the vehicle control (11x105 total cells) at 5 x 102 and 5 x 103 
nMol/L (7.5 and 8.1x105 total cells). Further doses at 5 x 104 and 5 x 105 nMol/L remained 
around the total cell number seen with the vehicle control, with a dose of 7.7 x 105 nMol/L 
increasing cell number to 14 x 105. Once again, cells within the medium of all concentrations 
were washed and reseeded onto their corresponding AlgiMatrix™ scaffolds at 7.3 x 105 total 
cells and left to incubate for a further 24 hours. After a second 24 hour incubation, those 
cells within the medium of treated AlgiMatrix™ scaffolds, saw an increase in total cell 
number, compared to the vehicle control (8 x 105 total cells), at 7.7 x 105 nMol/L to 11 x 105 
total cells, inducing a fold increase of 1.4. The total cell number within the AlgiMatrix™ 
scaffolds, similar to previous results, remained around 24x105 with a drop only seen at a 
concentration of 5 x 105 nMol/L to 20 x 105 total cells. 
 
It can be concluded from these results, that the introduction of known genotoxic and 
pharmacological positive compounds, will induce an increase in total cell number compared 
to the vehicle control, in the medium only. This would infer that MMC, etoposide, paclitaxel, 
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dexamethasone and prednisolone, at these concentrations, are not cytotoxic. However, 
caffeine appears to be cytotoxic at low concentrations. As the 24 hour cell counts within the 
AlgiMatrix™ scaffolds were not assessed, to maintain the cellular environment within, 
cytotoxicity within the scaffold and thereby within each well cannot be completely 
concluded. However, to truly assess the cytotoxicity of each compound, the RPD outlined 
by the OECD, should be calculated from the identified PD’s within the medium on each day 
to assess if cells remain in a proliferating state. 
 
As the total cell number within the medium was ascertained for MMC, etoposide, paclitaxel, 
dexamethasone, prednisolone and caffeine over the 48 hour treatment period, PD used for 
eventual RPD, was calculated (Table 4-6). Those cells treated with the vehicle control only, 
in all compound groups achieved a PD of 0.6 within 0-24 hours of dosing. Within the same 
time period during the original seeding growth curve, the PD within the medium was 0.8. 
Doses of MMC (7, 60 and 140 nMol/L), etoposide (1 nMol/L), paclitaxel (1 and 33 nMol/L), 
dexamethasone (1, 5 and 8 x 105 nMol/L), prednisolone (1 x 106 nMol/L) and caffeine (5 x 
102, 5 x 103, 5 x 104 and 5 x 105 nMol/L) resulted in a PD below 0.6 inferring a reduction in 
proliferation at these concentrations. However, doses of MMC (35 nMol/L), etoposide (40.8, 
64.5, 100.2 and 203.9 nMol/L), paclitaxel (17, 21 and 45 nMol/L), dexamethasone (3 and 
10 x 105 nMol/L), prednisolone (2.5 and 5 x 105 nMol/L) and caffeine (7.7 x 105 nMol/L) 
gave a PD >0.6 inferring that these concentrations increased proliferation.  
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Table 4-6. The population doubling of cells within the medium of the 3D in vitro multicellular model when exposed 
to mitomycin C, etoposide, paclitaxel, dexamethasone, prednisolone and caffeine. The table shows the population 
doubling (PD) of cells exposed to each compound for 24 hour (0-24 hours) and recovery after compound is removed (24-
48 hours). PD was only achieved in the medium as, 24 hours after dosing, cell number within the AlgiMatrix™ scaffold 




















0 0.6 0.2 0 0.6 0.2 0 0.6 0.2 
7 0.4 1.5 1 0.5 1.8 1 0.5 1 
35 0.9 1.6 40.8 0.9 1.3 17 1.3 0.6 
60 0.4 1.7 64.5 0.9 1.5 21 0.7 0.7 
90 0.6 1.5 100.2 1.0 1.5 33 0.3 0.8 



















0 0.6 0.2 0 0.6 0.2 0 0.6 0.2 
100000 0.2 0.6 50000 0.6 0.3 500 0 0.4 
300000 0.7 0.2 250000 0.7 0.4 5000 0.2 0.1 
500000 0.2 1 500000 0.8 1.1 50000 0.5 0.4 
800000 0.3 0.6 750000 0.6 0.1 500000 0.4 0.3 
1000000 1.2 1 1000000 0.3 0.3 770000 1 0.6 
 
The medium was then harvested and reseeded at 7.3 x 105 total cells onto the corresponding 
AlgiMatrix™ scaffolds and incubated for a further 24 hours. As the cells had been reseeded 
at the same density as they had been dosed at 24 hours earlier, the PD should remain the 
same at 0.6. However, between the 24-48 hour time point, the PD within the vehicle control 
medium, reduced to 0.2 in all compound groups. This was not the case for those cells dosed 
with MMC or etoposide, as in all concentrations, cells doubled more than once. An increase 
>0.2 in PD was also seen with doses of paclitaxel (1, 17, 21, 33 and 45 nMol/L), 
dexamethasone (1, 5, 8 and 10 x 105 nMol/L), prednisolone (5 x 104, 2.5, 5 and 10 x 105 
nMol/L) and caffeine (5 x 102, 5 x 104, 5 x 105 and 7.7 x 105 nMol/L) inferring that all of 
these concentrations increased the proliferation of the cells within the medium. These results 
once again conclude that at these concentrations, compounds are not cytotoxic and seem to 
be increasing proliferation. However, the PD was not calculated for cells within the 
AlgiMatrix™ scaffold itself. Therefore, the PD for total cells within the AlgiMatrix™ 
scaffold and medium combined cannot be ascertained. At this dose range, concentrations do 
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not seem to be cytotoxic and an RPD is normally needed to be calculated to agree with 
OECD guidelines, in order for the genotoxicity of each dose to be investigated. 
 
Once the AlgiMatrix™ scaffold had been exposed to each concentration of compound, 
within the 48 hour treatment period, AlgiMatrix™ scaffolds were harvested along with their 
corresponding medium and assessed for MN utilising AO staining. The cells harvested from 
the AlgiMatrix™ scaffold were scored separately to those cells in the medium. The results 
in Figure 4-11, show the MN induced in 1000/ mononucleated cells in the medium, scaffold 
and the combined MN of both, which have been exposed to differing concentrations of 
MMC, etoposide, paclitaxel, dexamethasone, prednisolone and caffeine. The percentage 
change between the total MN induced in the regulatory 2D MN assay, compared to the 
combined total MN of the scaffold and medium within the multicellular 3D model was also 
calculated.  In all concentrations, regardless of compound, there was no significant 
difference between the number of MN within the scaffold and medium in the multicellular 
3D model.  
 
The results seen in Figure 4-11 A show that the combined total MN for MMC exceed twice 
the number in the vehicle control (15 MN/1000 mononucleated cells) at 60 nMol/L (59 
MN/1000 mononucleated cells), inferring a genotoxic compound at this concentration and 
higher. This level of MN induction, within the 2D regulatory assay, was seen between 35-
60 nMol/L. A lower concentration of 7 nMol/L was seen to exceeded twice the vehicle 
control of 7 MN/1000 mononucleated cells, which gave a MN induction of 25 MN/ 1000 
mononucleated cells. There is a significant increase in MN between the vehicle control of 
the 2D and 3D assay, with 7 MN / 1000 mononucleated cells identified in 2D but 15 MN / 
1000 mononucleated identified in 3D a percentage incerse of 53%. As the concentration of 
MMC increases within both the 2D and 3D assays, the number of MN/ 1000 mononucleated 
cells in the 2D assay surpasses that induced by 3D model at a concentration of 35 nMol/L, 
continuing this for the following concentration. The final two doses of MMC (90 and 140 
nMol/L) weren’t scored in the 2D assay, as they induced an RPD of <50% ± 5% in previous 
study (Figure 4-6). 
 
The results seen in Figure 4-11 B, identify that the combined total MN for etoposide exceed 
twice the number of the vehicle control (15 MN/1000 mononucleated cells) at a 
concentration of 40.8 nMol/L (32 MN/1000 mononucleated cells), inferring a genotoxic 
compound at this concentration and above. This level of MN induction, within the 2D 
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regulatory assay, was seen with a concentration of between 1-40.8 nMol/L. A lower 
concentration of 1 nMol/L was found to be genotoxic induction 20 MN/ 1000 
mononucleated cells, twice that of the vechile control (8 MN/1000 mononucleated cells). A 
significant increase in MN between the vehicle control of the 2D and 3D assay, with 8 MN 
/ 1000 mononucleated cells identified in 2D but 15 MN / 1000 mononucleated identified in 
3D a percentage increase of 44%. The number of MN/ 1000 mononucleated cells induced 
by etoposide in the 2D assay, surpasses that induced by 3D model at a concentration of 40.8 
nMol/L, continuing to increase in MN for the following concentration. The final two doses 
of etoposide (100.2 and 203.9 nMol/L) weren’t scored in the 2D assay, as they induced an 
RPD of <50% ± 5% in previous study (Figure 4-6).




Figure 4-11. MN induction in cells within the medium and scaffold, harvested from a 3D model after dosing with compound. HS5 cells seeded onto AlgiMatrix™ scaffolds incubated for a 168 hours before 
the addition of TK6 cells. After a 72 hour incubation, concentration of mitomycin C (A), etoposide (B), paclitaxel (C), dexamethasone (D), prednisolone (E) and caffeine (F) were added, incubated for 24 hours, 
medium washed, cells reseeded, incubated for a further 24 hours before the medium and scaffold were harvested and assessed for MN using an AO stain. The combined total MN was then compared to that found 
within the regulatory 2D in vitro MN assay, with percentage change in total micronuclei (percentage increase from 2D to 3D) also assessed. Lines indicate vehicle control and 2x vehicle control MN counts within 
the 3D assay. Those concentrations without a 2D MN count induced a RPD of >50% ± 5% and weren’t counted. A minimum of 2000 mononucleated cells were assessed for micronuclei (n=3) Significant 
differences between samples were calculated using a Two-Way ANOVA followed by a Dunnett’s test. The P values are indicated by * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001), actual 
p values can be found in appendix 1.
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The results for the two clastogenic compounds MMC and etoposide conclude, that even 
though a higher percentage of MN are induced for the 3D model within the vehicle control 
in comparison to the 2D regulatory assay, a higher concentration of MMC and etoposide is 
needed in the 3D model to replicate the equivalent MN induced within the 2D regulatory 
assay. This would infer that MMC and etoposide are less genotoxic in the 3D model than in 
2D but are still genotoxic. 
  
The results seen in Figure 4-11 C show the MN induction and percentage change for the 
known positive genotoxic compound paclitaxel. The combined total MN for paclitaxel saw 
an induction of 34 MN/ 1000 mononucleated cells, twice the number in the vehicle control 
(15 MN/1000 mononucleated cells), at a concentration of 1 nMol/L in 3D, inferring a 
genotoxic compound at this concentration and above. However, this level of MN induction 
was seen between 17-21 nMol/L within the 2D regulatory assay, with a concentration of 17 
nMol/L of paclitaxel required to induce a positive genotoxic response (21 MN/1000 
mononucleated cells). There is a significant increase in MN induced between the vehicle 
controls of the 2D and 3D assays, with a percentage increase of 53%. The level of MN 
induction in 3D appears to plateau between a concentration of 1 and 45 nMol/L with around 
40 MN/1000 mononucleated cells.  The final two concentration of paclitaxel (33 and 45 
nMol/L), within the 2D regulatory assay, weren’t scored as they induced an RPD of <50% 
± 5% in (Figure 4-6). These results conclude that paclitaxel requires a concentration of 
around 1 nMol/L in the 3D model, to induce a MN score twice that of the vehicle control 
inferring a positive genotoxic compound. A concentration higher than this has no significant 
effect on the induction of MN.  It can also be concluded that paclitaxel is more genotoxic in 
the 3D model than the 2D regulatory assay. 
 
The results seen in Figure 4-11 D and E show the MN induction and percentage change for 
dexamethasone and prednisolone. The concentrations of either compound, within the 2D 
assay was found to be non-genotoxic as MN did not exceed twice that of the vehicle control 
(15 MN/1000 mononucleated cells). The combined total MN for both dexamethasone at a 
concentration of 8 x 105 nMol/L and prednisolone at 5 x 105 nMol/L saw an induction of 32 
and 31 MN/ 1000 mononucleated cells respectively, exceeding twice the number in the 
vehicle control (15 MN/1000 mononucleated cells), inferring a weak positive genotoxic 
compound at these concentrations. However, once either compound had reached its 
respective genotoxic concentration, further increases in concentration didn’t induce a higher 
level of MN; instead, MN remained at the level stated earlier. The maximum induction of 
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MN/ 1000 mononucleated cells in the 2D assay was around 16 and 14 for dexamethasone 
and prednisolone. There was no statistical difference between the 3D and 2D vehicle controls 
for either compound. The percentage increase of MN between 3D and 2D for dexamethasone 
and prednisolone remained around 35 and 50% respectively for all concentrations tested. 
These results conclude that within a 3D multicellular model, concentrations of >8 x 105 and 
>5 x 105 nMol/L of dexamethasone and prednisolone, induced an increase in MN, thereby 
inferring a genotoxic concentration, in what is seen as a non-genotoxicant in the 2D 
regulatory assay. These data offer an important outcome within this research and supports 
the validity of the 3D model in bridging the gap between 2D and in vivo testing. The data 
presented here align with previous 2D work (demonstrating non-genotoxic), as well as 
outcomes for in vivo animal testing (weak genotoxic positive) with these compounds. 
 
The results seen in Figure 4-11 F show the MN induction and percentage change for known 
negative compound caffeine. Within both the 2D regulatory assay and 3D multicellular 
model, at all concentrations, an induction of MN twice that of the vehicle control was not 
achieved reinforcing the use of caffeine as a negative genotoxic control. There was no 
significant difference in MN between 2D and 3D within the vehicle control.  However, at 
low concentrations (5 x 102 and 5 x 103 nMol/L) a percentage increase can be seen in MN 
between the 3D and 2D of 45% and 24% respectively.  This increase then plateaus at 5 x 104 
nMol/L for the remainder of the concentrations. In conclusion, these results show that 
caffeine is non-genotoxic at all concentrations tested, therefore, reinforcing its use as a 
negative control. 





As stated in the previous chapter, the eventual aim of this research was to develop a 
physiologically relevant model of the in vivo BM, for use in genotoxicity testing. The 
genotoxicity of new compounds is routinely undertaken within the pharmaceutical industry, 
using a battery of tests as mentioned in section 1.2.2. The pharmaceutical company AZ 
utilises the bacterial AMES assay, before progressing each compound into the single 2D 
culture in vitro regulatory MN assay. The in vitro regulatory MN assay is intended to predict 
the genotoxic capability of a compound when advanced to in vivo studies. However, it has 
been documented that known non-genotoxic compounds, such as the glucocorticoid receptor 
agonists dexamethasone and prednisolone, are negative utilising the in vitro MN assay and 
within the clinic but marginally positive when progressed in vivo and thus have been named 
pharmacological positives (Hayes et al., 2013). A compound-related disturbance in the 
rodent which increases the MN within the BM, but which is not genotoxic, such as changes 
in core body temperature and increased erythropoiesis, has been postulated as the 
mechanism behind these pharmacological positives (Tweats et al., 2007, Pontén et al., 
2013). Even though we have an understanding regarding the mechanisms by which 
dexamethasone and prednisolone cause this weak increase in MN, other new compounds my 
produce the same outcome with no in vivo human and or rodent data to reassure that they 
are safe, possibly shutting down further development of an otherwise valuable resource. 
Therefore, the use of an in vitro, multicellular model of the BM, which mimics to the 
outcomes of compounds identified within the in vivo setting to confirm the 2D result, would 
be a useful tool in investigating the exact mechanisms and true genotoxicity of compounds 
before moving in vivo. 
 
In this chapter an optimised, in vitro model of the BM containing both MSC derived (HS-5) 
and TK6 cell lines, upon an artificial ECM, which acted in a similar manner to that seen in 
vivo (Figure 4-1), was used to assess the cellular characteristics and genotoxicity of  
compounds with known positive, negative and ‘pharmacological positive’ genotoxic 
outcomes in relation to both rodent and human data within the literature.  A series of 
regulatory 2D MN assays were initially undertaken at AZ and UWE for comparative scoring 
to ensure the transfer of assay and conditions between the laboratories. The compound dose 
range identified through these experiments which gave an RPD of 50% ± 5%, were then 
expanded to incorporate a toxic dose (<50% ± 5% RPD) for use within the 3D model. This 
chapter also reports on the MN induction and cellular changes of cells within the 3D model, 
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as a result of exposure to a dose range of known positive, negative and ‘pharmacological 
positive’ genotoxic compounds.  
 
4.4.1. Genotoxicity of known positive, negative and pharmacological positive 
compounds within the in vitro regulatory 2D micronucleus assay. 
 
In the present work, the 2D regulatory in vitro MN assay was used to identify a compound 
dose range of genotoxic (MMC, etoposide, 4NQO and paclitaxel), negative (caffeine) and 
pharmacological positive (dexamethasone and prednisolone) compounds which gave an 
RPD >50% ± 5%.  The four positive genotoxic compounds MMC, etoposide, 4NQO and 
paclitaxel were first assessed at AZ for MN induction and RPD, which was then carried out 
again at UWE for comparison of scoring. The results seen in Figure 4-5 show that for the 
same slide, scoring of MN between UWE and AZ was the same. However, when the range 
finding was conducted at UWE, with the concentration first identified at AZ, there was a 
difference in RPD and MN production at the same scorable dose which gave an RPD >50% 
± 5%.  
 
When tested at AZ, MMC, etoposide and paclitaxel identified the highest scorable dose with 
an RPD >50% ± 5% at 70 (46%), 69.7 (52%) and 26 (57%) nmol/L with MN/1000 
mononucleated cells at 55, 97 and 40 respectively. However, at UWE, the same doses of 
MMC, etoposide and paclitaxel gleaned an RPD of 47, 46 and 44% with MN/1000 
mononucleated cells at 87, 91 and 50 respectively. This change in RPD and MN can be 
attributed to the number of biological repeats conducted at UWE and AZ. As this was only 
a prelimary study at AZ, an N number of one (n=1) was conducted. However at UWE three 
biological repeats were conducted per compound. It has been found that there can be a 10% 
shift in RPD and MN induction between the same dose of compound with differing 
biological repeats (Fellows et al., 2008). Work by Smart et al., (2020) Brüsehafer et al. 
(2014), Thougaard et al., (2014), Hashimoto et al. (2012) and Dollapudi et al. (2019) in 
TK6, agreed with MN frequency and RPD induction found for MMC, etoposide and 
paclitaxel, with a maxium scorable dose within a 10% shift of those found at UWE.  
 
The fourth positive genotoxic compound, 4NQO, did not identify a maximal scorable dose 
of 50% ± 5% at AZ. However, at UWE, an RPD of 50% was found at a concentration of 
184.1 nMol/L (35 ng/ml) with a MN induction of 23. The MN induction did not increase in 
a dose dependent manner, unlike RPD and the other three genotoxic compounds, and 
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appeared to remain around 23, which had increased from the negative control of 11 MN. A 
study by Brüsehafer et al. (2016) on TK6 cells, found that a concentration of 30-50 ng/ml 
was required to cause an increase in MN from the negative control. However, this study 
found that even at a dose of 157.8 nMol/L (30 ng/ml) at an RPD of 60%, MN formation had 
not increased from the first escalation after the negative control. This compound was still 
deemed positive as  in both the Brüsehafer paper and at UWE it exceeded twice that of the 
negative control, with the positive also gleaning a score twice that of the negative control. 
 
The inital dose range of MMC, etoposide, 4NQO and paclitaxel, found at UWE, was then 
expanded to include concentrations for each compound that induced an RPD <50% ± 5%. It 
has been shown that higher concentrations of compound are required within 3D models and 
in vivo than in conventional 2D assay, due to reduction in bioavailability, detoxification and 
exposure of the compound (Nudischer et al., 2020; Mathews et al., 2016). However, as 
compounds are only tested to identify an RPD of 50% ± 5%, the literature does not reveal 
the MN and RPD of compounds above this. This study, therefore, is the first to identify the 
cytotoxicity of MMC, etoposide, 4NQO and paclitaxel ranging from an RPD of 100- 0%. 
However, the literature cited for the initial dose of each compound did see a dose dependent 
decrease in RPD, which if continued would correlate with the findings of the dose range 
expansion at UWE.  
 
The pharmacological positive compounds dexamethasone and prednisolone, along with the 
genotoxic negative caffeine, were then assesssed for genotoxicitiy at UWE only. In 
accordance with OECD guidelines, each compound was tested to a maximum dose of 1 mM 
or highest concentration that was still soluble. At a 1 mM dose of dexamethasone, an RPD 
of 60% was identified with a MN induction of 18, which did not reach twice that of the 
vehicle control at 10.  At a 1 mM dose of prednisolone an RPD of 46% was found. However, 
at this dose MN induction was only 14, four more than the vehicle control. This inferred that 
even though both compounds were non-genotoxic, as they did not induce a MN score twice 
that of the vehicle control, both induced some level of cytotoxicity. It has been noted that 
glucocorticoids of this nature are cytotoxic to cells of the immune system such as 
lymphocytes and, therefore, could cause some cytotoxicity to TK6 without being genotoxic 
(Lee et al., 2018). Work by Bryce et al. (2013) and Wilde et al. (2017) found that in TK6 
cells, both dexamethasone and prednisolone at 1 mM did not have an increase in MN twice 
that of the vehicle control. However, they did find a reduction in RPD over the selected 
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concentration similar to that found at UWE, with 1 mM dexamethasone producing an RPD 
score of 60% and prednisolone 50%.  
 
The non-genotoxic, but known cytotoxic compound caffeine was then assessed, with 
increasing concentrations up to a top dose of 7.7x105 nmol/L which was the maximum 
concentration that was soluble.  At the highest dose, caffeine produced an RPD of 60% with 
a MN induction of 17, less than twice the vehicle control of 11. This level of cytotoxicity 
aligns with the literature as Chapman et al., (2020), found that TK6 dosed with 7.7x105 
nmol/L of caffeine in a 24 hour treatment - 24 hour recovery MN assay, an RPD of 60% and 
a MN frequency of 1.2% of the vehicle control was established. However, within UWE the 
MN frequency was 1.5% but as previously addressed, concentrations can fluctuate by 10% 
between biological repeats and laboratories.   
 
4.4.2. Genotoxicity of known positive, negative and pharmacological positive 
compounds within the multicellular 3D model. 
 
Following the findings of MN induction and relative RPD within the 2D MN assay, five 
concentrations of MMC, etoposide, paclitaxel, dexamethasone and prednisolone were 
identified for use in the 3D model. These five concentrations spanned an RPD of 100-80, 
80-60, 60-40, 40-20, 20-0% for MMC, etoposide and paclitaxel. However, the five 
concentrations of dexamethasone and prednisolone ranged from 100 to 50%, as a lower RPD 
was not acquired within the 2D dose range finder. Owing to the lack of induction of MN 
with the compound 4NQO and the selection of two other clastogenic compounds (MMC and 
etoposide) 4NQO was not taken forward for 3D assessment.  
 
Each concentration of compound was added directly to the centre of the scaffold on day 0 
and allowed to perfuse out of the scaffold over the following 24 hours. This inferred a 
dynamic dosing regimen which doesn’t occur within the 2D MN assay as cells are dosed 
directly. Dynamic dosing allows a change in compound concentration over time as 
bioavailable compound, which hasn’t adhered to proteins or the scaffold, perfuses out into 
the surrounding medium. The addition of the drug directly to the scaffold also allows the 
BM stromal cells, already noted as being metabolically competent, to metabolise the 
compound. This type of dosing is seen within the in vivo environment (LaBonia et al., 2016). 
However, within the in vivo setting a low but constant flow of blood facilitates the 
transportation of bioavailable compound into and out of the BM microenvironment, instead 
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of perfusion as seen with the scaffold (Torisawa et al., 2016). To tackle this lack of flow 
within this 3D static model, once compound was added, the medium surrounding the 
scaffold was forced through the centre of the scaffold. This allowed the distribution of 
compound throughout the well and scaffold. The high level of sheer force produced from 
this method of compound distribution has been shown to alter gene expression and remove 
cells from the scaffold entirely, disrupting the microenvironment which has been developed 
(Prabhakarpandian et al., 2011). However, by distributing the compound for a small amount 
of time (<5 minutes), this would infer that the level of sheer force wouldn’t alter the cellular 
adherence or gene expression but would distribute the compound to the whole well not just 
the scaffold.  
 
After a 24 hour direct exposure to the compound, medium was removed from the well 
surrounding the scaffold. In order to maintain the microenvironment within the scaffold that 
had developed, the scaffold was not washed with medium, so the scaffold is likely to still 
contain remaining compound (and possibly metabolites). The half-life of MMC (50 mins), 
etoposide (1.5 hours), paclitaxel (13 hours), dexamethasone (190 mins), prednisolone (60 
mins) and caffeine (5 hours) are shorter than the 24 hour period the drug had been within the 
system (McKenna et al., 2012, Fang et al., 2018, Gerson et al., 2018, Wang et al., 2011, 
Cevc & Blume, 2004, Bindreither et al., 2014 & Alsabri et al., 2018). As previously 
explained, the bioavailability, perfusion into the surrounding medium and potential 
metabolism by the stromal layer would greatly reduce the concentration of each compound 
over the initial 24 hour period. Therefore, the residual medium left within the scaffold would 
likely have had low, if any active compound.  
 
The lack of wash did mean that the cellular contents of the scaffold could not be identified, 
unlike the surrounding medium which was counted and reseeded at the concentration at 
which the well was dosed.  Furthermore, reseeded cells were reintroduced into the centre of 
the scaffold and mixed 3 times encouraging non-adhered cells within the scaffold out into 
the medium. This reintroduction of washed cells to the centre of the scaffold, displaced 
unwashed medium from the centre to the surrounding medium. Furthermore, cytokines and 
signalling molecules within the scaffold, could be reintroduced to the fresh surrounding 
medium, at a reduced concentration than that which had been removed through washing, , 
allowing a level of cellular communication to be maintained. As the cellular components of 
the scaffold weren’t harvested in order to maintain the microenvironment, reintroducing 
cells in medium through the scaffold would likely increase the expected final cell 
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concentration within the well. This was accounted for by only reintroducing cells through 
the scaffold at the density measured in the medium when dosing, not the concentration of 
the well as a whole. The well of each scaffold was also washed, as it was seen that both HS-
5 and TK6 cells resided on the well surface. Each culture was then left for a further 24 hours 
for a recovery period. 
 
Once the recovery period had concluded, the scaffold and medium were harvested separately 
in order to count the cell number and MN in each compartment. The scaffold was removed 
first and then the surrounding medium, which had been washed across the surface of the well 
to collect any cells remaining on the surface. As the scaffold was removed first, the action 
of removal could have introduced (or removed) more cells to/from the scaffold surface, 
hence the total MN in each well was also calculated from the individual compartments. The 
identification of MN within the TK6 only, using the staining protocol of CD19 and CD20 
identified in section 3.3.4.1 was the initial aim, with those MN residing with the DAPI only 
stained HS-5 also of interest. However, when the CD markers were stained, TK6 were not 
identifiable away from the HS-5 as shown in section 3.3.4.1. It has been noted that mutations, 
caused through de novo or chemical alteration in the genetic sequence of the CD marker, 
can cause the loss or abnormal expression of that CD marker (Shahrabi et al., 2020). The 
loss of these CD markers in 2D compound treated cells has not been documented in the 
literature’. However, as previously mentioned, the co-culture of cells can alter gene 
expression without chemical alteration. 
As these CD markers were present during preliminary 3D study, the addition of compound, 
especially those that have detrimental effect on the genome, may have been the cause of this 
loss. Therefore, AO was used to identify MN within each compartment but was unable to 
differentiate TK6 from HS-5. A study by Sharma et al., (2015) identified that stromal cells, 
when treated with compound in 2D culture, did not induce a high level of MN compared to 
that of the vehicle control. Even though, this study was conducted within a 2D environment 
it implies that the MN seen within our study would be predominately induced within the 
TK6.  
 
As the 3D static model used within this study is meant to be representative of the in vivo 
human and/ or rodent, the comparison and explanation of MN induction and cellular 
alterations using the compounds mentioned previously, was achieved utilising the literature 
of pharmacokinetic profiles of each compound in both the human and rodent. Due to the 
novel aspect of this model, utilising in vivo data seemed more appropriate than comparing 
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this model with other in vitro models within the literature which differed in cell type, scaffold 
use and medium supplementation. As described previously, the concentration of each 
compound in the model would not be the final concentration biologically available to the 
cells, due to binding to proteins, scaffold and detoxification from the stromal layer. 
 
4.4.2.1. The addition of known genotoxic compounds 
 
The total cell number acquired for the two clastogenic compounds MMC and etoposide, 
after the 48 hour treatment period, appear to be higher in the treated wells compared to that 
of the negative control DMSO. As previously mentioned, cells were reseeded onto the 
scaffold after washing, at a reduced concentration (i.e. initial seeding density) to maintain 
the TK6 in their exponential phase, and yet cells within the medium were more than double 
that of the control for both compounds. When looking at the PD in 3D, after dosing (0-24 
hours after addition of compound) cells within the medium do not have at least one PD, 
unless treated with high levels of etoposide.  However, once reseeded, the cells within the 
recovery stage (24-48 hours) have more that 1.5 PDs compared to the control which was 
only at 0.2.  
 
The increase in cell number over this timeframe could be explained by the dose range 
provided. It was found that in humans with non-small cell lung cancer, given a clinical dose 
of 6 mg/ m-2 or sub-clinical dose of 50 ng/ m-2 of MMC, an unbound plasma concentration 
of 440 ng/ml and 126ng/ml respectively was found within the bloodstream (Higley et al., 
2006). Within the 2D assay, the highest dose used which gave an RPD of 16%, was 
46.8 ng/ml added directly to the model. As described previously, this concentration 
added to the model would signify the total, not unbound plasma concentration. The 
reduced concentration used within the model gives reason for the lack of cell death 
seen. However, this does not explain why the cellular concentration was increased 
so dramatically from the DMSO control. 
 
To explain this increase in cell number we must turn to the in vivo rodent MN 
assay. When Swiss albino mice were given 1 mg/ kg intravenously of MMC, the 
unbound plasma concentration was found to be 45 ng/ ml, similar to the top 
concentration added to our model. At this low dose, the erythrocyte population in 
the blood stream declined. However, erythrocytes and erythroblasts found within 
the bone marrow increased; this was postulated to be because they were homed to 
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the BM to aid in repair and if repair couldn’t be achieved, the production of new 
erythroblasts from HSCs in the BM niche was required (Yang et al., 2019). This would 
infer that the TK6 cells within our model, once dosed, homed to the scaffold for repair (or 
perhaps protection from the HS-5), resulting in a depletion of cells within the medium after 
24 hours of direct treatment. As the TK6 had migrated to the scaffold, the cell number within 
the medium after 24 hours was not representative of the actual cell number within the well 
as a whole. The cells that had migrated to the scaffold which hadn’t been washed or counted, 
may have evacuated out of the scaffold with the reintroduction of washed cells. This would 
in some way explain the increase in cell number in the medium after 48 hours. However, 
with all compounds not just MMC, the level of cells within the scaffold, after 48 hours 
remain at the same level, inferring that a population of cells at around 2.5 x 105 cells 
remained adhered to the scaffold. Unfortunately, due to the lack of discrimination in staining, 
it cannot be stated the concentration of TK6 or HS-5 within this population. 
 
Furthermore, studies by Niikawa et al., (2001) & Bowen et al., (2011) also found similar 
findings when treating both Swiss albino mice and rats with 1 mg/ kg of MMC over a 3 day 
or 7-day dosing period. At this dose the unbound plasma concentration was thought to be 
around 45 ng/ ml, and once again an erythrocyte population was slightly increased 
from 47.9 to 47.92% after dosing. At this concentration an 8 to 16-fold increase in 
MN was scored within the polychromatic erythrocytes. However, within the 3D 
system, at a concentration of 46.8 ng/ml, only a 6-fold increase from the vehicle 
control was seen. However, within the rodent, the constant flow from the 
circulatory system reduces the compound gradually, unlike our model which has a 
complete wash 24 hours after dosing. This extended dosing period, seen in each 
study could have attributed to the increase in MN. The 2D MN assay at the 
maximum scorable dose of 20.1 ng/ ml gave a 7- fold increase in MN from the 
vehicle control, highlighting the overestimation of genotoxicity of MMC at this 
dose. 
 
The increase in cell number within the etoposide treated wells was likely due to 
factors similar to that of MMC. Within human treatment regimens, a clinical dose 
of 26.8 mg/kg gives a total unbound plasma concentration of 10,000 ng/ ml (Duong 
et al., 2019). The highest concentration administered in the current model was 120 ng/ ml, 
which was significantly less than that seen in humans, giving reason for the lack of 
cytotoxicity. However, within the 2D MN assay this concentration gave an RPD of 11% 
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showing a high level of cytotoxicity at this concentration. Unlike MMC, etoposide had 
higher levels of cells within the medium after 24-hours of direct treatments and was 
attributed to the concentration of compound added to the model. The highest total 
concentration of MMC was 10-fold lower than that found in the human’s unbound plasma, 
with the highest concentration of total etoposide used here equating to an 83-fold lower 
concentration compared to human plasma. This reduced level of compound (relative to 
clinically measured concentrations) thus did not cause equivalent cytotoxicity in the model, 
within the first 24 hours. 
 
This explanation of lack of cytotoxicity with etoposide was also highlighted within the 
rodent in vivo MN assay. Sprague-Dawley rats intravenously administered with 3 kg/ mg 
resulted in an unbound plasma concentration of 30,000 ng /ml, 3x more than the human 
levels and 250x more than the maximum concentration administered within our model (Li 
& Choi 2009). A level of cytotoxicity was only seen at a high concentration of 20 mg/ kg, 
administered to Swiss albino mice, resulting in a small decrease of polychromatic 
erythrocytes from 6248 to 6153 (Choudhury et al., 2004). Due to the lower concentrations of 
etoposide within the current model, unlike MMC, TK6 did not migrate to the BM as they 
did not appear to accumulate damage. Hence when washing and reseeding occurred, less 
cells in comparison to the MMC treated wells were evacuated into the medium. This gives 
further evidence to the decrease in cell number in the medium with increase in density after 
a 24 hour recovery period, as the number reseeded was more accurately depicting the well 
as a whole.  
 
Once again, the addition of low concentrations of etoposide had an impact on MN 
production. The B62DF1 mouse was intravenously administered with 1 mg/ kg at an 
unbound plasma concentration of 10,000ng/ ml (Turner et al., 2001). At this concentration 
a 25-fold increase in micronucleated polychromatic erythrocytes was found, unlike at the 
highest dose (120 ng/ ml) within our model of a 3-fold increase compared to the vehicle 
control. When looking at the results of the 2D MN, the highest scorable dose of 38 ng/ml 
gave an induction 11-fold higher, inferring overestimation of the genotoxicity of this 
concentration. 
 
Similar to the two clastogenic compounds mentioned previously, paclitaxel has an increase 
in cell number within the medium of treated wells compared to that of the DMSO control. 
Once again, the highest concentration administered to the 3D model was lower compared to 
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that seen in vivo. In the treatment of metastatic breast cancer, a human clinical dose of 260 
mg/ m2 gave an unbound plasma concentration of 350 ng /ml, with patients at this 
concentration suffering from neutropenia, leukopenia, anaemia and thrombocytopenia. The 
highest concentration within our model was 38.4 ng/ ml; 9-fold less than the human 
clinically relevant dose. At this concentration within the 2D MN assay an RPD of 20% was 
recorded, showing a higher level of cytotoxicity in vitro than seen in vivo.  
 
As the highest concentration of paclitaxel used within the model did not induce cytotoxicity, 
the genotoxicity of the compound within the model was investigated. Studies in mice found 
that when injected with 10 mg/ kg of paclitaxel, an unbound plasma concentration of 900ng/ 
ml was achieved and the erythrocyte’s population declined rapidly (Li et al., 2018). Once 
again this is higher than the concentration tested within the current model. However, when 
mice were tested with a therapeutic (0.6 mg/ kg), intermediate, (1.2 mg/kg) and high dose 
(1.8 mg/ kg) of paclitaxel, the unbound blood plasma concentration was 53, 113 and 150 ng/ 
ml respectively. At these concentrations, after a 24 hour incubation period, the MN induction 
slowly increased in a dose dependent manner, inducing around a 16-fold increase from the 
negative control (Zaid et al., 2012 & Rabah et al., 2010). This gradual increase in MN was 
seen within the current model at all concentrations above the vehicle control. However, only 
a 3-fold increase could be seen with even the highest concentration of paclitaxel, but as 
previously mentioned this could be a result of lower concentration of compound within the 
model. This gradual induction of MN was not seen within the 2D MN assay as induction 
increased rapidly from the vehicle control. At the highest scorable dose of 17.9 ng/ ml a 7-
fold increase in MN could be seen, overestimating the level of genotoxicity. 
 
4.4.2.2. The addition of pharmacological positive compounds 
 
Unlike the known positive genotoxic compounds, dexamethasone and prednisolone did not 
induce the same increase in cell number within the medium or increased the PD over the 0-
24 direct treatment or 24-48hour recovery period. Cell number within the two compounds 
fluctuated at each time point, with concentration of both dexamethasone and prednisolone 
causing an increase/ decrease in cell number after the direct and recovery treatment periods 
with no perceivable correlation. However, this fluctuation of cell number can be explained 
by looking within human studies, as compounds of this class have been noted as 
immunosuppressant and anti-emetic which are taken routinely through oral administration 
(Zabirowicz et al., 2018). 




A study by Jobe et al. (2020) showed, that when administering a 6 mg dose of 
dexamethasone to pregnant women to reduced morning sickness either intramuscularly or 
orally, the unbound blood plasma concentration peaked at between 95-100 ng/ml. The study 
found that at this concentration, T cell lymphocytes reduced 5-fold in cell number from the 
baseline line value to a nadir at 6 hours after administration. The concentration of T cells 
then returned back to baseline at 40-42 hours but continued to rise with a plateau 56 hours 
after initial treatment, 1.6-fold higher than the original baseline. This pattern also occurred 
within the basophil population. It was thought that this increase above and beyond the 
baseline was the remnant of a negative feedback loop, increasing the production of each to 
compensate for the initial loss. However, dexamethasone had the opposite effect on 
neutrophils; 24 hours after initial dosing the concentration of neutrophils increased 3-fold 
higher than the baseline, with concentrations returning and remaining at the baseline 46 
hours after exposure. 
 
The TK6 cell line used within the model is a B lymphoblast, unlike the T cell lymphocytes 
seen within the Jobe et al. (2020) study. The concentration of unbound dexamethasone found 
within (95-100 ng/ ml) the study was also far lower than the lowest dose used within the 
model (390,000 ng/ ml). However, as previously mentioned the concentration added to the 
model was unlikely the final concentration biologically available to the cells. Therefore, if 
one considers the highest dose of 390,000 ng/ ml, an increase in cell number after a 24 hour 
treatment or 48 hour recovery compared to the vehicle control was seen. The TK6 cell line 
has a doubling time of 14 hours unlike T cells which have a >24 hour cycle which would 
reduce the timeline seen in vivo (Macallan et al., 2019).  Therefore, the increase in cell 
number is not a lack of cytotoxicity, but the plateau above the baseline seen in humans with 
concentrations of dexamethasone <120,000 ng/ml representing those cells within the growth 
stage after initial reduction/inhibition. 
 
This same occurrence can be used to explain the results seen with prednisolone. In a similar 
study, Magee et al. (2001) found that oral administration of 0.27 mg/ kg of prednisolone led 
to an unbound blood concentration of 100 ng/ml; 5x less than the bound concentration at 
500 ng/ml. Once again, T cells declined to below the baseline to a nadir at 5 hours, which 
then increased past the baseline to a consistent plateau at around 18 hours post treatment. 
The neutrophil concentration also followed the same pattern as seen with dexamethasone, 
increasing post-treatment and returning to baseline 32 hours later.   




Given the information on TK6 and T cell proliferation times above and the Magee et al. 
(2001) study, the results seen within the 3D model can also be attributed to a reduction in 
the in vivo timeline. As noted, prednisolone found a nadir at 5 hours post-treatment and 
plateaued above the baseline at 18 hours. This timeline was much longer with 
dexamethasone, with a nadir after 6 hours and increase above the baseline at 56 hours. This 
already reduced timeline and use of a more rapidly dividing cell line, is compounded by the 
concentration used within the model. As can be seen in Figure 4-10 E, the cell number at 24 
and 48 hours after first exposure steadily increases in a dose dependent manner up to a 
concentration of 180,000 ng/ ml (500,000 nmol/L), 1800x higher than that used within 
humans. This would infer that the concentrations <180,000 ng/ ml corresponded with the 
increase in cell number up to a plateau seen at a concentration of 180,000 ng/ ml. Therefore, 
as concentrations >180,000ng/ ml did not increase in cell number, this is a sign of true 
cytotoxicity. 
 
Given that the studies above suggested that the in vitro model was able to withstand 
concentrations of dexamethasone and low levels of prednisolone, in a similar manner to the 
in vivo setting, genotoxicity was then evaluated using data from the in vivo rodent BM MN 
assay. The total MN induction within the model for both dexamethasone and prednisolone 
exceeded that found in the corresponding 2D MN assay. A concentration greater than 
800,000 (310,000ng/ ml) and 500,000 nMol/L (180,000ng/ ml) were found to induce a MN 
score twice that of the negative control. These concentrations are consistent with the 
proliferation past the baseline and plateau stages seen within Hayes et al. (2013). The level 
of MN within prednisolone plateaus with concentrations >180,000ng/ ml, correlating with 
the evidence that the cell number seen here is an indication of true cytotoxicity. 
 
Within Swiss albino mice, given 8 mg/kg of dexamethasone, a peak unbound plasma 
concentration of 2300 ng/ ml was recorded (Li et al., 2018). Utilising the same species, when 
dosed with 1, 5 or 10 mg/ kg, the unbound plasma concentration was 287.5, 1437.5, 2875 
ng/ ml respectively. At these concentrations, the MN induced was 3, 3 and 5-fold higher than 
that of the vehicle control respectively (Singh et al., 1994). Within our model a concentration 
of 310,000 ng/ ml, 107x higher than the highest concentration found within the rodent, gave 
a 2-fold induction of MN. This would infer that the biological, unbound concentration of 
dexamethasone was less than 287.5 ng/ ml within the model. This finding reinforces the 
increase in timeline due to increased proliferation of TK6 within the in vitro model, 
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compared to the human in vivo data, as this concentration is still 2.8x higher. However, at 
the same concentration used within the 2D MN there was less than a 1-fold increase in MN. 
  
A concentration of 25mg/ kg of prednisolone administered to rats gave a peak bound, not 
unbound, plasma concentration of 80,000 ng/ml (Meno-Tetang et al., 1990). Within the 
same species, a dose of 500, 1000 or 1500 mg/kg was administered and a 2-fold increase in 
MN compared to the vehicle control was seen. It was also noted that similar to the in vivo 
human, as concentration increased the level of white blood cells, lymphocytes and 
reticulocytes decreased and neutrophils increased in a dose dependent manner. Within the 
model a 2-fold increase in MN was seen with concentrations <180,000ng/ ml, which also 
correlated with the reduction in cell number seen within the in vivo rodent and human. This 
indicates that considering the level of prednisolone in conjunction with the increased cellular 
proliferation of TK6, it can be surmised that the concentration utilised in vivo was also 
administered within our model. However, at the same concentration used within the 2D MN, 
once again, there was less than a 1-fold increase in MN, highlighting the inability of the 2D 
MN assay to predict the outcome in rodent studies. 
 
4.4.2.3. The addition of a negative genotoxic compound. 
 
The negative genotoxic compound caffeine was the only drug, compared to the 5 previous 
compounds, which did increase cell number and PD, excluding the maximum dose of 7.7 x 
106 nMol/L (1.5 x 105 ng/ ml). At each concentration the cell number remained similar to 
that found within the vehicle control of water. When investigating the effects within humans, 
White et al., (2016), found that when participants orally ingested 0.32 mg/ ml of caffeine, 
the peak unbound plasma concentration was 3500 ng/ ml a 91-fold reduction with no 
determinantal effects to the participant. If this reduction was true within our model, the 
highest concentration of 150,000 ng/ ml would only give a biologically available 
concentration of 1648 ng/ ml and may explain the lack of cytotoxicity seen. 
 
When rats were given orally administered 1 mg/ kg caffeine, a peak unbound plasma 
concentration of 350 ng/ ml was recorded, again with no detrimental effects to the rats (Noh 
et al., 2015). It was found that at an increased concentration of 126 mg/ kg the level of MN 
remained <1-fold increase from the control (Bramebill et al., 2013). This finding was 
consistent with the total MN production within the model and 2D MN assay. However, 
within the 2D assay a concentration of 150,000 ng/ ml gave an RPD of 60%, whereas there 
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was no effect on cellular number within the in vivo human and in vitro model, highlighting 
the overestimation of cytotoxicity within the 2D MN assay. 
4.5. Conclusion 
 
This study has shown the effects of a range of known positive, negative and pharmacological 
positive compounds within the 2D MN assay and 3D model, on the cell number and MN 
induction over a 48-hour treatment period. The 2D regulatory MN assay is meant to be 
predictive of the in vivo environment. However, findings from the 2D MN assay show that 
the results gleaned from positive genotoxic compound overestimates the level of cytotoxicity 
and underestimated the MN induction when compared to an in vivo environment. The use of 
pharmacological positive compounds had the opposite effect within the 2D assay, as both 
the level of cytotoxicity and genotoxicity was overestimated compared to the in vivo human 
and or rat.  
 
The addition of each compound to the 3D model invoked an effect that was more in vivo 
relevant than that of the 2D MN assay. The cytotoxicity and genotoxicity more closely 
resembled that which was found within the literature for in vivo studies. However, a higher 
concentration of positive genotoxins and lower dose of the pharmacological positive 
compounds was required to fall in line with the clinically relevant, biologically available, 
doses seen within both human and rodents. Identifying the unbound concentration within the 
model would therefore be beneficial. However, the concentrations used within the 3D model 
were identified using OECD guidelines within a single cell culture and within a cytotoxic 
range, inferring that the addition of the HS-5 stromal line causes this change in effects, 
possibly via its metabolic competence. This result also sheds light on the suitability of OECD 
guidelines in the 21st century, and perhaps their need to be revisited. 
 
In conclusion the addition of each compound to the 3D model provided a more in vivo 
genotoxic and cytotoxic response than that seen within the 2D MN assay. However, to 
identify the mechanism behind the change in genotoxicity and cytotoxicity with positive and 
pharmacological positive compounds, further investigation is needed into the role of the HS-
5 stromal cell line when cultured within a 3D environment, both in isolation and with the 
addition of TK6. 









The BM microenvironment is made up of differing cellular compartments consisting of 
haematopoietic and non-haematopoietic stromal cells such as osteoblasts, adipocytes and 
fibroblasts within a liquid compartment comprising of growth factors, cytokines, enzymes 
and chemokines (Lemaire et al., 2011). It is this interaction between the stromal cells of the 
BM and the haematopoietic niche, that has been identified as the cause of drug detoxification 
and /or activation in vivo, leading to altered outcomes of drug interactions between in vitro 
and in vivo assays (Ria et al., 2020; Chen et al., 2020).  The primary human stroma has been 
found to act in a similar manner to human hepatocytes, by expressing a variety of phase 1 
and 2 metabolic enzymes (CYP450) as well as associated drug transporters (Alonso et al., 
2015 & Boutin et al., 2020). Conversely, the human HSC compartment has low expression 
of drug metabolism enzymes and associated drug transporters (Chen et al., 2019).  
 
In order to assess the genotoxic capability of a pro-drug within the regulatory in vitro MN 
assay as haematopoietic cell lines such as TK6 do not express metabolic enzymes, the 
addition of the rat liver 9000 xg supernatant fraction (S9), extracted from rats pre-treated 
with drug metabolite enzyme inducers such as aroclor, is used to increase the expression of 
the phase I and II metabolic enzymes CYP1A1, 1A2, 2B1, 2B2, 2C6, 3A1 and 3A2 similar 
to that expressed by the liver (Kishino et al., 2019). However, as previously mentioned cells 
of the haematopoietic niche do not express metabolic enzymes or contain the associated drug 
transporters noted within the in vivo stroma.  The use of the rat S9 fraction, therefore, is only 
applicable to those compounds altered by the above family of CYP enzymes. In order to 
have a true representation of the genotoxicity of compounds, the addition of a cell line with 
a similar metabolic profile to that seen within in vivo stroma is required. Therefore, as HS-5 
have been chosen as a cell line model of the in vivo BM stroma, it needs to be assessed for 
its ability to also express the equivalent enzymes in vitro, validating the current model. 
 
The work in previous chapters has identified a method of co-culturing cell lines upon an 
artificial ECM (section 3.3.2.5), which when treated with known positive, negative and 
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pharmacological positive genotoxicity compounds induced a response similar to that seen in 
vivo (section 4.3.6). The aim of this chapter was to identify the metabolic profile of the HS-
5 cell line, used as the stromal layer within the 3D model, in comparison to that seen within 
the in vivo BM. In brief, HS-5 cells were cultured as a 2D monolayer and within the 3D 
scaffold using a previously mentioned technique (section 2.3.1), with and without the 
addition of TK6 separated by a trans-well insert at a concentration identified in section 
3.3.2.5. The HS-5 cell line from each culture was then harvested, RNA extracted, and 
quantitative polymerase chain reaction (qPCR) conducted for expression of phase I and II 
drug metabolic enzymes and associated drug transporters.  This was then compared to 
HepG2 spheroids, cultured in-house, for comparison of relative expression. The HS-5 cell 
line was then cultured as a monolayer, before the addition of TK6 within a trans-well insert, 
to study the effects of the pro-drug cyclophosphamide with and without the addition of S9. 
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5.2. Materials and methods 
 
5.2.1. Spheroid formation  
 
As a positive control, HepG2 spheroids were generated using the protocol conducted within 
May et al., (2012). Cells were grown for seven days as denoted in section 2.2, trypsinised 
and cells seeded into a 6-well plate at a concentration of 1 x 106 cells/ml in 3 mls of complete 
medium. Each plate was incubated on an orbital shaker at 37 oC, 5% CO2 at 83 RPM for 24 
hours and then 79 RPM for an additional 120 hours. A 50% medium change was conducted 
every 48 hours until maturation on day 6. 
 
5.2.2. RNA extraction 
 
HS-5 cells grown within an Algimatrix™ scaffold in 12 well plates (as described in section 
2.3.1), were either harvested immediately or co-cultured with TK6 cells (separated by a 12-
well 0.2 µm pore insert) for a further 48 hours (50% medium change every 24 hours), and 
then extracted for RNA. HepG2 spheroids were also collected as a positive control. RNA 
was extracted using the RNeasy Plus mini kit (Qiagen, Germany) following the 
manufacturer’s guidelines using RNA free tips, pipettes and working area which had been 
sprayed down with RNase zap (Thermo Scientific, Loughborough).  
 
Briefly, around 1 x 106 cells from each condition were collected by centrifugation (300 x g, 
7 minutes), medium removed, 350 µl of RLT buffer (with addition of 2% 2 M dithiothreitol; 
DTT) added and mixed vigorously for 1 minute. The lysate was transferred into a 
QIAshredder (Qiagen) spin column in a 2 ml collection tube and centrifuged at 8000 x g for 
2 minutes. The homogenized lysate was transferred into a gDNA Eliminator spin column 
(Qiagen) and spun at 8000 x g for around 30 seconds. A 1:1 ratio of 70% ethanol (100% 
molecular grade ethanol in RNase free water) to homogenized lysate was combined, mixed 
and 700 µl transferred to a RNeasy spin column. The column was then centrifuged for 15 
seconds at 8000 x g and the flow-through discarded. Buffer RW1 (700 µl) was added to the 
RNeasy spin column and centrifuged at 8000  xg for 15 seconds with the flow-through 
discarded. RPE buffer (500 µl at working solution with 100% ethanol) was then added to 
the RNeasy spin column and centrifuged at 8000 x g for 15 seconds with the flow-through 
discarded; this step was then repeated for a second time. The RNeasy spin column was then 
transferred to a new 2 ml collection tube and centrifuged for 1 minute at 8000 x g to further 
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dry the membrane. The RNeasy spin column was transferred to a new 1.5 ml centrifuge tube, 
10 µl of RNase-free water added directly to the membrane and centrifuged for 1 minute at 
8000 x g before the flow-through was placed back onto the membrane and centrifuged again 
for 1 minute at 8000 x g. The RNA sample was kept on ice or stored at -80 oC until 
quantification. 
 
5.2.3. Assessment of RNA quality and concentration 
 
RNA was assessed for concentration and purity using the Nanodrop 1000 spectrophotometer 
(Thermo Scientific, Loughborough). Each sample was analysed in duplicate with 2 µl of 
extracted RNA. An absorbance ratio at A260nm/280nm was obtained for each sample with a ratio 
of around 1.8 denoting “pure” DNA and around 2.0 as “pure” RNA. A secondary absorbance 
ratio at A260nm/230nm was recorded; a value of >2.0 denotes “pure” nucleic acid, anything 
lower would indicate degradation or contamination of the RNA (Desjardins et al., 2010). 
RNA quality was verified by 1% agarose gel electrophoresis containing 1x tris-acetate-
EDTA (TAE buffer; 40 mM Tris acetate, 10 mM EDTA at pH 8.3) and 10 µg/ml of ethidium 
bromide. RNA from each sample (around 700 ng) was combined with loading buffer 
(Bioline, UK) at a 5:1 ratio before loading along with a 1 Kb plus DNA ladder 
(ThermoFisher scientific) and electrophoresed at 100 V for 30 minutes. The 28s and 18s 
ribosomal RNA was then visualised by ultraviolet transilluminator to verify intact RNA. 
 
5.2.4. Quantitative polymerase chain reaction of human drug metabolism 
components.  
 
cDNA was synthesised using the recommended RT2 first strand kit for use with the RT2 
profiler PCR array of human drug metabolism following the manufacturer’s instructions. In 
accordance with the kit handbook, all reagents were first thawed to RT and centrifuged for 
15 seconds to collect the reagent in the bottom of the tube. To convert the RNA to cDNA 
using the RT2 first strand kit, a genomic DNA elimination mix was prepared for each RNA 
sample in PCR tubes (RNA 0.5 µg, GE buffer 2 µl and brought to a total volume of 10 µls 
with RNase-free water), mixed by gentle pipetting, centrifuged to bring the components to 
the bottom of the tube and incubated on a thermocycler for 5 minutes at 42 oC. Once 
completed, the reaction was moved to ice for 1 minute whilst the reverse transcription mix 
was prepared (4% 5x buffer BS3, 1% control P2, 2% RE3 reverse transcription mix and 3% 
RNase-free water in a total volume of 10 µl per sample). Reverse transcription mix (10 µls) 
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was added 1:1 to each PCR tube, mixed, incubated on a thermocycler for 15 minutes at 42oC 
then immediately heated to 95 oC for 5 minutes. An additional 91 µls of RNase-free water 
was then added to each reaction, mixed and placed on ice for use in the RT2 profiler PCR 
array of human drug metabolism. 
 
The gene expression of 84 associated drug metabolism genes including drug transporters 
(metallothioneins and p-glycoprotein family), phase 1 metabolic enzymes (CYP450 family 
phase 2 metabolic enzymes; carboxylesterases, decarboxylases, dehydrogenases, 
glutathione peroxidases, lipoxygenases, hydrolases, kinases, oxidoreductases, paraoxonases, 
glutathione S-transferases), 5 housekeeping genes, and 7 controls were assessed using the 
RT2 profiler PCR array of human drug metabolism (Qiagen) following the manufacturer’s 
instructions with each gene randomised across the plate (Table 5-1).  
 
Briefly, reagents were thawed to RT whilst the PCR components mix was prepared in 
accordance with the kit handbook.  PCR component mix (25 µls) was then added to each 
well using an 8-channel pipettor, sealed with an optical adhesive film, centrifuged at 1000 x 
g for 1 minute and run on a QuantStudio 12K Flex Real-time PCR system (Thermo 
Scientific) using the following programme: 1 cycle for 10 minutes at 95oC, 40 cycles of 95oC 
for 15 seconds, and 60oC for 1 minute. Three repeats per sample were conducted.  
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Table 5-1. The list of genes within the RT2 profiler PCR array of human drug metabolism plate.  
Position on 
plate Symbol  Description 
A01 ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 
A02 ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 
A03 ABP1 Amiloride binding protein 1 (amine oxidase (copper-containing)) 
A04 ADH1B Alcohol dehydrogenase 1B (class I), beta polypeptide 
A05 ADH1C  Alcohol dehydrogenase 1C (class I), gamma polypeptide 
A06 ADH4 Alcohol dehydrogenase 4 (class II), pi polypeptide 
A07 ADH5 Alcohol dehydrogenase 5 (class III), chi polypeptide 
A08 ADH6 Alcohol dehydrogenase 6 (class V) 
A09 AHR Aryl hydrocarbon receptor 
A10 ALAD Aminolevulinate dehydratase 
A11 ALDH1A1 Aldehyde dehydrogenase 1 family, member A1 
A12 ALOX12 Arachidonate 12-lipoxygenase 
B01 ALOX15 Arachidonate 15-lipoxygenase 
B02 ALOX5 Arachidonate 5-lipoxygenase 
B03 APOE Apolipoprotein E 
B04 ARNT Aryl hydrocarbon receptor nuclear translocator 
B05 ASNA1 ArsA arsenite transporter, ATP-binding, homolog 1 
B06 BLVRA Biliverdin reductase A 
B07 BLVRB Biliverdin reductase B (flavin reductase (NADPH)) 
B08 CES1 Carboxylesterase 1 
B09 CES2  Carboxylesterase 2 
B10 CES3 Carboxylesterase 3 
B11 CHST1 Carbohydrate (keratan sulphate Gal-6) sulphotransferase 1 
B12 COMT Catechol-O-methyltransferase 
C01 CYB5R3 Cytochrome b5 reductase 3 
C02 CYP11B2 Cytochrome P450, family 11, subfamily B, polypeptide 2 
C03 CYP17A1  Cytochrome P450, family 17, subfamily A, polypeptide 1 
C04 CYP19A1 Cytochrome P450, family 19, subfamily A, polypeptide 1 
C05 CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 
C06 CYP2B6 Cytochrome P450, family 2, subfamily B, polypeptide 6 
C07 CYP2C19 Cytochrome P450, family 2, subfamily C, polypeptide 19 
C08 CYP2C8 Cytochrome P450, family 2, subfamily C, polypeptide 8 
C09 CYP2C9 Cytochrome P450, family 2, subfamily C, polypeptide 9 
C10 CYP2D6 Cytochrome P450, family 2, subfamily D, polypeptide 6 
C11 CYP2E1 Cytochrome P450, family 2, subfamily E, polypeptide 1 
C12 CYP2F1  Cytochrome P450, family 2, subfamily F, polypeptide 1 
D01 CYP2J2  Cytochrome P450, family 2, subfamily J, polypeptide 2 
D02 CYP3A4 Cytochrome P450, family 3, subfamily A, polypeptide 4 
D03 CYP3A5 Cytochrome P450, family 3, subfamily A, polypeptide 5 
D04 EPHX1  Epoxide hydrolase 1, microsomal 
D05 FAAH Fatty acid amide hydrolase 
D06 FBP1 Fructose-1, 6-bisphosphatase 1 
D07 GAD1 Glutamate decarboxylase 1  
D08 GAD2  Glutamate decarboxylase 2  
D09 GCKR Glucokinase (hexokinase 4) regulator 
D10 GPI Glucose-6-phosphate isomerase 
D11 GPX1 Glutathione peroxidase 1 
D12 GPX2  Glutathione peroxidase 2  
E01 GPX3 Glutathione peroxidase 3  
E02 GPX4  Glutathione peroxidase 4  
E03 GPX5 Glutathione peroxidase 5  
E04 GSR Glutathione reductase 
E05 GSTA3 Glutathione S-transferase alpha 3 
E06 GSTA4  Glutathione S-transferase alpha 4 
E07 GSTM2 Glutathione S-transferase mu 2  
E08 GSTM3 Glutathione S-transferase mu 3  
E09 GSTM5 Glutathione S-transferase mu 5 
E10 GSTP1 Glutathione S-transferase pi 1 
E11 GSTT1 Glutathione S-transferase theta 1 
E12 GSTZ1  Glutathione transferase zeta 1 
F01 HK2 Hexokinase 2 
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F02 HSD17B1 Hydroxysteroid (17-beta) dehydrogenase 1 
F03 HSD17B2 Hydroxysteroid (17-beta) dehydrogenase 2 
F04 HSD17B3 Hydroxysteroid (17-beta) dehydrogenase 3 
F05 LPO  Lactoperoxidase 
F06 MGST1 Microsomal glutathione S-transferase 1 
F07 MGST2  Microsomal glutathione S-transferase 2 
F08 MGST3 Microsomal glutathione S-transferase 3 
F09 MPO Myeloperoxidase 
F10 MT2A Metallothionein 2A 
F11 MT3 Metallothionein 3 
F12 MTHFR Methylenetetrahydrofolate reductase (NAD(P)H) 
G01 NAT1 N-acetyltransferase 1 (arylamine N-acetyltransferase) 
G02 NAT2 N-acetyltransferase 2 (arylamine N-acetyltransferase) 
G03 NOS3 Nitric oxide synthase 3 (endothelial cell) 
G04 NQO1 NAD(P)H dehydrogenase, quinone 1 
G05 PKLR Pyruvate kinase, liver and RBC 
G06 PKM2 Pyruvate kinase, muscle 
G07 PON1  Paraoxonase 1 
G08 PON2 Paraoxonase 2 
G09 PON3  Paraoxonase 3 
G10 SNN Stannin 
G11 SRD5A1 
Steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-
dehydrogenase alpha 1) 
G12 SRD5A2 
Steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-
dehydrogenase alpha 2) 
H01 ACTB Actin beta 
H02 B2M  Beta-2-microglobulin 
H03 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
H04 HPRT1 Hypoxanthine phosphoribosyltransferase 1 
H05 RPLP0 Ribosomal protein large, P0 
H06 HGDC Human Genomic DNA Contamination 
H07 RTC Reverse Transcription Control 
H08 RTC Reverse Transcription Control 
H09 RTC Reverse Transcription Control 
H10 PPC Positive PCR Control 
H11 PPC Positive PCR Control 
H12 PPC Positive PCR Control 
Blue: drug transporters, green: phase I metabolic enzymes, orange: phase II metabolic enzymes, yellow: ‘associated genes’, 
grey: housekeeping and white: controls. 
 
5.2.5. Addition of cyclophosphamide to HS-5 cells for the assessment of pro-
drug activation. 
 
HS-5 cells were grown to confluency before trypsinisation and counting via trypan blue stain 
(Section 2.2). HS-5 cells were then seeded at 70 - 80% confluency into a 12 well plate (7 – 
8 x 104 cells/cm2) in 2 ml of medium and incubated at 37 oC, 5% CO2 for 24 hours. TK6 
cells, were then added into a 0.2 µm trans-well insert within a 12 well plate with or without 
HS-5 cells, at a concentration of 1 x 105 cell/ml in 3 mls. HS-5 cells alone was also included. 
Cells in all conditions were treated with a clinically relevant dose of cyclophosphamide (500 
µM in DMSO <0.005%) ± S9 mix (20% S9, 19 mMol/L MgCl2, 37.5 mMol/L potassium 
chloride, 0.11 mM sodium phosphate buffer (pH 7.4) 6.12 mMol/L mM glucose-6-
phosphate and 4.7 mMol/L nicotinamide adenine dinucleotide phosphate) taken from 
Doherty (2012) at a final concentration of S9 at 1%. S9 mix alone, S9 mix + vehicle control, 
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vehicle control alone and untreated cells were included as controls. Cells were treated for 24 
hours after which each sample was washed with PBS and assessed for cell number and 
viability via trypan blue staining on the Luna counter. 
 
5.2.6. qPCR analysis  
 
The difference between means within the qPCR data was calculated based on a Student’s t-
test of the replicate 2(- ΔCT) values for each gene in the control group and treatment groups. 
The p-value calculation used is based on parametric, unpaired, two-sample equal variance, 
two-tailed distribution. The cycle threshold (CT) value was identified for each plate, using 
the manufacturer’s guidance whereby a positive PCR control (PPC) CT of 20 ± 2 and a 
reverse transcription control (RTC) of 22 ± 2 was required. Normalisation was achieved by 
calculating the geometric mean of the five housekeeping genes per plate (H01- H05). The 
geometric means from the biological repeats for each sample were then averaged to give an 
average geometric mean for normalisation. Once normalisation had been conducted, the 
results for HS-5 cultured in 2D was compared with HS-5 cultured within the model. HS-5 
cultured within the model was then compared to HS-5 cultured within the model with the 
addition of TK6.  
 
A threshold of 35 cycles, indicated by the manufacturer as the minimum detectable limit 
with the quantity of cDNA added to each well, was used with a CT value >35 indicating an 
extremely low level of expression and therefore negative for that gene, a CT of 40 indicated 
that the gene was undetectable. This threshold was only applicable if the human genomic 
DNA control was undetectable at a CT of >35, PPC of CT 20 ± 2 and RTC of 22 ± 2. The 
fold regulation (FR) was said to be biologically relevant if they resulted in a p value <0.05 
and a FR >2. FR represents the fold change but in a biologically meaningful manner with a 
negative value indicating a down-regulation and a positive indicating an up-regulation with 
a value of 1 or -1 indicating no change.  





5.3.1. Spheroid formation 
 
As previously discussed, the stromal cells of the BM have the ability to act in a similar 
manner to hepatocytes of the liver in that they are metabolically competent. Therefore, a 
hepatocyte cell line would be beneficial as a positive control to identify the level of 
expression of metabolic enzymes between the developed 3D model and a known 
metabolically active cell. The hepatocellular carcinoma cell line HepG2 has been seen to 
express many genes similar to that seen within the liver. However, the expression of these 
genes is greatly reduced when cultured in a 2D flask as a monolayer, compared to that of a 
3D spheroid (Ramaiahgari et al., 2014).  As expression of metabolic enzymes and associated 
drug transporters are reduced in 2D compared to 3D, the generation of HepG2 spheroids was 
conducted.  The images in  Figure 5-1 show the formation of HepG2 spheroids utilising the 
protocol set out by May et al., (2012). HepG2 cells were grown to 80% confluency where a 
monolayer can be seen (Figure 5-1 A) before trypsinisation, reseeded in 3 mls of medium at 
a concentration of 1 x 106 cells/ml in a 6 well plate, incubated for 24 hours on an orbital 
shaker at 83 RPM, the speed reduced to 79 RPM, and incubated for a further 120 hour with 
a 50% medium change every 48 hours.  After 3 days the formation of spheroids can be seen 
(Figure 5-1 B), with fully matured spheroids identified on day 6 (Figure 5-1 C). 







Figure 5-1. Light microscopy images  of the formation of spheroids over a 6-day period in the HepG2 cell lines. Hep-G2 cells at 80% confluency (A) were trypsinised then reseeded at 3x106 cells per well 
in 3mls of culture medium and incubated on a gyratory shaker at 83 RPM. After 24 hours the speed was decreased to 79 RPM and left for the remaining 5 days. A 50% medium change was conducted every 48 
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5.3.2. RNA concentration and quality of each experimental condition. 
 
The results in Table 5-2 show the concentration and absorption ratios of each experimental 
condition.  Briefly, HS-5 cells were either seeded within a flask for 7 days with a 50% 
medium change every 48 hours, grown on a 50% firmed Algimatrix™ scaffold for 7 days 
or grown on a 50% firmed Algimatrix™ scaffold for 7 days before the addition of TK6 
within a trans-well insert. HepG2 spheroids which were cultured for 6 days were also 
harvested and RNA extracted. As previously noted, the absorbance of each experimental 
condition at A260nm/280nm was around 2 indicating “pure RNA”. The absorption for each 
experimental condition at A260nm/230nm was >2 indicating a lack of contamination or 
degradation.   
 
Table 5-2. The ng/ml and absorbance ratios for RNA extracted from HS-5 cultured in 2D, 3D, 3D with the addition 
of TK6 and HepG2 spheroids. An aliquot of 2 µls from each sample was analysed using the Nanodrop 1000 
spectrophotometer for the concentration and purity of each RNA sample. Each sample number denotes a biological repeat. 
Sample ng/µl 260/280 260/230 
HS-5 alone in 2D 1 536.5 2.06 2.11 
HS-5 alone in 2D 2 416.5 2.06 2.25 
HS-5 alone in 2D 3 628.8 2.06 2.23 
HS-5 seeded onto scaffold 1 328.8 2.07 2.26 
HS-5 seeded onto scaffold 2 131.3 2.03 2.13 
HS-5 seeded onto scaffold 3 207.6 2.04 2.06 
HS-5 seeded onto scaffold + 
TK6 insert 1 
476.5 2.06 2.16 
HS-5 seeded onto scaffold + 
TK6 insert 2 
621.9 2.02 2.21 
HS-5 seeded onto scaffold + 
TK6 insert 3 
670.6 2.02 2.19 
HepG2 spheroid 1 146.4 2.05 2.20 
HepG2 spheroid 2 187.3 2.08 2.18 
HepG2 spheroid 3 276.3 2.09 2.19 
 
 
To confirm that the extracted RNA was not degrading, visualisation of the ribosomal RNA 
28s and 18s was conducted for each experimental condition utilising a 1% agarose gel. The 
results in Figure 5-2 show two clear bands for each experimental condition (around 700 ng 
of RNA per lane) and biological repeat at 1 kB (18s) and 2 kB (28s), thus demonstrating 
good quality RNA samples.  





Figure 5-2.  RNA integrity of each sample by agarose gel analysis. A 5 µl aliquot, containing around 700 ngs of RNA 
was combined with 1 µl of loading buffer and loaded along with a 1 kB DNA ladder into a 1% agarose gel stained with 
ethidium bromide. The gel was then run at 100 V for 30 minutes. Visualisation of the 28s and 18s ribosomal RNA was 
achieved via ultraviolet transilluminator. 
5.3.3. QPCR analysis 
 
Once RNA quality and concentration were identified, conversion of RNA into cDNA was 
conducted before analysis using qPCR. Each sample condition and biological repeat was 
analysed for CT value, normalised to the house-keeping genes, before being assessed for FR 
in gene expression.  
 
5.3.3.1. Raw CT values 
 
Once qPCR had been conducted on each sample, the threshold value was set in comparison 
to the known CT values of the Human Genomic DNA Contamination control (HGDC), PPC 
and RTC within each plate. The PPC gave a CT value at 20 ± 2, HGDC >35 and RTC 22 ± 
2, with the same threshold value utilised for each plate. The results in Figure 5-3 shows the 
raw mean CT values for HS-5 grown in a 2D flask, an Algimatrix ™ scaffold within and 
without the addition of TK6, and HepG2 spheroids for each gene. The HSGC, PPC and RTC 
CT gave justification to values >35 (red) indicating that this gene had extremely low 
presence, below the leave of detection, therefore was considered negative for that gene, 













Figure 5-3. Raw CT values for each experimental condition. The raw mean CT values before normalisation of HS-5 
seeded within a flask, AlgiMatrix™ scaffold with and without TK6 and HepG2 spheriods. Those results in red resulted in 
a mean CT value >35, with those in green gaining a mean CT value <35. The CT value can be found in each corresponding 
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The results in Figure 5-3, highlighted in red, show those genes which resulted in a mean CT 
value >35, therefore would be consider for their use once normalised to the housekeeping 
genes had occurred. Those genes resulting in a mean CT value >35, for all four experimental 
groups included CYP2C9, AOC1, CYP2C8, GAD2, LPO, SRD5A2, GPX5, ALOX5 and 
CYP2C19. Those genes which resulted in a CT value >35 for the HS-5 experimental groups 
only (not HepG2 spheroids) were GCKR, CYP3A4, ADH4, FBP1, and ADH1B. Those genes 
with a CT value >35 within the HS-5 2D experimental group, in addition to those mentioned 
above, were ALADH1A1, CYP2F1, GSTM5, PKLR, CYP19A1, HSD17B3, CYP2B6, 
ADH1C, NOS3, ADH6, HSD17B2, ALOX15, GSTA3 and CES3 with AOC1, CYP2C9 and 
GCKR gaining a CT value of 40.  
 
Those genes with a mean CT value >35 within the HS-5 AlgiMatrix™ without TK6 
experimental group, in addition to those mentioned above, were ABCB1, CYP2F1 and 
GSTM5 with CYP2C9 resulting in a CT value >40. Those genes with a CT value >35 within 
the HS-5 AlgiMatrix™ with TK6, in addition to those mentioned above, were ABCB1, 
ALDH1A1, PKLR, HSD17B3, ADH1C, HSD17B2 and PON1, once gain CYP2C9 resulted 
in a CT value of >40. Finally, those genes with a mean CT value >35 within the HepG2 
spheroid experimental group were CYP2F1, HSD17B3, ALOX12, CYP2E1 and CHST1. Out 
of the 87 genes associated with metabolism, 51 resulted in a CT value <35 in all four 
experimental conditions.  
 
The housekeeping genes ACTB, B2M, GAPDH, HPRT1 and RPLP0 were present in all 
experimental conditions. The mean CT value for each housekeeping gene of the three HS-5 
experimental groups had a SD of <1 cycle, with ACTB, GAPDH, RPLP0 resulting in a CT 
value <20, B2M <25 and HPRT1 >30. However, the SD of the mean CT values gleaned from 
the HepG2 spheroids for ACTB, B2M and GAPDH were between 1.2 and 1.3 cycles when 
compared to the three HS-5 experimental groups with a CT value between 20 and 25. This 
was not the case for HPRT1 and RPLP0 which had a SD <1 cycle between all. Out of the 84 
genes assed, those HS-5 cells cultured on a AlgiMatrix™ scaffold with/without cells resulted 
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5.3.3.2. Fold regulation comparison between each experimental condition   
 
The raw CT values were then normalised to the geometric mean of the housekeeping genes 
on each plate for comparison of FR of gene expression. The normalised gene expression (2(- 
ΔCT)) of the test sample was then divided by the normalised gene expression (2(- ΔCT)) in the 
control sample to calculate FR of each gene. The results in Figure 5-4, shows the FR between 
HS-5 cells grown on an Algimatrix™ scaffold compared to HS-5 seeded within a flask. The 
results also show the FR between HS-5 cells grown on an Algimatrix™ scaffold; compared 
to HS-5 cells grown on a Algimatrix™ scaffold with the addition of TK6. Those cells with 
a negative (red) value indicate a down-regulation. Conversly, those with a positive (green) 
value indicate an up-regulation in gene expression. A biological change was concluded if a 
± 2 FR from the baseline was seen with a p value <0.005. Genes which had resulted in a CT 
value of >35 for all 4 experimental conditions were excluded from the analysis, this included 
AOC1, ADH1C, ALOX5, CYP2C19, CYP2C8, CYP2C9, CYP3A4, FBP1, GAD2, GCKR, 
GPX5, LPO and SRD5A2 . 
 
When the FR of the gene expression was compared between HS-5 cells grown on a 
Algimatrix™ scaffold compared to those seeded within a flask, six genes had a biologically 
relevant change in gene expression including ADH6 (FR=18.09, p=0.01), CES3 (FR=28.41, 
p=0.0007), CYP2B6 (FR=14.96, p=0.0003), MT2A (FR=165.42, p=0.0018), SNN (FR=4.76, 
p=0.0003) and GSTM2 (FR=-3.48, p=0.0005). It was also seen that AHR, EPHX1 and GPX3 
inducing a FR of -1 indicating no change in gene expression between the two samples.  
 
The FR in gene expression between HS-5 cells grown on an Algimatrix™ scaffold; 
compared to those grown on a Algimatrix™ scaffold with the addition of TK6 resulted in 
the up-regulation of GPI (FR=2.06, p=0.0002) and down-regulation of CES2 (FR=-2.06, 
p=0.01977), GSR (FR=-2.91, p=0.0326) and GSTM2 (FR=-2.67, p=0.0452). It was also seen 
that AOC1, ALOX5, CYP2C19, CYP2C9, CYP3A4, GAD1, GCKR, MPO, SRD5A1 and 









Figure 5-4. The comparisons of gene expression, through FR, of HS-5 experimental conditions following 
normalisation. After normalisation, HS-5 cells grown in Algimatrix™ scaffolds were compared to HS-5 seeded within a 
flask. Then the normalised values for HS-5 cells grown Algimatrix™ scaffolds were compared to those grown on 
Algimatrix™ scaffolds with the addition of TK6. Results in shades of red indicate a reduction in fold regulation, green 
increase in FR and orange no change. Genes which gave a CT value >35 and therefore were negative in all conditions, have 
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The mean gene expression of each HS-5 experimental condition was then compared to that 
of the positive HepG2 spheroid control. The results in Figure 5-5 show the change in mean 
gene expression of HS-5 cells seeded within a flask, Algimatrix™ scaffold with and without 
TK6 when compared to the mean gene expression of the HepG2 spheroid control. The results 
show that gene expression levels within HS-5 cells cultured in Algimatrix™ scaffolds with 
and without TK6 resulted in a FR of 1 for SRD5A1, BLVRB and SRD5A1, when compared 
to HepG2 spheroids indicating no change in gene expression.  The expression of 11, 22 and 
14 genes were found to have a FR <2/ <-2 (Table 5-3) when HS-5 cells seeded within a flask 
and Algimatrix™ scaffold with and without TK6 were compared to that of the HepG2 
spheroids, showing similar gene expression levels between the samples.  
 
However, as the HS-5 cell line is not of hepatic lineage and the BM has only been seen to 
express genes similar to a hepatic cell, the results in Table 5-3 show the high number of 
biologically relevant altered gene expressions between the HS-5 samples and HepG2 
spheroids. Those genes that were exceptionally down-regulated (<-600) in all HS-5 
conditions when in comparison to HepG2 spheroid’s (Figure 5-5, Table 5-3) included 
ABCB1, ALDH1A1, APOE, GPX2 and HSD17B2. Interestingly the gene GSTP1 was up-
regulated in all three HS-5 conditions when in comparison to HepG2 spheroid’s with a FR 
of >1000. Out of the 84 genes associated with metabolic enzymes and drug transporters, 60 
had a biologically relevant altered expression within the HS-5 experimental samples, 
compared to that of the HepG2 spheroids.  A biologically relevant altered regulation was 
seen in 52, 39 and 47 genes when HS-5 seeded in a flask, Algimatrix™ with and without 
TK6, were compared to HepG2 spheroids.  A total of 7, 5 and 5 genes were up-regulated 
with a FR of >2, with 63, 56 and 64 downregulated (FR <-2) in the same conditions inferring 
that metabolic expression is not as high in the HS-5 samples under any seeding conditions 
in comparison to the 3D HepG2 spheroids.  
 





Figure 5-5. The change in gene expression of each HS-5 experimental condition compared to HepG2 spheroids 
indicated as FR. After normalisation the mean gene expression of HS-5 cells seeded within a flask, Algimatrix™ scaffold 
with and without TK6 were compared to that of the HepG2 spheroid. Cells in shades of red indicate a reduction in FR, 
green increase in FR and orange no change. Genes which gave a CT value >35 and therefore were negative in all conditions 
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Table 5-3. Biologically relevant changes in gene expression compared to HepG2 spheroids. The FR and p values for 
gene expression between the HS-5 cells seeded within a flask, Algimatrix™ scaffold with and without TK6 were compared 
to that of the HepG2 spheroid. Those genes with a line inferes no cahnge in gene expression.  
 Compared to HepG2 spheroids 
 HS-5 grown within a flask HS-5 grown in an Algimatrix™ 
scaffold 
HS-5 grown in an Algimatrix™ scaffold + 
TK6 
Gene Fold regulation P value Fold regulation P value Fold regulation P value 
ABCB1 -689.3 <0.0001 -2080 <0.0001 -2491 <0.0001 
ABCC1 -4.5 0.0003 -4.26 0.0003 -4.67 0.0005 
ACTB 2.2 <0.0001 - - - - 
ADH1B -13.1 0.0187 -8.95 0.0268 -10 0.0206 
ADH1C -25.8 0.0054 -9.04 0.0147 -19.32 0.0057 
ADH4 -705.2 <0.0001 -479.1 <0.0001 -537.5 <0.0001 
ADH5 -2.0 0.0009 -2.29 0.0045 -3.79 0.0002 
ADH6 -2419.0 <0.0001 -133.7 <0.0001 -263.9 <0.0001 
AHR -8.1 <0.0001 -8.12 0.0005 -27.88 <0.0001 
ALAD -3.6 0.0001 -2.41 0.0032 -2.83 0.0007 
ALDH1A1 -5826.8 0.0002 -1595 0.0002 -3167 0.0002 
ALOX15 -19.0 0.0421 -9.78 0.0492 - - 
APOE -2355.3 0.0001 -1347 0.0001 -2640 0.0001 
ARNT -2.1 0.0002 - - - - 
ASNA1 - - - - -3.06 0.0350 
B2M - - - - 2.35 0.0001 
BLVRA -2.9 0.0185 -5.07 0.0115 -8.63 0.0064 
CES1 -59.2 0.0001 -106 0.0001 -212.6 0.0001 
CES2 -6.7 0.0012 -4.86 0.0018 -10.02 0.0010 
CES3 -119.6 0.0026 -4.21 0.0070 -3.39 0.0092 
CHST1 5.8 0.0256 - - - - 
COMT -5.6 <0.0001 -3.82 0.0003 -7.08 <0.0001 
CYB5R3 - - -2.99 0.0005 -4.56 0.0003 
CYP19A1 -272.5 0.0004 -54.42 0.0004 -146.3 0.0004 
CYP2B6 - - - - 4.16 0.0150 
CYP2E1 3.7 0.0112 - - - - 
CYP2J2 - - -5.65 0.0066 -30.9 0.0008 
CYP3A5 -13.9 <0.0001 -8.8 0.0238 -10.74 <0.0001 
EPHX1 -7.7 0.0016 -7.91 0.0095 -18.12 0.0012 
FAAH -30.2 0.0019 -9.26 0.0269 -14.41 0.0022 
FBP1 -22.8 0.0001 -17.93 0.0001 -14.17 0.0001 
GCKR -92.1 0.0009 -72.55 0.0009 -70.22 0.0009 
GPX1 - - - - -2.14 0.0016 
GPX2 -7422.3 <0.0001 -3076 <0.0001 -1452 <0.0001 
GPX3 -45.0 0.0005 -45.12 0.0006 -235.4 0.0005 
GPX4 -2.2 0.0015 -3.19 0.0008 -3.37 0.0005 
GSTA4 -9.8 0.0003 -11.97 0.0012 -16.27 0.0003 
GSTM2 2.2 0.0008 - - -4.19 0.0045 
GSTM3 - - - - -5.04 0.0030 
GSTP1 2112.7 0.0011 2808 0.0151 1672 0.0010 
GSTT1 -39.2 <0.0001 -60.41 <0.0001 -149.8 <0.0001 
GSTZ1 -2.2 <0.0001 - - - - 
HK2 -6.4 0.0002 -2.77 0.0229 -2.33 0.0061 
HPRT1 -2.0 0.0001 - - -2.01 0.0002 
HSD17B1 -11.3 0.0018 -3.76 0.0112 -9.11 0.0021 
HSD17B2 -8777.0 <0.0001 -1711 <0.0001 -6690 <0.0001 
MGST2 -493.9 <0.0001 -327.1 <0.0001 -703.1 <0.0001 
MGST3 2.1 0.0027 - - - - 
MT2A -124.4 <0.0001 - - - - 
NAT1 -4.4 0.0012 - - -2.19 0.0062 
NAT2 -2.2 0.0004 - - - - 
NOS3 -18.4 0.0204 - - -11.18 0.0239 
NQO1 -5.9 <0.0001 -6.68 0.0002 -19.62 <0.0001 
PKLR -131.4 <0.0001 -49.35 <0.0001 -88.81 <0.0001 
PKM 3.4 0.0001 -14.85 0.0043 -23.44 0.0016 
PON1 39.7 0.0034 -5.85 <0.0001 -10.44 <0.0001 
PON2 108.1 0.0035 -81.25 <0.0001 -323.4 <0.0001 
PON3 176.5 0.0037 - - - - 
RPLP0 245.0 0.0039 - - - - 
SNN 313.4 0.0040 - - - - 
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5.3.4. Addition of cyclophosphamide to TK6 seeded within a trans-well insert 
with or without HS-5 seeded scaffolds. 
 
Now that the genetic expression of metabolic enzymes and selected drug transporters within 
HS-5 cells seeded in a flask and Algimatrix™ scaffold with/ without TK6 has been 
identified, it was relevant to explore if the same level of activation of the known pro-drug 
CPM, which is predominantly metabolised by CYP2B6 shown to be up-regulated from 2D 
to 3D (Figure 5-4) (Connarn et al., 2015), when compared with the rat liver S9 fraction used 
within the regulatory in vitro MN assay, to identify if the expression in 2D was sufficient 
enough for activation of the compound.    
 
Briefly, the results in Figure 5-6 show the addition of 500 µM of CPM added directly to 
either TK6 and or HS-5 with/ without the addition of S9. This concentration of CPM was 
also added to a co-culture of HS-5 seeded wells combined with TK6 in a trans-well insert, 
with all samples incubated for 24 hours before being washed and counted with TB. The 
addition of cyclophosphamide or its vehicle control (DMSO <0.005%) to TK6 without S9, 
induced a small but insignificant reduction (4 and 5 x 105 cells respectively) in total cell 
number from the untreated control at 6 x 105 cells. However, the addition of S9 significantly 
reduced the TK6 total cell number within all conditions when compared to the same without 
S9. No significant difference was seen between those conditions treated with S9, however a 
reduction of 7 x 104 cells was seen between TK6 + S9 with or without DMSO and those 
treated with S9 + CPM. Conversely, HS-5 cells treated with DMSO or CPM with or without 
S9 did not see a change in total cell number from the untreated control.  
 
When TK6 were added to a trans-well insert with 80% confluent HS-5 cells, there was no 
reduction in total TK6 cell number when treated with DMSO compared to those without. 
However, there was a significant decrease in cell number (5 to 1.5 x 105 cells) with the 
addition of CPM compared to the untreated and DMSO co-culture controls. The result was 
also significantly decreased compared to the CPM treatment of TK6 without S9. 
Furthermore, the reduction in cell number was at a similar level to that seen with the TK6 + 
S9 + CPM treatment. Once again, CPM had no effect on HS-5 cells in co-culture; with a 
similar level of total cell number (3 x 105 cells) seen with treatments without the addition of 
TK6.  
 




Figure 5-6. The cytotoxic effect of cyclophosphamide on TK6 with and without HS-5 cells and S9 fraction. HS-5 cells 
were seeded at 1x104 cells/cm2 in a 12 well plate and left for 24 hours to adhere. TK6 cells were then added within a trans-
well insert and 500 µM of the pro-drug cyclophosphamide added, left for 24 hours, washed with PBS and cell number 
assessed via trypan blue. Each cell line was dosed with vehicle control (DMSO <0.005%), with/ without cyclophosphamide 
and the liver fraction S9. (n=3). Colour shading represents: Red = TK6 in isolation without S9; Green = TK6 in isolation 
with S9; Blue = HS5 in isolation without S9; Black/white = HS5 in isolation with S9; Purple = TK6 from co-culture with 
HS5; Pink = HS5 from co-culture with TK6. Significant differences between samples were calculated using a Two-





























































































































































































































The stroma of the in vivo BM has been seen to activate or detoxify compounds through 
metabolic enzymes and drug transporters similar to that seen within the liver, resulting in 
the reduction or induction of genotoxic alterations to haematopoietic cells by xenobiotic 
compounds (Ria et al., 2020; Chen et al., 2020; Alonso et al., 2015; Boutin et al., 2020). 
Within the 2D regulatory MN assay, the rat liver S9 fraction is used to induce a similar level 
of metabolic alteration seen within the liver, to assess the genotoxicity of pro-drugs. 
However, the BM is not made of hepatic tissue and therefore may not express the same 
metabolic components seen within the in vivo liver. Therefore, in order to create an in vivo 
relevant model of the BM in vitro, a metabolic profile similar to that seen within the in vivo 
BM stroma is necessary and may be the key to discovering the mechanism behind 
pharmacological positives.  
 
In this chapter, HS-5 cells seeded within a flask and AlgiMatrix™ scaffold with/ without 
TK6 cells within a trans-well insert, were analysed by qPCR for the expression of phase 1 
and 2 metabolic enzymes, drug transporters and associated genes, compared to their 
expression within the in vivo stroma reported in the literature, validating the use of 3D 
cultured HS-5 as a more in vivo relevant model for future genotoxicity study. The 
hepatocellular carcinoma cell line HepG2, was grown as spheroids and assessed as a positive 
control for the expression of each metabolic associated gene. Furthermore, this chapter also 
reports the comparison of cytotoxicity of CPM on TK6 cells within a trans-well insert, 
with/without S9 and /or HS-5 cells seeded within a well. However, the gene expression via 
qPCR, within each experimental sample mentioned above was conducted first.  
 
The cut-off threshold for qPCR of 35 was conducted utilising the manufacturer’s instructions 
and signifies that a CT value >35 indicates that gene expression is not present. It was found 
that many genes resulted in no change (of 1 or <1 cycle) near the 35 cut off (34 to 35), 
indicating that the gene was being expressed at equivalent, but extremely low amounts in 
both samples. However, if the expression of the gene was low and represented only 1 copy 
at 0 cycles, by the 34th cycle this would have notionally amplified to 1.7 x 1010 copies and 
again further doubled to 3.4  x 1010 by the 35th cycle showing an extremely large increase in 
copy number between the two cycles. This simple maths demonstrates that if a sample is not 
detected by cycle 34/35, it is reasonable to assume that gene expression is likely to be 
switched off. Literature has argued that a threshold >35 but <40 can still result in the 
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detection of gene expression, which can be altered with changes in starting cDNA 
concentrations and use of SYBR green or TaqMan probes (Caragual et al., 2011; Lockey et 
al., 1998). However, due to the nonspecific nature of SYBR green used within the RT2 
profiler, the quantity of starting cDNA from pure uncontaminated RNA analysed by 
nanodrop and agarose gel electrophoresis, optimised by the manufacturer for use with this 
plate, a threshold of 35 is justified. Furthermore, given the information above and that the 
positive (PPC and RTC) and negative (HGDC) controls within each plate giving the correct 
CT value, biological change in gene expression will be discussed in those genes present in 
both experimental samples. Additionally, if a gene is absent (CT >35) in one experimental 
sample but present in the next (CT <35) this will also be discussed.   
 
5.4.1. The expression of Phase I metabolic enzymes  
 
The phase 1 metabolic enzymes predominantly activate a compound through the addition or 
modification of a functional group through oxidation, reduction or hydrolysis (Bachmann,  
2009; Winiwarter et al., 2006). The CYP450 family of enzymes specifically those residing 
in the CYP1, CYP2, CYP3 and CYP4 families, induced in vivo by polycyclic aromatic 
hydrocarbons, barbiturates and glucocorticoids are fundamental to xenobiotic metabolism 
(Stanley, 2017). Out of the 15 phase I CYP450 metabolic enzymes tested for, within the 
three HS-5 experimental groups, 11 were seen to have expression in one or all of the 
experimental samples with CYP2C19, CYP2C8, CYP2C9 and CYP3A4 expression absent in 
all three conditions. The phase I metabolism enzymes expressed in all 3 HS-5 experimental 
groups included CYP11B2, CYP17A1, CYP1A1, CYP2D6, CYP2E1, CYP2J2 and CYP3A5 
with CYP19A1 and CYP2B6 expression present in HS-5 seeded in AlgiMatrix™ with and 
without TK6 and CYP2F1 only present in HS-5 seeded in AlgiMatrix™ with TK6. The only 
biologically significant increase in expression occurred in CYP2B6 between HS-5 cells 
seeded in 3D compared to 2D, with the addition of TK6 causing no significant change in 
expression. Therefore, as AlgiMatrix™ seeded HS-5 cells with the addition of TK6 had the 
greatest number of expressing CYPs (Figure 5-3, Figure 5-4), compared to HS-5 seeded in 
a flask or AlgiMatrix™ without TK6, and more closely resembled the model seen in Figure 
4-1, the results obtained from this experimental condition were compared to the literature 








The profile of phase I CYP450 enzymes, expressed by the in vivo BM stroma has limited 
literature. However, studies by Su (2019), Alonso (2015) and Chang (2019) found that 
within the primary human stroma, similar to the results obtained via qPCR analysis of HS-5 
cells seeded in AlgiMatrix™ with the addition of TK6, the expression of CYP17A1, 
CYP19A1, CYP1A1, CYP2D6, CYP2E1, CYP2F1 and CYP3A5 were present. Conversely, 
the presence of CYP11B2, CYP2B6 and CYP2J2 were only found within the HS-5 samples 
not the in vivo stroma. Furthermore, HS-5 cells did not express CYP2C19, CYP2C8 and 
CYP3A4 which were present within the in vivo BM stroma. The lack of expression of 
CYP3A4 within the HS-5 conditions was disconcerting as it is responsible for ~30-40% of 
phase I metabolism of drugs including antibiotics (erythromycin), antidepressants 
(diazepam) and steroids (testosterone) (Fang et al., 2017). Therefore, the presence/ absence 
of these CYPs found in HS-5 will be explored for their role, if any, in the altered metabolism 
of compounds in the model during the final discussion. However, this lack of expression in 
either setting may be due to the constituents of the BM stroma itself versus the simple nature 
of the HS-5 culture. The human in vivo BM stroma is made up of fibroblasts, macrophages, 
adipocytes, osteoblasts and endothelial cells whereas only HS-5, (a fibroblastic but primarily 
BM stromal cell line) is present within the 3D HS-5 AlgiMatrix™ cell culture (Arrieta & 
Isringhausen, 2017).  
 
The papers by Su (2019), Alonso (2015) and Chang (2019) were also the only to compare 
the expression of those CYPs seen within the in vivo BM stroma with a hepatic cell line 
(HepG2). The work found comparative levels of each CYP present within the BM stroma 
with that found in the HepG2 culture. However, the HepG2 culture within these papers was 
conducted as a monolayer not spheroid. It has been found that the expression of CYPs within 
HepG2 monolayers is dramatically reduced compared to spheroid culture, with the 
expression of many CYPs not present (Takahashi et al., 2015). This could aid in the 
explanation of why in the current 3D HS-5 model (Figure 5-5, Table 5-3), the majority of 
CYPs tested when compared to the HepG2 spheroid had a down-regulation in expression 
compared to those seen within the studies above. Furthermore, as the liver is the primary 
organ for biotransformation of compounds, an increase in expression would be anticipated 
compared to the BM stroma (Trefts et al., 2017). Therefore, the qPCR results acquired from 
the HepG2 spheroids, could only be used as a positive control for CYP expression. However, 
are HepG2 spheroids a more appropriate positive control for the expression of CYPs than a 
simple monolayer? 




When investigating those CYPs predominantly expressed by the liver, responsible for the 
biotransformation of 70-80% of all drugs, CYP3A4, CYP2C9, CYP2C8, CYP2E1, CYP1A2, 
CYP2A6, CY2D6, CYP2B6, CYP2C19, CYP3A5, CYP2J2, CYP1A1 and CYP1B1 were found 
to be expressed (Zanger & Schwab, 2013). When compared, HepG2 cells grown as spheroids 
in this study, showed expression of CYP1A1, CYP2B6, CYP2D6, CYP2J2, CYP3A4 and 
CYP3A5 unlike those grown in 2D within the papers mentioned previously, which expressed 
CYP1A1, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4 and CYP3A5. Neither the 2D 
monolayer in the paper or spheroids within this study expressed all 13 CYPs predominantly 
found within the liver, with around half expressed in both conditions. As HepG2 cells are 
not primary hepatic tissue but an immortalised cell line and grown in two different conditions 
(2D and spheroid), it is understandable that all 13 would not be expressed. However, as 
around half of the key CYPs responsible for biotransformation of compound were expressed, 
its use as a positive control for the expression of phase 1 metabolic enzymes was justified. 
 
5.4.2. The expression of Phase II metabolic enzymes 
  
The phase II drug metabolism enzymes, unlike phase I, detoxify xenobiotic compounds 
through conjugation with charged species such as glutathione, sulphate, glycine or 
glucuronic acid occurring at carboxyl, hydroxyl, amino and sulphate groups (Jancova et al., 
2010). The expression of phase II enzymes residing within the carboxylesterases, 
decarboxylases, dehydrogenases, glutathione peroxidases, lipoxygenases, hydrolases, 
kinases, oxidoreductases, paraoxonases, glutathione S-transferases family of enzymes along 
with CHST1, COMT, NAT1 and NAT2 were assessed in all experimental conditions. It was 
found that the phase II genes ADH6 (dehydrogenase), CES3 (carboxylesterase), and GSTM2 
(glutathione S-transferase) were biologically up-regulated between the 2D and 3D HS-5 
culture with the expression of CES2 (carboxylesterase), GSR (oxidoreductase) and GSTM2 
(glutathione S-transferases) down-regulated between HS-5 grown in 3D with and without 
TK6. This indicated that there was a change in expression of phase II enzymes between 2D 
and 3D, with those seeded with an AlgiMatrix™ with/ without TK6 having greater 
expression than 2D, reinforcing the use of 3D models over 2D assays.  
 
As this was the first study to identify the expression of phase II enzymes expressed by a cell 
line of the BM stroma, there was a lack of literature for in vivo comparison. However, many 
of these enzymes are present in the liver but can also be expressed in the small intestine, 
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kidneys, lungs, brain, haematopoietic/immune cells and the testis so may not be expressed 
in the in vivo BM (Laizure et al., 2013; Rajendram et al., 2016; Mashima & Okuyama, 2015; 
Draganov et al., 2005; Nebert & Vasiliou, 2004). A collaborative database by Uhlén (2015) 
brought together 483 samples from 37 different human, normal, tissue types and 69 cell lines 
(none of which are HS-5 cells) for deep sequencing using RNA-seq which identified 15320 
genes. Therefore, a comparison will be made between this collaborative data set and the 
results obtained from the qPCR analysis to assess if AlgiMatrix™ seeded HS-5 with/ without 
TK6, simulated the expression seen within the human in vivo BM more closely that HS-5 
seeded in 2D, validating the use of 3D culture as a more in vivo relevant model for 
genotoxicity testing. The collaborative data set assessed the expression of genes within the 
BM tissue as a whole and within primary mesenchymal fibroblast cells. Therefore, a 
secondary comparison will be made to identify which cell lineage, if any particular one, HS-
5 expression compares to in the in vivo BM environment.  
  
The carboxylesterases assessed within HS-5 experimental samples included CES1, CES2 
and CES3. The collaborative data set found that within the in vivo human BM both CES1 
and CES2 were present but CES3 was not. When analysed within the database, the 
expression of both CES1 and CES2 were found within the primary fibroblast cell line but 
CES3 was not, indicating that CES1 and CES2 could be expressed by fibroblasts of the BM 
unlike CES3. In line with the human tissue, the expression of CES1 and CES2 were seen 
within all HS-5 experimental conditions, however only HS-5 grown in a 2D flask were 
absent of CES3. This infers that in vivo CES1 and CES2 are expressed by fibroblasts of the 
BM, suggesting that those HS-5 cells seeded in 2D act more like fibroblasts of the in vivo 
BM than those cultured within an AlgiMatrix™ scaffold with/ without TK6. As previously 
noted, HS-5 are fibroblastic and can differentiate into fibroblasts but are primarily BM 
stromal cells, therefore the similar expression between 2D and in vivo indicates HS-5 could 
have differentiated into fibroblasts.  
 
The decarboxylases GAD1 and GAD2, were both detected within the BM tissue within the 
database but were negative within fibroblast cells, inferring that a differing cell lineage 
within the BM was responsible for their expression. The presence of GAD1 corresponded 
that seen within all HS-5 experimental samples; however, the same HS-5 samples were 
negative for GAD2. This infers that the culture of HS-5 had no impact on the ability to 
replicate the in vivo positive and negative expression respectfully of GAD1 and GAD2.  
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The dehydrogenase enzymes assessed in this study included ADH1B, ADH4, ADH5, ADH6, 
HSD17B1, HSD17B2, HSD17B3, ADH1C, ALAD and ALDH1A1. Those present within the 
in vivo BM tissue comprised of ADH5, HSD17B1, ALAD and ALDH1A1 with all also present 
within the primary fibroblast cells tested. Therefore, it can be suggested that the fibroblasts 
of the in vivo BM are solely responsible for the expression of ADH5, HSD17B1, ALAD and 
ALDH1A1. However, when compared to the HS-5 experimental conditions, those HS-5 
seeded within 2D expressed ADH5, HSD17B1 and ALAD, AlgiMatrix™ without TK6 
expressed 4 out of 4 and with TK6 expressing ADH5, HSD17B1 and ALAD, inferring that 
HS-5 cells seeded in an AlgiMatrix™ without TK6 simulated the in vivo fibroblast 
population. Conversely, each HS-5 condition was seen to express further genes not denoted 
in the in vivo BM. When HS-5 cells were seeded within a flask, AlgiMatrix™ scaffold with 
and without TK6, a further 6, 4 and 2 genes were expressed. This suggests that HS-5 cells 
seeded in 2D are less comparable to the in vivo BM than those HS-5 cells seeded within an 
AlgiMatrix™ scaffold, with respect to the expression of dehydrogenase enzymes. 
 
The glutathione peroxidase enzymes evaluated within this study included GPX2, GPX3, 
GPX4, GPX5, GSTA3, GSTA4, GSTM2, GSTM3, GSTM5, GSTP1, GSTT1, GSTZ1, LPO and 
MPO. Those genes found to be present in the in vivo BM tissue included GPX3, GPX4, 
GSTM2, GSTM5, GSTP1, GSTZ1 and MPO. The genes present within the in vivo BM were 
also expressed by the fibroblast cell lines with the exception of MPO, inferring that cells 
other than fibroblasts of the BM are responsible for the expression of MPO. When compared 
to the HS-5 experimental conditions, those seeded within 2D and AlgiMatrix™ without TK6 
expressed 6 out the 7 genes expressed by the in vivo BM, with GSTM5 absent. However, 
those HS-5 seeded in an AlgiMatrix™ with TK6 expressing 7 out of 7. This infers that those 
HS-5 cells seeded in an AlgiMatrix™ scaffold with TK6, simulated the in vivo BM more 
closely than 2D or 3D alone. However, as the condition did express MPO, HS-5 cells seeded 
on an AlgiMatrix™ scaffold with TK6 appears to simulate cells other than fibroblasts found 
in the in vivo BM. Conversely, each HS-5 condition was seen to express further genes not 
denoted in the in vivo BM but tested for in this study. When HS-5 cells were seeded within 
a flask, AlgiMatrix™ with and without TK6, a further 3, 2 and 2 genes were expressed. This 
once again, suggests that HS-5 cells seeded in 2D are less comparable to the in vivo BM than 
those HS-5 cells seeded within an AlgiMatrix™ scaffold. 
 
The lipoxygenase enzymes evaluated within this study included APOE, ALOX5, ALOX12 
and ALOX15, with APOE, ALOX5 and ALOX12 present within the in vivo BM. The only 
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gene that was expressed in the fibroblast cell lines was APO, inferring that the expression 
the lipoxygenase enzymes tested for, were expressed by cell lineages other than fibroblasts 
in the in vivo BM.  When those genes expressed by the in vivo BM were compared to the 
HS-5 experimental conditions, all three conditions expressed APO and ALOX12 but not 
ALOX5. This suggested that the expression of lipoxygenase enzymes was not altered by the 
culture condition of HS-5 cells. However, those HS-5 seeded within a flask expressed also 
ALOX15 which was not seen to be expressed in the in vivo BM, reinforcing the use of 3D 
HS-5 as a more in vivo relevant model of the in vivo human BM when compared to 2D.  
 
The hydrolase enzymes evaluated within the study included ASNA2, EPHX1, FAAH and 
FBP1 with all present in the in vivo BM tissue and primary fibroblast cells, inferring that the 
primary source of expression of the hydrolase enzymes tested may be the primary fibroblast 
cell. When those genes expressed by the in vivo BM fibroblasts, were compared to all three 
HS-5 conditions, all three expressed ASNA2, EPHX1 and FAAH but not FBP1, suggesting 
once again that the culture condition had no effect on the expression of the hydrolase 
enzymes tested. 
 
The kinase enzymes evaluated within the HS-5 experimental conditions included HK2, 
PKLR and PKM with all present in the in vivo BM tissue. However only HK2 and PKM were 
also expressed by the primary fibroblast cells, inferring that PKLR was expressed by a 
different population within the in vivo BM. Those HS-5 cells seeded in 2D and within an 
AlgiMatrix™ scaffold with TK6, simulated the expression seen within the in vivo fibroblast 
cells, with both HK2 and PKM present, reinforcing the fibroblastic nature of HS-5. However, 
those HS-5 seeded within an AlgiMatrix™ scaffold without TK6 expressed all three genes, 
fully replicating the in vivo BM environment, unlike the other culture conditions used within 
this study. 
 
The oxidoreductase enzymes evaluated in this study included AOC1, BLVRA, BLVRB, 
CYB5R3, GSR, MTHFR, NOS3 NQO1, SRD5A1 and SRD5A2. Those genes expressed in 
both the in vivo BM and the primary fibroblast cells, comprised of BLVRA, BLVRB, CYB5R3, 
GSR, MTHFR, NOS3 and SRD5A1. When compared to the HS-5 experimental conditions, 
HS-5 seeded onto an AlgiMatrix™ scaffold with/ without TK6 expressed all genes seen to 
be expressed by the fibroblast and in vivo BM, with those HS-5 cultured in 2D not expressing 
NOS3. This suggests that HS-5 cultured in 3D, simulated the expression of oxidoreductase 
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enzymes seen in vivo. However, all three conditions did also express NQO1 not seen to be 
expressed in the in vivo BM.  
 
The paraoxonase enzymes evaluated included PON1, PON2 and PON3 with only PON2 
present in the in vivo BM tissue and also expressed by the primary fibroblast cells. When the 
in vivo expression was compared to the HS-5 experimental conditions, those HS-5 cultured 
in 2D and AlgiMatrix™ scaffold without TK6 expressed all three genes. However, HS-5 
cultured on AlgiMatrix™ scaffold with TK6 only expressed PON2 and PON3. Even though 
HS-5 cultured on AlgiMatrix™ scaffold with TK6 did express PON3, it simulated the 
environment more closely than the 2D culture.  
 
The glutathione S-transferase enzymes evaluated in this study included GSTA3, GSTA4, 
GSTM2, GSTM3, GSTM5, GSTP1, GSTT1, MGST1, MGST2 and MGST3. Those present in 
both the in vivo BM and primary fibroblasts comprised of GSTM2, GSTM5, GSTP1, GSTT1, 
MGST1, MGST2 and MGST3. HS-5 cells cultured on an AlgiMatrix™ scaffold with TK6, 
was more in vivo relevant as it expressed those genes seen within the in vivo BM above, with 
HS-5 cultured in 2D and AlgiMatrix™ without TK6 found to be absent of GSTM5. This 
reinforces the in vivo relevance of HS-5 cells cultured in 3D with TK6 present, as they appear 
to act like fibroblasts when expressing glutathione S-transferase enzymes. However, cells in 
3D culture also expressed GSTA3 and GSTM3 not seen to be expressed by the in vivo BM. 
An additional four genes associated with phase II metabolism were also analysed namely 
CHEST1, COMT, NAT1 and NAT2. Those present within the in vivo BM tissue, identified 
within the fibroblast population, comprised of CHEST1, COMT and NAT1. It was found that 
regardless of culture method all three HS-5 experimental conditions expressed all four genes.  
 
In total 43 out of the 67 genes tested were expressed within the in vivo human BM, with 37 
of these genes found within the primary mesenchymal fibroblasts, inferring that a 
multicellular environment is required within the in vivo BM for the complete expression of 
these metabolism enzymes. However, as described above, 38 out of the 43 genes found 
within the in vivo BM environment were expressed by HS-5 cells cultured within an 
AlgiMatrix™ scaffold with/ without TK6, compared to 35 expressed by those seeded in 2D, 
suggesting the expression seen within a multicellular in vivo BM can be achieved, in part, 
with HS-5 cells cultured in AlgiMatrix™ scaffolds. This comparison reinforces the use of 
HS-5 in 3D culture as more in vivo relevant model for genotoxicity study. However, HS-5 
expressed a further 14, 6 and 10 genes in 2D, 3D without TK6 and 3D with TK6, not seen 
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within the in vivo BM, identifying a possible limitation of this cell line. Therefore, the 
present/ absence of these genes in HS-5 compared to the in vivo BM, will be explored for 
their role, if any, in altering compound metabolism in the final discussion. 
 
As mentioned previously the main site of expression of these phase II metabolic enzymes is 
the liver therefore the downregulation compared to the HepG2 spheroids was expected. 
However, the highly biologically significant upregulation of GSTP1 in all three HS-5 
experimental samples was intriguing. The GSTP1 gene codes for an enzyme which decreases 
oxidative damage in cells by catalysing the conjugation of toxic compounds to glutathione, 
and can have a downregulation, due to hypermethylation, in a cancerous state (Guiroli et al., 
2018). The HS-5 cell line has been transformed from a patient without disease however, 
HepG2 cells are taken from a hepatocellular carcinoma, inferring that the altered expression 
may actually be the result of possible hypermethylation of the gene in HepG2, not changes 
in the specific cell type. 
 
5.4.3. The expression of drug transporter, receptor and protein genes 
associated with metabolism 
 
The qPCR analysis of the 3 HS-5 experimental groups (2D flask, AlgiMatrix™ scaffold 
with/ without TK6) also looked at those key genes associated with metabolism but are not 
categorised into phase I or II. These genes, however, can be categorised into drug 
transporters (members of the metallothioneins and p-glycoprotein families), receptors (AHR 
and ARNT) and regulatory proteins (GCKR and SNN). Once again, as this is a novel piece of 
study, there is limited research in the literature pertaining to the expression of the above 
family of genes within in vitro BM models. As there is limited literature, a comparison will 
be made between the 3 experimental groups and those genes expressed by the in vivo human 
BM, for validation of its use as a more in vivo relevant model. This will identify if the HS-5 
cell line simulates the expression seen within the in vivo BM therefore implicating its use as 
a surrogate for primary stromal cells. 
 
The metallothionein family of proteins play a vital role in metal ion homeostasis and 
detoxification through binding to both physiological (zinc & copper) and xenobiotic 
(cadmium & mercury) heavy metals (Calvo et al., 2017). The binding of these cysteine-rich 
cytosolic proteins to zinc and copper, vital for cellular health, aids in cell growth, 
proliferation and reduction of oxidative stress whilst also protecting against metal toxicity 
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caused by xenobiotic metals such as cadmium (Lang & Si. 2018). Those members of the 
metallothionein family analysed via qPCR included MT2A and MT3 which were seen to be 
present in all 3 experimental HS-5 groups. When compared to those genes seen within the 
in vivo human BM, MT2A was present in the BM stromal cells of humans. However, the in 
vivo BM stroma did not express MT3 unlike all HS-5 condition which expressed both MT2A 
and MT3 (Ren et al., 2011 & Uhlén et al., 2015).  
 
The p-glycoprotein family of ATP-driven transmembrane transporter proteins are involved 
in the efflux of compounds out of the cell and have been associated with multidrug 
resistance, with the co-administration of erythromycin increasing sensitivity to compounds 
(Li et al., 2010). With a similar substrate spectrum to CYP3A4, they are involved in the 
transportation and therefore detoxification of antineoplastics (etoposide) compounds from 
the cell (Finch & Pillans. 2014). Those members of the p-glycoprotein family analysed 
included ABCB1, ABCC1 and GPI. Gene expression of ABCB1 was only present in those 
HS-5 cells seeded within a flask, whereas ABCC1 and GPI were present in all 3 HS-5 
experimental groups. Within the in vivo human BM stroma, fibroblasts have been seen to 
express all 3 genes inferring that the HS-5 seeded alone in 2D was more in vivo relevant than 
its 3D counterparts (Han et al., 2016; Uhlén et al., 2015) 
 
The AHR gene encodes a ligand-dependent transcription factor which regulates the 
transcription of key metabolic enzymes such as the CYP450 family and interacts with 
hormone receptors and associated ARNT, in response to a wide range of compounds classed 
as polycyclic aromatic hydrocarbons, benzimidazole and flavonoids (Hýzdalová et al., 
2018). The presence of both genes was seen in all 3 HS-5 experimental groups. This falls in 
line with the literature regarding in vivo expression, as both AHR and ARNT are expressed 
by the fibroblasts of the BM (Heidel et al., 1998; Uhlén et al., 2015) 
 
The GCKR gene encodes the protein of the same name responsible for inhibiting glucokinase 
in regulating glucose metabolism solely in the hepatic tissue not within the in vivo human 
BM (Rees et al., 2014). This was found to be negative within all HS-5 experimental groups 
therefore, its expression within only the HepG2 spheroids corresponds with the in vivo 
human.  
 
The SNN gene encodes the protein stannin which is associated with the toxic effects of 
organotines by acting and altering expression of cyclin D1, TP53 and regulators of the G1 
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phase of cell cycle and was present in all 3 HS-5 experimental groups (Reese et al., 2005). 
This expression corresponds with that seen in the in vivo human as the in vivo BM has been 
seen to express SNN (Uhlén et al., 2015). 
 
5.4.4. Assessment of the cytotoxicity of cyclophosphamide on TK6 cells with/ 
without HS-5 or S9 
 
The pro-drug CPM is metabolised predominantly by CYP2B6, which is present within the 
S9 fraction, to 4-hydroxy-cyclophosphamide which then enters the cells as aldophosphamide 
(Connarn et al., 2015). This can then be converted into the genotoxic product, PM via β-
elimination or inactivated by ALDH to o-carboxyethylphosphoramide mustard (Kurauchi et 
al., 2017). The addition of CPM within this study was conducted on TK6 cells seeded within 
a trans-well insert with/ without HS-5 cells seeded on the surface not 3D scaffold. However, 
when HS-5 cells were seeded in a flask and within an Algimatrix scaffold with/ without 
TK6, the CYP2B6 gene was present and significantly up-regulated in the HS-5 3D scaffolds, 
with and without the addition of TK6 cells compared to those seeded within a well (Figure 
5-4). As CYP2B6 was not present in 2D, therefore CPM was not metabolised to its active 
compound in HS-5 cells seeded within a flask, this would elucidate the lack of cytotoxicity 
seen when CPM was added directly to HS-5 cells within the well. However, the total cell 
number of TK6 significantly reduced when CPM was added to the co-culture. As CYP2B6 
was present with HS-5 cells seeded onto an AlgiMatrix with TK6, this could infer that the 
addition of TK6 soluble factors was influential in the metabolism of CPM into PM as it 
appears to have induced CYP2B6 production.  
 
The gene ALDH1A1 part of the ALDH superfamily, also present within the S9 fraction, 
which catalyses the oxidation of toxic aldehydes to a non-toxic form, such as that seen above 
with aldophosphamide, was absent in HS-5 cells seeded within a flask and in 3D with the 
addition of TK6 (Ciccone et al., 2018). As HS-5 cells were seeded within the well not a 
scaffold within this study, this would infer that ALDH1A1 was absent, allowing the β-
elimination of CPM to its genotoxic product PM. As CYP2B6 was present and ALDH1A1 
absent within HS-5 cells seeded within an AlgiMatrix scaffold with the addition of TK6, 
combined with the results seen within the CPM study showing a significant reduction in 
TK6 when in co-culture, this infers that co-culture and addition of TK6 soluble factors is 
influential in the genotoxicity of the compound not necessarily the three-dimensionality. 
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However, as HS-5 cells seeded within a flask with the addition of TK6 were not analysed 
for gene expression this conclusion cannot be confirmed.  
 
When the cytotoxicity of CPM was compared between those wells containing TK6 only with 
and without the addition of S9, a significant decrease in total cell number can be seen 
between all experimental groups (Figure 5-6). When in co-culture with HS-5 this significant 
reduction in TK6 total cell number can only be seen with those wells treated with CPM, 
inferring that a 24 hour treatment with S9 has a higher background cytotoxicity level than 
with the co-cultured HS-5 cells. However, S9 has been seen to be highly cytotoxic due to 
the compounds used to induce the production of metabolic enzymes, such as aroclor, 
therefore when used in the regulatory in vitro MN assay only a 3 hour direct treatment not 
24 is used (Ooka et al., 2020). However, when patients are given a clinically relevant dose 
of CPM, detoxification and excretion takes >24 hours, with around 5 µg/ml still present 
within the plasma at 24 hours (Adams et al., 2014). As S9, due to its high level of 
cytotoxicity, is only present for 3 hours within the assay before being washed out, 
detoxification cannot be achieved, therefore it gives a false indication of the level of 
cytotoxicity produced. This infers that HS-5 cells in co-culture have the ability to simulate 
the exposure time identified in vivo without background cytotoxicity seen with S9 inferring 





















In recent years it has been determined that the in vivo BM stroma has the ability to activate 
and detoxify compounds causing drug resistance, reduced efficacy, protective role of HSC 
and increased genotoxicity in compounds which have been identified as non-genotoxic in 
regulatory in vitro MN assays (Ria et al., 2020; Chen et al., 2020). The use of a single cell 
culture with the addition of a liver S9 fraction, to simulate liver metabolism, does not take 
into account the variation in expression between the in vivo liver and BM providing a result 
which can over/ underestimate cytotoxicity. 
 
The data presented here clearly demonstrates the difference in expression of metabolic 
enzymes, drug transporters, receptors and regulatory proteins between cell lines of the liver 
(HepG2) and BM (HS-5). The expression of phase I and II metabolic enzymes was greatly 
reduced in HS-5 (2D and 3D cultured) cells compared to that of the HepG2 spheroid liver 
cell line, which was hypothesised due to the liver being the primary source of metabolism in 
vivo. However, HepG2 spheroids acted as a positive control to identify metabolic enzyme’s 
absence/ presence in HS-5 compared to the in vivo BM. The analysis of the expression of 
those genes tested within this study by the AlgiMatrix™ seeded HS-5 with/without TK6, 
more closely resembled that of the in vivo BM, reinforcing its use as a more in vivo relevant 
model compared with 2D culture. However, it was found that HS-5 cells in all three 
experimental conditions expressed further genes which were not denoted in the in vivo BM, 
therefore the possible role of these disparities in gene expression will be considered in altered 
genotoxicity in the final discussion. 
 
When used as a substitute for metabolic activation inducing increased cytotoxicity of CPM, 
HS-5 cells seeded within a well induced the same level of cytotoxicity seen with the 
regulatory S9 fraction, with a reduction in background cytotoxicity. This would infer that a 
simple 2D culture of HS-5 cells in a flask, with the presence of TK6 in a trans-well insert 
would be a simpler model for cytotoxicity. However, as genotoxicity wasn’t investigated 
with this simple model, it cannot be inferred that this is more in vivo relevant than the three-
dimensional model trialled, only that the low levels of expression seen in 2D compared to 
3D (Figure 5-4), is adequate for activation of the compound. 
 
The data presented within this chapter is the first to assess the metabolic profile of a BM cell 
line in 2D and 3D to the best of our knowledge, with and without the addition of TK6. The 
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expression profile of HS-5 cells compared to that of a hepatic cell line and comparative in 
vivo data, highlights the need for the addition of a BM cell line for regulatory assessment of 
compounds, not liver, to give a true indication of their toxicity. Furthermore, the findings in 
this chapter suggest that soluble factors between TK6 and HS-5 cells are adequate for the 
expression of metabolic enzymes similar to the in vivo human BM. Overall, the HS-5 cell 
line appears to be an appropriate surrogate for the primary BM stromal cells in the 
assessment of compounds in vitro. 




6. Final Discussion 
 
6.1. General discussion and conclusion 
 
The human BM is a complex interplay between differing microenvironments containing a 
multitude of cell types upon a three-dimensional ECM (Baryawno et al., 2019). This 
interaction between cell types of each niche has been seen to cause resistance or increased 
sensitivity to compounds within the in vivo human BM (Ria et al., 2020). In an effort to try 
to predict the genotoxicity of new compounds seen within the in vivo BM, the single cell 
type and 2D in vitro regulatory MN assay is used before the compound, if negative, is moved 
into in vivo rodents. However, a single cell line within a flask does not simulate the complex 
environment seen in vivo, therefore may be responsible for the disparity between in vitro 
and in vivo MN results with compounds such as glucocorticoids (Hayes et al., 2013).  
 
The overall aim of this PhD was to develop an in vitro model of the human BM which would 
be more in vivo relevant for the assessment of genotoxic compounds, in an effort to predict 
discrepancies between regulatory in vitro and in vivo MN assays and potentially develop a 
model that may offer insight into mechanisms causing these discrepancies. This was 
achieved by first developing an in vitro co-culture of relevant BM and regulatory cell lines 
(HS-5 and TK6) upon an artificial ECM (chapter 3), which was then used to assess the 
genotoxicity of known positive, negative and pharmacological positive genotoxic 
compounds, and results compared to historical in vivo and in vitro MN data (chapter 4). 
Finally, the expression profile of phase 1 and 2 metabolic enzymes present within HS-5 cells 
was analysed, and compared with the in vivo BM stroma (chapter 5), as a possible 
mechanism of altered genotoxicity between the regulatory in vitro and in vivo MN assay. 
Here, it will be explained how these strands ‘knit together’ to show how the developed model 
simulates the genotoxicity and toxicity of compounds similar to that seen in vivo. 
 
Over the past decade the use of 3D cell culture techniques to try to recreate the in vivo healthy 
or cancer states of the BM has gained popularity, with the majority of studies moving away 
from simple spheroids and instead opting to incorporate primary cell types found within the 
human BM (primary human MSC and HSCs), expanding and differentiating upon an 
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artificial matrix with little to no use of cell lines (Yeung et al., 2019; Inglis et al., 2019; Yu 
et al., 2018; Elango et al., 2019; Braham et al., 2018; Fairfield et al., 2019; Sieber et al., 
2018; Sun et al., 2011). These cultures are then combined with medium supplementation by 
a fluidic system for a prolonged period of time in order to simulate the complexity seen 
within the in vivo BM (Raic et al., 2019). Studies by Sieber (2018), Hauang (2016) and Raic 
(2014) highlighted that this type of system does create an environment which simulates that 
seen within the in vivo BM, containing relevant extracellular markers and signalling proteins 
whilst also withstanding long term culture (>28 days). However as stated previously, these 
systems are costly (peristaltic pumps, microfluidics and primary cells), require extensive 
optimisation (sheer force, flow rate, cells not adhering to scaffold, long term culture before 
and after seeding) and include polymorphic primary cells which expand into differing 
lineages making it difficult for assay-to-assay comparisons and identification of the 
influential factor in altered compound genotoxicity (Khurshid et al., 2018; Campuzano & 
Peeling, 2019; Kovisto et al 2019). These factors are not problematic for in-depth 
mechanistic studies where a full model of the BM is required. However, in order to replace 
a predictive routine assay, such as the regulatory in vitro MN assay, which utilises an 
economical single clonal cell culture within a static flask, allowing batch to batch 
comparisons, this system is too complex, variable and costly, and is still requires many years 
of development before becoming a routine regulatory assay with set guidelines. 
Furthermore, this complexity may not be necessary for the in vitro assessment of 
compounds.   
 
In order to reduce cost, maintain batch to batch comparability and identify the cause of the 
altered genotoxicity of compounds, the two clonal cell lines, HS-5 and TK6, were used as a 
simple less complex foundation to elucidate if the fibroblastic nature of the stroma was 
influential in the altered genotoxicity of compounds, as denoted in the literature (Chen et al., 
2020), with scope to add further cell lines if necessary. This method allowed the simple 
evaluation of each addition rather than trying to analyse multiple layers at once seen with 
those models utilising primary MSC and HSC. The HS-5 cell line was chosen as it is the 
only non-cancerous BM stromal cell line currently on the market, reducing genotoxic 
influences which may occur as a result of a cancerous state (Adamo et al., 2020). 
Furthermore, this is the first study to analyse the expression of metabolic enzymes and 
investigate the use of HS-5 cells within genotoxicity testing. The TK6 cell line was chosen 
because of its routine use within the in vitro MN assay therefore, results can be compared 
between the model and those obtained from the in vitro assay.  




As can been seen in chapter 3, this research developed a 14 day culture procedure which 
incorporated both HS-5 and TK6 without the use of a fluidic system which maintained both 
viability and proliferation. The initial 7 day seeding protocol of HS-5, encapsulated within 
an AlgiMatrix™ with pore sizes that corresponded the BM ECM, reduced cells evacuating 
the scaffold which was a problem within recent fluidic and static studies, whilst also 
maintaining viability (Sieber et al., 2018; Hauang et al., 2016; Raic et al., 2014). The seeding 
and culturing protocol for the direct addition of TK6 fulfilled the requirement of the MN 
assay by achieving actively proliferating TK6 for the addition of compound. When TK6 
were added in a trans-well insert to HS-5 cells within an AlgiMatrix™ scaffold cultured for 
7 days, an increase in HS-5 viability and live cell number was seen over the remaining 96-
hour period, inferring a beneficial crosstalk between the two cell types. A trans-well insert 
was used to allow the separation of each cell type for analysis, this would also allow 
extraction of RNA from the HS-5 cells only, which had not been ‘diluted’ by RNA from the 
TK6.  Due to this increase in HS-5 proliferation with the addition of TK6, RNA was 
extracted from HS-5 cells 48 hours after TK6 addition, as this was also the point at which 
TK6 began to enter the exponential phase of proliferation. As the addition of TK6 within a 
trans-well insert to HS-5 seeded on AlgiMatrix™ scaffolds was the closest resemblance to 
those experiments exposed to compound, the metabolic profiles of these HS-5 were used to 
potentially elucidate (part of) the mechanism(s) behind the change in genotoxicity and 
cytotoxicity seen within this model, compared to the results obtained from the regulatory in 
vitro MN assay and historical in vivo data identified in chapter 4. 
  
The original analysis within chapter 4, inferred that the altered levels of genotoxicity and 
cytotoxicity seen with MMC, etoposide and paclitaxel within this model, was due to a 
reduction in bioavailability of each compound through adherence to the scaffold. However, 
it appears that the HS-5 cell line also played a detoxification role in reducing the genotoxic 
and cytotoxic damage not only to itself but to those cells around. As mention in chapter 5, 
the role of those genes found to be expressed in HS-5 cells were analysed for their role, if 
any, in altered compound toxicity. Out of the 63 genes found to be expressed by the 
Algimatrix™ seeded HS-5 with addition of TK6 in a trans-well insert, only 7 were inferred 
to have an influence on genotoxic and cytotoxic outcomes of the two clastogenic compounds 
MMC and etoposide specifically MT2A, ABCC1, GSTP1, NQO1, MGST1, CYP3A5 and 
CYB5R, with the aneugen, paclitaxel, only correlating with ABCC1. The anti-cancer 
compounds MMC and etoposide exert their main effect by inducing potent DNA crosslinks 
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or inhibition of the topoisomerase II enzyme respectively. In both cases the primary 
mechanism generates reactive oxygen species (ROS) which in turn cause further genotoxic 
damage increasing the level of MN (Wang et al., 2010; Shin et al., 2016; Xu et al., 2014). It 
was found that both compounds had a reduced level of MN and cytotoxicity, in line with 
historical in vivo data, at the concentrations used within the current 3D model compared to 
that seen within the regulatory in vitro MN assay.  
 
The reduction in MN and cytotoxicity was in part due to the detected expression of 
antioxidant genes, which correlate with their associated protein reducing oxidative stress 
within the HS-5 cells. These genes included MT2A, GSTP1, MGST1 and NQO1. The 
expression of MT2A, which in this 3D model was highly expressed, has been linked with 
MMC and etoposide resistance in vivo through the scavenging of free radicals through its 
cysteine residues (Rodrigo et al., 2020; Mangelinck et al., 2019). In a similar manner, both 
GSTP1 and MGST1 have also been shown to scavenge free radicals created by MMC and 
etoposide reducing the effects of either clastogen (Deng et al., 2015; Gisbergen et al., 2016). 
The expression of these genes correlates with that seen in the fibroblasts of the in vivo BM, 
highlighting the similarities between this 3D model and the in vivo setting (Uhlén et al., 
2015). Once again NQO1 has been implicated in the reduction of ROS created by etoposide’s 
interaction with the topoisomerase II enzyme however, NQO1 bioactivates MMC through 
intercellular bioreduction leading to increased DNA interstrand crosslinks (Zhang et al., 
2015; Oh & Park, 2015). This bioactivation would explain the higher level of MN with MMC 
within the model than that of etoposide however, NQO1 is not expressed in the in vivo BM.  
 
The HS-5 cells also expressed the transporter ABCC1 also found within fibroblasts of the in 
vivo BM and enzymes CYP3A5 and CYB5R (Uhlén et al., 2015). The ABCC1 gene codes for 
the superfamily of ATP-binding cassette transporters, transporting molecules across extra- 
and intra-cellular membranes and is involved in multi-drug resistance (Zhou et al., 2015). 
The overexpression of the gene has been implicated in resistance to MMC, etoposide, 
paclitaxel and cyclophosphamide as the transporter extracts the drug molecule as it is 
diffused across the membrane, flipping them to the outer leaflet or allowing them into the 
extracellular environment for detoxification (Sampson et al., 2019). This would give further 
justification to the lack of cytotoxicity seen with MMC, etoposide, paclitaxel and 
cyclophosphamide within the 3D model. The presence of CYP3A5 reinforces the increase in 
MN and cytotoxicity seen with etoposide compared to MMC, as the enzyme O-demethylates 
etoposide into catechol which is seen to increase geno- and cytotoxicity of the compound 
Chapter Six: Final Discussion 
 
 193 
(Kishi et al., 2006). The enzyme CYPB5R, is key in mediating MMC redox cycling and 
generation of ROS with the addition of CYP2B4 which would increase geno- and 
cytotoxicity (Çelik & Arinç, 2013). However, due to the aforementioned antioxidant’s 
presence within the model, these ROS would be scavenged reinforcing the reduction in MN 
and cytotoxicity seen between the in vitro 2D and 3D results.  
This would infer that the addition of HS-5 to TK6 acted as an antioxidant, reducing the levels 
of ROS within the culture whilst also protecting itself through multidrug resistance 
transporters in a similar manner to that seen within the in vivo BM however, this is only the 
case if the TK6 cells do not express these genes in the regulatory in vitro MN assay. The 
metabolic profile of the TK6 cell was not conducted in this study as work by Revollo (2016) 
looked at the whole genome and normalised mRNA sequencing on the TK6 cell line in 
monoculture. Their work found that TK6 did in fact express the majority of the above genes, 
excluding CYP3A5 and CYB5R, at a similar level seen within B cell lymphoblasts of the in 
vivo BM however, single nucleotide polymorphisms were detected within the NQO1 and 
ABCC1 genes decreasing their ability to function. 
 
The addition of dexamethasone and prednisolone induced cytotoxicity and a higher 
induction of MN within our model, similar to that seen within the in vivo historical data, than 
induced at the same concentration within the regulatory in vitro MN assay. These results 
were interesting as even though the increase in MN correlated with the in vivo historical 
data, glucocorticoids of this nature have been seen to have a protective nature (Hassan et al., 
2018). The addition of dexamethasone or prednisolone has been seen to promote and 
overexpress CYP enzymes (CYP3A5, CYP2E1, CYP2D6 and CYP1A1), antioxidant 
proteins (pon2, 3 MT2A) and multi-drug resistance transporters (ABCC1) found to be 
expressed by the in vivo BM and HS-5 cells, hence their routine use in combination with 
further compounds to reduce secondary toxicity (Lim & Kim, 2009; Vrzal et al., 2015; Sato 
et al., 2013; Aberuyi et al., 2020). These data suggest that the ability of the glucocorticoids 
to promote the expression of these enzymes, infers that metabolic capability is not the 
mechanism of increased MN or cytotoxicity seen in the model, due to their protective role. 
A definitive mechanism behind the increase in MN within the in vivo setting has still not 
been identified however, the ability of glucocorticoid, specifically dexamethasone and 
prednisolone, to cause cytotoxicity has been well documented with one such mechanism 
having the ability to cause increased genotoxicity through the generation of ROS by 
glucocorticoid-induced apoptosis (Yin et al., 2018). It has been seen that high levels of 
dexamethasone or prednisolone decreases the expression of glucose metabolism enzymes, 
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such as HK2, inducing apoptosis and the release of ROS within cells (Xu et al., 2020). At 
the highest concentrations used within the model, a level of MN twice that of the vehicle 
control was observed, reinforcing the role of ROS in genotoxicity through glucocorticoid-
induced apoptosis. However, as previously mentioned, glucocorticoids of this nature 
increase the expression of many antioxidant genes which would combat the genotoxic effects 
of ROS therefore, this would infer that ROS is not the main cause in the increase of MN 
seen within the model and in vivo BM.  
 
Overall, the development of an in vitro model of the BM using appropriate cell lines has 
enabled the confirmation of the genotoxicity of known positive, negative and 
pharmacological positives seen within the in vivo historical data, but not identified within 
the regulatory in vitro MN assay. Furthermore, this study has identified the metabolic profile 
of HS-5 stromal cells and their ability to detoxify compounds, reducing MN induction, and 
the conversion of a pro-drug into its cytotoxic counterpart without the background toxicity 
observed with S9 fraction.   
 
This study set out to achieve three key aims in order to achieve the final goal of creating a 
3D model of the BM for toxicity and genotoxicity testing. In doing so, it has created a viable, 
proliferating co-culture of cell lines with the ability to identify a level of genotoxicity of 
known positive, negative and pharmacological positive compounds at a level seen within the 
in vivo BM. Identified the expression of phase I and II metabolic enzymes, for the first time 
in 2D and 3D HS-5 cultures with/ without TK6, whilst also showing that expression in 3D 
culture was more in vivo relevant than 2D. This research is the first within the literature to 
successfully simulate the genotoxicity of compounds without the use of fluidics, primary 
cells or complex scaffolds in vitro. The comparative nature of this simple, reproducible 
model to the in vivo BM, allows the true genotoxicity of compounds to be routinely assessed 
in any laboratory.  
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6.2. Limitations of the study 
 
It is important to highlight that this study has not been without limitations which may have 
an impact on the findings. As the TK6 cell line was used to assess the genotoxicity of a 
compound, the model was cultured in complete RPMI 1640 medium as this is recommended 
for TK6 cell’s growth in order to reduce influences on cell cycle. Conversely, the HS-5 cell 
line is recommended to be cultured in Dulbecco’s Modified Eagle’s Medium; as HS-5 were 
cultured in RPMI 1640 this could cause an altered gene expression and functionality from 
the HS-5 cells. However, HS-5 cells have been successfully cultured in RPMI-1640 
previously but changes in gene expression were not noted (Beaulieu et al., 2011).  
 
The metabolic profile of the HS-5 cells, in co-culture with TK6, was conducted with a trans-
well insert. Therefore, cellular communication only occurred through soluble signalling 
molecules not cell to cell contact, seen with those cells within the model treated with 
compound. As this separation was needed in order to reduce RNA contamination from the 
TK6 cells, only a correlational link can be established between the metabolic expression 
seen in the treated model and the trans-well insert studies. 
 
As the reagents required for creating, maintaining and dissolving the Algimatrix™ scaffold 
altered the CD markers used for discrimination of TK6 from HS-5 cells, the increase in MN 
cannot be attributed to either HS-5 or TK6 as identification of MN within a single cell line 
could not be conducted. Further optimisation of different fluorophores and markers would 
negate this issue. 
 
In order to maintain the cellular environment within the scaffold, medium within the scaffold 
during the compound wash day was left. Even though every effort was made to remove as 
much compound as possible the number of cells within the scaffold at this time was not 
identified. This lack of identification meant that the lack of cytotoxicity seen with some 
compounds could be due to inconsistency in medium removal at this stage. However, even 
without this cell number cytotoxicity did correlate with that seen within studies of the in vivo 
BM.
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6.3. Future work 
 
The model created in this study induced the same level of genotoxicity seen within the in 
vivo BM at the concentrations tested, inferring that the cellular communication and 
signalling molecules within corresponded with that of the human BM. Even though this is 
the first study to correctly predict the in vivo genotoxicity and cytotoxicity of known 
positive, negative, pharmacological positive and pro-drug compounds in vitro, the metabolic 
profile of the cells may only play a small part in the eventual genotoxic and cytotoxic 
outcome of a compound.  
 
The in vivo BM contains a number of signalling pathways (JAK-STAT), chemokines/ 
cytokines (interleukins, cyclin D1, c-Myc), receptors (C-X-C chemokine receptor) which 
replenish and differentiate the cellular components of the in vivo BM without genotoxic 
damage (Gomariz et al., 2018; Yi et al., 2019; Garcia et al., 2012; Weng et al., 2016). The 
alteration of any of these could lead to an induction of genotoxic damage, therefore could 
give an explanation to the results seen with the glucocorticoids. The mechanism by which 
glucocorticoids such as dexamethasone and prednisolone, induce their effect includes both 
genomic and non-genomic mechanisms, which alter the expression of interleukins, cellular 
proliferation and differentiation (Clarisse et al., 2020; Shimba et al., 2018; Gupta & Mayer, 
2013). Now that the model is at a point that it simulates the genotoxicity seen within the in 
vivo BM, identifying the possible changes in cytokines, signalling pathways and receptor 
expression to compound could unpick the results seen with these compounds.  
 
As the metabolic profile of the HS-5 was conducted with a trans-well insert, the addition of 
known genotoxic and pro-drug compounds to this experimental condition would allow the 
comparison between those MN induced within the contact model and those induced when 
cells are not in contact. If the level of MN was negatable between the two experimental 
conditions, this would reinforce the comparison of MN and the expression by HS-5 of 
metabolic enzymes seen in chapter 5.  The metabolic profile of the HS-5 after treatment 
would also be beneficial to assess if the overexpression of those genes, discussed previously 
in this chapter, does occur in a manner seen within the in vivo BM. As the original aim of 
the study was to produce a simple model of the BM for genotoxicity testing of compounds, 
the addition of primary BM stromal cells would allow more mechanistic studies due to the 
expansion and differentiation of the cells. Utilising the Algimatrix™ scaffold and culturing 
technique, the addition of primary BM cells would require less optimisation, with the 
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eventual aim of producing a blood system within the flask for in-depth genotoxicity and 
mechanistic studies. 
 
Within the 2D in vitro MN assay, an RPD is required in order to identify samples which MN 
can be counted in, this is not the case for the in vivo MN. However, 3D models, like the one 
constructed in this PhD, are not conducted in vivo therefore, require some form of RPD if 
they are to be used in regulatory geneotoxicity testing in the future. Preliminary work was 
conducted to try and combine markers of apoptosis, proliferation and cell specificity in order 
to calculate an alternative to RPD, with extra time and resources this could be achieved 
changing cytotoxicity measurements in 3D cultures. It was also noted that in order to negate 
the issues with identification in co-culture, future work could be conducted on creating a 
stable transfected, GFP labelled TK6 cell line. This would allow ease identification of the 
TK6 cell line in a co-culture. 
 
With more funding and time, the expansion of the 3D bio-printing in chapter 3 would be 
beneficial with the recent advances in printer technology. The use of printing will allow the 
production of bespoke scaffolds, with and without cells, connected to whole organ structures 
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Appendix 1 1: The P values calculated within this thesis  
 
Figure 3-1   ** p=0.0074 
Figure 3-2  A. ** p=0.0049, * p=0.0373  
B. *** p=0.0004, **** p<0.0001 C. *** p=0.0002. 
Figure 3-3 A. * p=0.0135, ** p=0.0089  
B. **** p <0.0001, *** p <0.0010  
C. * p=0.0127, * p=0.0401.  
Figure 3-4 A. * p=0.0131, **** p <0.0001  
B. **** p<0.0001. 
Figure 3-9 A. **** p <0.0001, * p=0.0420, ** p=0.0021  
B. **** p <0.0001, * p=0.0284  
C. *** p=0.0002, ** p=0.0017, * p=0.0186, * p=0.0102  
D. **** p <0.0001  
E. ** p=0.0013, ***  p=0.0004, **p=0.0026, *** p=0.006, * p=0.0107  
F. *** p=0.0004, **** p <0.0001  
G. **** p <0.0001, ** p=0.0075, *** p=0.0004, *** p=0.0006  
H. * p=0.0309, **** p <0.0001. 
Figure 3-10 A. 25 vs 24 **** p <0.001, 25 vs 12 *** p=0.0010 & 12 vs 24 ****p <0.0001  
B. 25 vs 24 ** p=0.0014 & 12 vs 24 * p=0.0286  
C. 25 vs 24 **** <0.0001, 25 vs 12 *** p=0.002 & 12 vs 24 * p=0.0148 
Figure 3-11 B. 24 hour 2.5 vs 168 hour 2.5 **** p <0.0001, 168 hour 2.5 vs 5 **** p 
<0.0001 
C. 24 hour 2.5 vs 168 hour 2.5 ****p <0.0001 
Figure 3-12 ** p=0.0015, **** p<0.0001 
Figure 3-15  A.  ** p=0.0015, *** p=0.0003  
B. ** p=0.0121, **** p <0.0001 
Figure 4-6 A. ** p=0.0015 
B. **** p<0.0001 
C. * p=0.0409, **** p<0.0001 
D. **** p<0.0001 
Figure 4.7 A & B. **** p<0.0001 





Figure 4-11 A. * p=0.034, *** p=0.001, **** p=<0.0001 
B. ** p= 0.0032, *** p=0.001, **** p=<0.0001 
C. * p=0.023, *** p=0.001, **** p=<0.0001 
D. * p=0.0325, * p=0.0421, * p=0.0318, ** p=0.0022, ** p=0.0044 
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